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Abstract 
Kidney disease is a common, expensive, and growing worldwide health problem.  Genetic 
factors play an important role in the aetiology of kidney disease.  Current research suggests 
that these genetic factors are predominantly rare variants with large phenotypic effects.  In 
this thesis I have used a range of genetic techniques to identify rare variants in different 
families with kidney disease, and to study how they might cause disease.   
The Turkish-Cypriot population of Northern Cyprus has a high incidence of renal disease, much 
of which is undiagnosed and may be inherited.  I collected DNA from the entire population on 
renal replacement therapy and identified three individuals with the G871C mutation in 
COL4A3.  I used conflicting homozygosity analysis to demonstrate a minimal shared haplotype, 
thus dating this mutation to 17 generations ago.   
I used linkage analysis and whole genome sequencing in a large Greek-Cypriot kindred to 
identify 3 novel non-synonymous variants associated with kidney disease.  Expression of these 
variants was examined in cultured primary urothelial cells from this family.  
I have studied another large pedigree with maternal transmission of renal disease.  Sequencing 
of the mitochondrial genome demonstrated the presence of a novel polymorphism in the 
heavy strand promoter region at homoplastic levels. Mitochondrial function in primary dermal 
fibroblasts demonstrated a significant reduction in baseline oxidative respiration with a 
compensatory increase in glycolysis.   
Lastly, I have studied a novel compound heterozygous mutation in VHL.  This variant showed 
abnormal degradation of HIF without activation of HIF target genes in patient-derived B-cells.  
It is possible that these cells are able to employ some kind of VHL-independent HIF regulatory 
mechanism. 
These studies demonstrate, in differing ways, the challenges of linking phenotype to genotype.  
Understanding the pathological and therapeutic importance of genetic information will 
become increasingly important to our management of kidney disease in this post-genomic era. 
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1.1  Overview 
My thesis focuses on the genetics of kidney disease.  I have studied the Turkish-Cypriot 
population of Northern Cyprus, which has a high incidence of familial renal disease.  I have 
studied families in which many members have kidney disease that has progressed to end-stage 
renal disease (ESRD).  I have identified a number of genetic polymorphisms that co-segregate 
with kidney disease in these families, and I demonstrate mechanistic work to show how these 
polymorphisms cause disease. 
In the introduction I will explain some of the principles of renal genetics.  Kidney disease is a 
common and increasing worldwide health problem with significant financial implications, and 
kidney cancer is among the most common adult malignancies.  In both cases, genetic factors 
play an important role.  Moreover, in both cases, the discovery of genes responsible for rare 
monogenetic syndromes has led to important developments in our understanding of the 
underlying pathophysiology.  I will briefly discuss two illustrative cases; firstly autosomal 
dominant polycystic kidney disease and secondly von Hippel-Lindau disease. 
Linkage analysis has been used for many years to map genetic loci through the study of related 
individuals.   This process has been simplified by the use of high density DNA arrays that give 
highly accurate estimates of recombination and measures of identity by descent.  More 
recently, next generation sequencing has enabled the rapid, and now cost-effective, 
assessment of all sequence variants in an individual.  Two key problems remain, however:  the 
quality of phenotypic information and the challenge of showing how a given sequence variant 
actually causes the observed kidney phenotype. 
While it is clear that the aetiology of most complex diseases has a genetic component, the 
process of elucidating this has been slow and difficult.  Linkage analysis has focused on rare, 
distinctive phenotypes, while the approach of association studies has mostly uncovered 
variants that confer only small increments in risk [1] (Figure 1.1).  The revolution in genomic 
technology has resulted in an exponential increase in our ability to investigate genetic risk 
factors [2].  In this post-genomic era it is hoped, therefore, that the study of rare families, 
especially those occurring in high risk populations, will help to find the remaining heritability of 
kidney disease. 
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Figure 1.1 Identification of genetic variants by allele frequency and effect size 
Linkage analysis has been used to identify highly penetrant alleles with large effect sizes (at the upper end of the 
figure), whereas genome-wide association studies (GWAS) have been powered to identify common alleles (at the 
right side of the figure).  Adapted from [1]. 
 
1.2  Background to kidney disease 
Chronic kidney disease (CKD) is a worldwide health problem, affecting an estimated 5-10% of 
adults in most populations that have been studied [3-5].  The prevalence is increasing, due to 
rising rates of diabetes mellitus, obesity, hypertension, and aging populations [6].  There is a 
strong inverse correlation between mortality and kidney function with more advanced kidney 
disease (GFR <45 ml/min) [7, 8], mainly due to increased cardiovascular risk [9].  Individuals 
with impaired kidney function are also at increased risk of progression to end-stage renal 
disease (ESRD) [10, 11]. 
Although only a small proportion of patients progress to ESRD, the cost of renal replacement 
therapy (RRT) makes this 0.1% of the population responsible for 1-2% of health-care spending 
in high-income countries [12].  Given that both the incidence of ESRD and cost of its treatment 
Introduction 
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are increasing, this has become an increasing public health challenge for high and middle 
income countries.  ESRD is of course not a single disease process, but rather represents the 
final common path of a wide variety of pathophysiological processes.   
Kidney disease encompasses a wide range of disorders, resulting from the complex interplay of 
many known and unknown environmental and genetic factors.  The genetic contribution to 
kidney function and kidney disease is supported by a number of lines of evidence.  First, there 
are a large number of monogenetic diseases of the kidney, such as autosomal dominant 
polycystic kidney disease (ADPKD) or Alport’s disease, that are important aetiologies for ESRD.  
Second, there are a number of studies showing significant heritability of a number of 
commonly used markers of renal disease.  Third, CKD shows familial aggregation and clustering 
by race, which probably reflects both shared environmental and genetic susceptibility.   
The last four decades have seen the emergence of diabetes and hypertension as the dominant 
cause of ESRD [13-15], reflecting both improved survival of diabetic and hypertensive patients 
and more liberal access to RRT [16].  However, CKD progression in individuals with 
hypertension and /or diabetes is variable, pointing towards the importance of additional risk 
factors, including genetic risk factors.  Moreover, familial clustering amongst incident dialysis 
patients is greatest for those where ESRD is caused by diabetes or hypertension [17]. 
Current treatment of kidney disease is designed to modify underlying risk factors, such as 
diabetes or hypertension, and reduce activation of the renin-angiotensin system.  Whilst this 
has undoubtedly slowed the rising incidence of ESRD [14], residual proteinuria is common and 
there is wide variation in the response to treatment.  In some cases, especially where there is 
active inflammation, specific treatments are successful.  However in the great majority of 
cases, current therapeutic options do not address the underlying pathophysiology of renal 
disease.  It is hoped that better understanding of the genetic contribution to kidney function 
and kidney disease will allow the development of novel therapeutic approaches that will delay 
or even prevent the progression to ESRD. 
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1.3  Kidney cancer background 
In addition to studying the phenotype of progressive kidney failure, this thesis also examines 
the phenotype of kidney cancer.  Kidney cancer is among the most common adult 
malignancies.  It accounts for over 3% of all new cases of cancer diagnosed in men and around 
2% of all cancers in women in the UK [18].  In the US, one in 75 people will develop renal 
cancer in their lifetime and approximately one-third will have metastatic disease at 
presentation.  Kidney cancer has a notoriously poor response to chemotherapy and 
radiotherapy, but treatment has evolved significantly in the past 10 years.   Key to these recent 
developments in therapy has been a revolution in our understanding of the molecular basis of 
renal tumour syndromes [19]. 
Much of our understanding of the molecular basis of renal cell carcinoma (RCC) has come from 
the study of a number of familial cancer syndromes.  Inherited RCC is characterised by an 
earlier age at diagnosis than in sporadic cases, and it is often multi-centric or bilateral.  
Although only 2-3% of all cases of RCC are familial [20]; the identification of such cases is 
important to allow screening of the affected individuals [21].  The presence of characteristic 
tumours or extra-renal signs may point to a diagnosis of a specific RCC susceptibility syndrome. 
  
Subtype 
Percentage of all 
renal cancers 
Syndrome Mutation 
Clear Cell 75-80% 
Von Hippel-Lindau 
disease 
Familial 
Paraganglioma 
VHL (loss of function) 
 
SDHB (loss of 
function) 
Papillary Type I 
10-15% 
(types 1 & 2) 
Hereditary Papillary 
Renal Carcinoma 
MET (activating) 
Papillary Type II 
Hereditary 
Leiomyomatosis and 
Renal Cancer 
FH (loss of function) 
Chromophobe 
+/- Oncocytic 
5% Birt Hogg Dubé 
FLCN (loss of 
function) 
Angiomyolipoma <1% 
Tuberous Sclerosis 
Complex 
TSC1 & TSC2 (loss of 
function) 
Collecting Duct <1% Lynch syndrome Unknown 
Table 1.1 Genetic causes of familial renal cancer 
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To date there are seven genes that have been implicated in familial renal carcinoma (Table 
1.1).  These genes were identified by positional cloning on the basis of characteristic histology 
and significant extra-renal signs; however they have been shown to be important in the much 
wider population of sporadic tumours. These genes are all implicated in two interrelated 
metabolic pathways, which mediate the cellular response to changes in oxygen tension and 
the availability of energy substrates.  Interestingly, mutations of these genes results in 
unrestricted proliferation of renal epithelial cells, but not the progression to ESRD caused by 
loss of normal physiological function.  The most common cause of inherited RCC is von Hippel–
Lindau (VHL) disease, which is caused by mutations in the VHL tumour suppressor gene. 
 
1.4  Evidence for genetic factors in kidney disease 
Chronic kidney disease and the progression to end stage renal disease is not a single disease 
process.  There are wide variations in incidence and prevalence both nationally and 
internationally, reflecting a wide range of contributory factors.  Broadly speaking, phenotypic 
variation in a population arises from two sources: genotypic differences (nature) and 
environmental factors (nurture).  Although CKD is itself a complex phenotype, there are a 
number of lines of evidence that genetic factors play a critical role in its aetiology. 
A significant challenge for this research, however, is that we are compelled to study an 
intermediate phenotype [22].   In the absence of a detailed understanding of its complex 
pathophysiology, CKD must be disassembled into components that may be more readily 
measured.  These components include such traits as albumin excretion, which reflects 
increased glomerular permeability, and serum creatinine concentration, which reflects 
glomerular filtration rate.  Direct analysis of renal tissue would enable assessment of more 
specific phenotypes.  While this is sometimes possible in small-scale family studies, it is 
impossible across the large numbers of mostly unaffected individuals needed for a population 
scale study.  Moreover, these traits may themselves be more closely attributable to underlying 
genetic variation than the disease phenotype. 
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1.4.01 Monogenetic kidney disease 
There are a significant number of rare kidney diseases that are caused by single gene defects.  
The spectrum of pathology here incorporates almost every single type of renal pathology, from 
developmental abnormalities to the haemolytic uraemic syndrome [23-25].  Many of these 
conditions have significant carrier rates in the general population.  Thus, mutations in type 4 
collagen, responsible for thin basement membrane nephropathy and Alport’s syndrome may 
occur in up to 1% of the population [26], and autosomal dominant polycystic kidney disease is 
one of the most common monogenetic disorders, with an incidence of 1:400 – 1:1000  [27]. 
The genes involved in these monogenetic disorders encode proteins involved in all segments 
of the nephron.  Their discovery in the last 30 years has often provided a starting point for the 
elucidation of the related disease pathogenesis [25].  This has led to the understanding of the 
critical role played by the glomerular podocyte in the maintenance of the glomerular filtration 
barrier, the role of numerous transporter and channel proteins in various types of 
tubulopathies, and the importance of the primary cilium in renal cystic disease. 
These monogenetic disorders exhibit various patterns of inheritance and age of onset.  
Moreover, the demonstration of genetic and clinical heterogeneity has confirmed that a 
significant proportion of simple monogenetic disorders are far more complex than previously 
thought.  This is especially true for developmental and cystic renal disorders.  Renal 
developmental disorders under the acronym CAKUT (congenital abnormalities of the kidney 
and urological tract), such as those caused by mutations in PAX2 and HNF-1B, exhibit a wide 
spectrum of abnormalities in different individuals carrying the same mutation [25].  Similarly, 
mutations in single ciliary genes are often associated with multiple cystic phenotypes.  
Conditions such as Bardet-Biedl syndrome are caused by mutations in multiple genes, and the 
severity of such conditions is associated both with the type and number of mutations, a 
concept called mutational load [28]. 
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1.4.02 Heritability studies 
Another argument for the importance of genetic factors in the development of renal disease 
comes from heritability studies.  These studies attempt to quantify the relative contribution of 
environment and genetic factors, although just as there are several ways to define genetic 
influences, there are many measures of heritability (Figure 1.2).  In the broadest sense 
heritability refers to the total genetic contribution, whereas in the narrowest sense, strict 
heritability refers to the additive genetic variance that drives the resemblance between 
relatives and can be quantified more easily [29].  Heritability estimates reflect the amount of 
variation in genotypic effects compared with variation in environmental effects, rather than 
absolute measures of the contribution of genetic and environmental factors to a phenotype.  
Estimates are therefore relative to population-specific factors, such as allele frequencies, 
measurable effects of gene variants, and the influence of environmental factors.  Increasing 
genetic variation, as with outbreeding populations, or decreasing environmental variation, as 
with controlled experimental conditions, can increase heritability estimates.  Nevertheless, in 
practice, heritability estimates of similar traits are often remarkably similar across populations 
[30]. 
 
 
Figure 1.2 Estimation of heritability 
Broad-sense heritability (H
2
) refers to the total genetic contribution to a given phenotype.  Strict, or narrow-sense 
heritability (h
2
) specifically refers to additive genetic variance.  Resemblance between relatives is mostly driven 
by additive genetic variance; therefore narrow sense heritability tells us how well a parent’s phenotype will 
predict that of the offspring.  By contrast, H
2
 tells us what proportion of phenotypic variation is caused by the 
genotypes of the individuals in the population.  Adapted from [29]. 
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Heritability estimates for the most commonly used measure of kidney function, glomerular 
filtration rate (GFR), range from 0.33 – 0.82. [31, 32].  This indicates that 33-82% of the inter-
individual variance in GFR estimates in these studies could be explained by additive genetic 
effects, in other words, narrow sense heritability.  Heritability estimates for urinary albumin 
excretion, a hallmark of diabetic nephropathy, range from 0.3 to 0.44 in Finnish, New England, 
and south-eastern US families enriched for members with type 2 diabetes [33-35].  Glomerular 
filtration rate (GFR) was similarly heritable in families with diabetes and hypertension, with 
estimates ranging from 0.36 to 0.75 [32, 35, 36].   
One problem with this kind of research is that kidney disease is not a tightly defined 
phenotype.  There are many available measure of kidney function, from inulin clearance to 
estimated GFR and cystatin C measurements, which appear to exhibit differing degrees of 
heritability.  Furthermore, GFR changes substantially over the human lifespan.  This is a 
recurrent problem with population-based approaches to assessing the genetic risk of kidney 
disease, and will be discussed further in the context of genome-wide association studies. 
Studies of heritability are often conducted in isolated, endogamous populations, such as the 
Zuni Indians of New Mexico [37], or the families of African descent in the Seychelles [32], 
where there disease phenotype under study occurs at significant levels.  However, the 
estimates of heritability are lower in outbred populations, such as that of the Framingham 
Heart Study [31, 34].  The advantage of using isolated populations to estimate heritability is 
that they show a shared stable environment and reduced genetic complexity [38].   
The population structure of a genetic isolate can be variable, ranging from the populations of 
Sardinia and Finland to tiny isolates reported in the South Tyrol and Val Borbera in Italy or in 
the Netherlands [38].  Isolated founder populations originating from recent common ancestors 
exhibit extended linkage disequilibrium relative to the general population.  The Val Borbera 
population of northern Italy shows that the heritability of serum creatinine is less than, for 
example, total cholesterol or mean cell haemoglobin, however it is still in the region of 20-35% 
[38].  In addition, these researchers noted that individuals presenting with extreme values for 
these traits exhibited a higher kinship coefficient, a measure of inbreeding, compared with 
individuals in other percentile groups. 
Inbred populations offer a similar theoretic advantage to geographical isolates for the study of 
complex disease [39].  Such populations show higher levels of homozygosity in recessive 
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alleles, which has been shown to be harmful in almost all species studied [40].  This occurs 
across a wide range of traits and suggests a large number of deleterious alleles located 
throughout the human genome.  Most studies of the effects of inbreeding have focussed 
mainly on its impact on reproduction, childhood mortality and rare monogenetic disorders 
[41].  However, natural selection would predict that the harmful effects of inbreeding would 
increase with age, and most genetic variants that have been identified causing complex 
disease in humans are partially recessive.  Examination of genetic isolates on three islands in 
the eastern Adriatic revealed that 23-48% of complex disease could be attributed to recent 
inbreeding [39].  Whilst these studies did not directly measure renal function, studies in the 
endogamous Zuni Indians showed significant heritability of many phenotypes related to kidney 
disease. 
 
1.4.03 Familial clustering 
Familial aggregation studies show that ESRD, and earlier stages of CKD, clusters in families [17, 
42].  Familial clustering has been reported in diabetic, hypertensive, systemic lupus 
erythematosis, and human immunodeficiency virus-associated nephropathies [43].  The 
presence of a family history of ESRD is a significant risk factor for the subsequent development 
of nephropathy, and the proportion of patients of RRT with a family history of ESRD is highest 
in young adults, non-Caucasians, and those where ESRD is caused by diabetes or hypertension. 
It was many years before the risk of diabetic nephropathy and progression to diabetic ESRD 
was ascribed to anything other than the simple duration of exposure to hyperglycaemia [44].  
However it is now clear that select individuals with diabetes are at differential risk for 
developing nephropathy, based on the familial aggregation of kidney disease [45].  This 
aggregation of diabetic nephropathy is independent of family size, the number of relatives 
affected with diabetes and hypertension, socioeconomic status, and inadequate access to 
health care, strongly suggesting the existence of susceptibility genes [42].  Analysis of nearly 
26,000 incident US dialysis patients, excluding those with known genetic disorders, showed 
that nearly 32% of black women, 27% of black men reported having close relatives with ESRD, 
compared with 15% and 12% of European Americans, respectively [17].  Segregation analyses 
in multiplex families supports the importance of major genetic effects [45].  Interestingly, 
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familial aggregation of specific renal histological diagnoses is also observed in siblings with 
diabetes, independent of diabetes duration and disease control [46]. 
Hypertensive renal disease presents a similar picture to diabetic nephropathy; in that only a 
minority of hypertensive patients go on to develop kidney disease.  Here again there is 
evidence of familial clustering and racial disparities in familial risk.  Thus 19% of ESRD patients 
with hypertension in the south-eastern US had a first or second-degree relative with ESRD, and 
this risk was greater in African Americans than European Americans [45].  This risk is 
preserved, even when family history of hypertension and other potential risk-aggravating 
factors are controlled for [42].  Lastly, these population studies are supported by a number of 
animal models showing that the risk of renal damage due to genetic factors is independent 
from the presence of hypertension [22]. 
 
1.5  Identifying the genetic basis of kidney disease 
Kidney disease is therefore a mixture of single gene defects with high phenotypic impact, and a 
combination of multiple genetic and environmental factors, with harmful environmental 
exposures acting on genetically susceptible individuals [47].  Our ability to uncover the genetic 
basis of kidney disease has been revolutionised by the recent explosion in genomic technology.  
There are two fundamental approaches to the identification of disease genes, linkage and 
association analysis.  Initial progress was made with linkage analysis, studying highly penetrant 
monogenetic disorders in large pedigrees.  Early association studies looked, without great 
success, at a series of candidate genes.  Subsequently, unbiased, genome-wide association 
studies were performed to look for common variants affecting the incidence of common 
diseases, such as CKD.  More recently, next generation sequencing is now becoming 
widespread, and holds out the promises and challenges of truly personalised medicine for the 
21st century. 
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1.5.01 Linkage analysis 
Linkage analysis can be used to identify regions of the genome that contain genes that 
predispose to disease [48].  This analysis uses pedigree information to see which genetic 
markers are co-inherited with a given clinical phenotype.  Two genetic loci are linked if they 
are transmitted together from parent to offspring more often than expected by chance (Figure 
1.3).  In other words, two loci are linked if, during meiosis, recombination occurs between 
them with a probability of less than 50% [49].  The probability of recombination is therefore a 
function of chromosomal distance between two loci, measured in centimorgans (cM).  Linkage 
analysis is a measure of mathematical probability, rather than being driven by a previous 
biologically driven hypothesis, and is therefore often the first stage in the genetic investigation 
of a trait. 
 
 
Figure 1.3 Co-inheritance of a disease gene (D) with three marker loci (A, B, and C) 
Only the father’s contribution to the genotype is shown.  All four affected offspring have inherited the A allele 
along with D at locus 1.  However II-1, II-5 and II-7 are recombinant for marker locus 3, and II-5 is also 
recombinant for marker locus 2, indicating that meiotic crossover has occurred between the two loci (adapted 
from [50]). 
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Parametric linkage analysis is the analysis of the co-segregation of genetic loci in pedigrees.  It 
is possible to determine the position of genetic markers relative to each other and a disease 
locus by studying their segregation through a pedigree.  The aim of such analysis is to 
determine the recombination fraction (θ), which is measured as an odds ratio of the two 
probability values (linked/unlinked).  Linkage is usually reported as a log10, or logarithm of the 
odds (LOD) score.  This score was first proposed by Morton in 1955 [51], and is a function of 
the recombination fraction (θ) or chromosomal position measured in cM.  This means that the 
LOD score varies depending on the value of θ.  Large positive values are evidence of linkage, 
while large negative values are evidence against.   
Early studies used a variety of genetic markers, commonly highly variable microsatellite 
repeats, and might have included two-point comparisons between marker and disease locus.  
It is now common practice to use a very set large of markers, whose position is well mapped, 
spread evenly throughout the genome.  Using multiple markers entails multiple estimates of θ, 
with the result that localisation is more accurate but the threshold of significance needs be 
amended.  By convention, a LOD score of 3 was regarded as significant evidence of linkage, 
equivalent to a p = 0.001 [52].  Likewise, a score of -2 or less equated to a definite rejection of 
linkage.  More recent work, taking into account the dense single nucleotide polymorphism 
(SNP) markers used, suggests that a threshold of 3.3 should be used, equivalent to a genome-
wide significance of 0.05 [53]. 
Parametric analysis assumes that the genetic model for the disease of interest is known.  This 
model, which must be specified at the start of analysis, includes the frequency of the disease 
allele, mode of inheritance, marker allele frequencies, and a full marker map for each 
chromosome.  These model parameter estimates are ideally taken from population-based 
studies of the disease.  Importantly, where these assumptions are incorrect, parametric linkage 
analysis can be severely compromised.  Many genetic conditions show variable penetrance or 
genetic heterogeneity with different modes of inheritance.  It is possible to overcome these 
obstacles, as was seen with the localisation of the breast cancer genes, BRCA1 and BRCA2 [54, 
55]. 
An alternative approach is to use non-parametric analysis where there is no clear mode of 
inheritance [48].  This can be useful for multifactorial diseases, where several genes may 
contribute to disease risk.  These kinds of analysis are based on the assumption that there is 
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excess sharing of haplotypes that are identical by descent (IBD) between affected relatives in 
the region of a disease causing gene, irrespective of the mode of inheritance.  Various methods 
have been developed using sibling pairs or other groups of relatives, using computational 
algorithms to cope with the complexity of large pedigrees and large number of markers. 
The choice of phenotypic trait is a significant issue with linkage analysis [48].  In simple 
Mendelian traits it can be straightforward to identify affected and unaffected individuals, and 
even in a disease such as cancer once the diagnosis is based on pathological findings.  However 
there are a number of conditions such as obesity or psychiatric illness where definitive 
diagnosis may depend on a particular threshold or constellation of distinct symptoms.  Chronic 
kidney disease a good example of this as it is often defined by the elevation of selected blood 
or urinary markers above a certain threshold.  There may be a good reason for simplifying a 
quantitative trait into a binary one for the purpose of analysis; however the use of an 
inappropriate threshold can result in a loss of power [56].  The absence of a clear definition of 
phenotype will lead to uncertainty about the classification of affected and unaffected 
individuals.  Moreover, in parametric linkage analysis, misclassification of individuals can 
dramatically reduce the size of calculated LOD scores. 
Finally, while linkage analysis has been used with great success for over half a century, it is only 
the first step toward identifying an exact disease locus.  In Mendelian traits, crossover events 
often narrow the locus sufficiently to define a small region of interest.  However, such regions 
may equally contain hundreds of genes, many of which are biologically plausible candidates.  
The process of locus identification then required painstaking Sanger sequencing of candidate 
genes within the linked interval.  The inclusion of additional affected individuals or more 
families with the same phenotype could improve this process, as Morton had originally 
envisaged [51], by increasing the LOD score and by introducing new recombinations to narrow 
the linked interval.  The availability of next generation sequencing has further revolutionised 
this process by providing a direct route to the identification of likely causative variants. 
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1.5.02 Association studies 
The alternative to looking for genetic factors within families is to conduct this analysis at the 
level of populations by means of association studies.  The first studies on disease association 
were published in the 1950’s and 1960’s looking at the association of conditions such as 
stomach cancer and pernicious anaemia with ABO blood types [57].  These techniques were 
first applied to the field of kidney disease to investigate the effect of variants in a number of 
candidate genes, such as angiotensin-converting enzyme and angiotensinogen [58].  However 
it was not until technical developments in assaying single nucleotide polymorphisms (SNPs) in 
the decade after 1997 that it became possible to conduct truly genome-wide, hypothesis-free 
analyses. 
In order to understand the basis of association studies, it is important to describe the nature of 
human genetic variation.  There are many ways in which the DNA molecule can vary between 
individuals.  SNPs are the commonest class of genetic variation among individuals, with nearly 
200 million currently reported; however there are many others including deletions, insertions, 
inversions, and copy number variants of varying size [59].  Genetic variants are typically 
described as either common or rare, depending on whether the minor allele frequency (MAF) 
in the human population is greater than 1% or not.  The vast majority of variants are predicted 
to have no effect on phenotypic variation.  Thus they are evolutionarily ancient and have 
achieved their frequency in the human population by chance alone. 
SNPs and other neutral variants located in the same genomic interval are often correlated with 
one another in what is termed linkage disequilibrium (LD) (Figure 1.4).  Studies of the human 
population, such as the international HapMap project, have shown that these groups of 
correlated SNPS can be broken down into just ~550,000 LD blocks for individuals of European 
or Asian ancestry and ~1,100,000 block for those of African ancestry.  By genotyping the DNA 
sample of an individual with a ‘tagging’ SNP from each LD bin, it is possible to estimate over 
80% of SNPs present at a frequency above 5% in the genome [59].  
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Figure 1.4 Linkage disequilbrium 
Linkage disequilibrium (LD) is the non-random association of alleles at two or more markers, resulting in the 
occurrence of some combinations of alleles in a population more or less often than would be expected from a 
random formation of haplotypes based on their frequencies alone.  (A) Red squared show high pairwise LD, thus 
markers 2-4 and 5-9 are in LD with each other, resulting in the formation of haplotype blocks.  (B) Genome-wide 
association studies use single nucleotide polymorphism (SNP) markers to assess the association between 
genotypic variation and phenotypic variation.  If SNPs 1 and 2 show complete LD, it is sufficient to only genotype 
alleles at SNP2 to assess the risk of disease caused by SNP1 (adapted from [47]). 
 
Since the first GWAS using a high-throughput SNP genotyping array was published in 2005, a 
number of studies have been conducted looking at phenotypic definitions of CKD including an 
eGFR of <60 ml/min/1.73m2 using the four variable Modification of Diet in Renal Disease Study 
equation, as well as GFR based on cystatin C and urinary albumin-to-creatinine ratio [47, 58].  
These studies, employing pooled consortia with up to 67,000 participants, have revealed and 
replicated nearly 30 loci associated with population-based CKD, diabetic nephropathy, eGFR, 
and albuminuria [58].  These loci are in addition to those, such as cystatin3 (CST3), which were 
detected and have a clear relationship with the phenotype in question (in this case, production 
of cystatin C).  They do, however, include many such as shroom family member 3 (SHROOM3) 
and dachshund homolog 1 (DACH1) which are expressed in the kidney and which appear to be 
important for normal development and function.  Importantly, these loci also include a 
number, such as uromodulin (UMOD) and alstrom syndrome 1 (ALMS1) which have been 
implicated in rare Mendelian diseases of the kidney.  This illustrates a key theme of findings 
from GWAS studies: common variants of genes responsible for severe, monogenetic disorders 
may be associated with milder presentations in the general population. 
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There are, however, a number of problems with the association study approach.  One impetus 
behind the development of genome-wide association studies (GWAS) was the ‘common 
disease-common variant’ hypothesis, which proposes that common complex traits are largely 
due to common variants with small to modest effect sizes [60].  Because of the constraints 
imposed by multiple statistical tests and current sample sizes, GWAS are only able to 
investigate variants with a MAF of >1-5% [61].  Moreover, for the most part, GWAS can 
establish that a tag SNP from an LD block is statistically associated with a trait, but they cannot 
identify the precise variant(s) in the block that have the causal role in contributing to variation 
in the trait. 
A good example of this limitations is given by a recent study using mapping by admixture 
linkage disequilibrium, which showed that the E-1 haplotype of nonmuscle myosin heavy chain 
9 (MYH9) on 22q11-13 was a powerful risk factor for ESRD, as well as increasing the risk of 
hypertensive nephrosclerosis and focal segmental glomerulosclerosis [62, 63].  Variants in the 
adjacent apolipoprotein L1 (APOL1) gene were found to have an even stronger statistical 
association with ESRD than those of MYH9, and a plausible explanation for their evolutionary 
selection due to increased resistance to African sleeping sickness [64].  However, analysis of 
another MYH9 variant in Caucasians indicates than more than one renal risk variant might be 
operational in this LD block [58]. 
Another issue with association studies relates again to the issue of how the phenotype is 
defined.  The first high-throughput GWAS in 2005 looked at age-related macular degeneration, 
and reported significant association with just 96 cases and 50 controls [65].  Since that time, 
the trend has been to create larger and larger study populations with the aim of increasing 
statistical power to detect small effects of variants in a large number of genes.  However, it 
may well be that studies performed on a narrowly defined disease entity with a high genetic 
component of risk attributable to a single or limited number of genes may have more success; 
notably, they can succeed with a small study population along the lines of the study by Klein et 
al [65].  A recent association study of idiopathic membranous nephropathy provides a good 
example of this.  Researchers took a cohort of just 556 patients with this condition 
(representing a significant proportion of all cases in the three countries that contributed to the 
study) and showed a highly significant association with variants in HLA-DQA1 and 
phospholipase A2 receptor 1 (PLA2R1) [66]. 
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GWAS studies have made significant contributions to our understanding of the genetic basis of 
a number of aspects of kidney disease, and yet so far less than 2% of the estimated heritability 
has been explained [67].  This is a recurring theme across GWAS studies in a number of 
conditions, and has led to the concept of ‘missing heritability’ [1].  The remainder may be 
missing for a variety of reasons, both related to the size and stratification of the sample 
population, and to genetic factors such as epistatic interactions or allelic frequency that will be 
discussed subsequently. 
 
1.5.03 Next generation sequencing 
In 2007, the first complete genome sequence of an individual, J. Craig Venter, was published 
and shortly followed by that of a second individual, James D. Watson [68, 69].  These were 
significant advances on the reference versions of the human genome published in 2001, as 
these were both derived from numerous donors and represented the human genome as a 
haploid sequence without annotated genetic variation [59].  Since 2005 next generation 
sequencing platforms have become widely available, reducing the cost of DNA sequencing by 
four orders of magnitude relative to Sanger sequencing [70].  By coupling targeted capture and 
massively parallel DNA sequencing it has become possible to determine nearly all the coding 
variation present in an individual human genome, a process termed exome sequencing.  This 
technique has become a powerful new approach for identifying the genes underlying 
Mendelian disorders.  Moreover it offers the possibility to identify those rare variants which 
are thought to underlie some of the missing heritability. 
Next generation sequencing is provided by a rapidly evolving set of technologies, however all 
platforms involve massively parallel sequencing of clonally amplified or single DNA molecules 
that are spatially separated in a flow cell [71].  This is a paradigm shift from that of Sanger 
sequencing, and the hundreds of megabases to gigabases of nucleotide sequence generated 
required an equal revolution in the computational pipelines used to assemble meaningful data.  
Targeted sequencing approaches have the general advantage of increased sequence coverage 
of regions of interest, although the different strategies of targeting capture introduce another 
layer of complexity and potential bias to the process. 
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The most immediate application of next generation sequencing is the discovery of the genetic 
defects underlying monogenetic inherited disorders.  The number of rare monogenetic 
diseases is estimated to be over 5500, and yet for nearly 2000 of these conditions the 
underlying genes remain unknown (http://omim.org/statistics/entry).  In addition, an 
increasing proportion of common disorders, such as schizophrenia or autism, that were 
previously thought to be due to complex multifactorial inheritance, are now thought to reflect 
a heterogeneous collection of rare monogenetic disorders [72].  Perhaps the most likely reason 
for missing heritability in GWAS studies described in the previous section is that many diseases 
are not a single disease caused by common variants with very low penetrance, but are actually 
a collection of different diseases, many of which have substantial contributions from rare 
variants with moderate or substantial phenotypic effects. 
There are a number of strategies for finding disease-causing alleles, most of which rely on 
three discrete filtering steps which enable the reduction of nearly 2 million variants per 
individual to a minimum number of high-priority candidates.  The first filtering step is used to 
eliminate candidate genes by assuming that any causative allele will not occur in a control 
population.  This control population is often a public database, such as dbSNP or the 1000 
Genomes Project, and represents a powerful approach because only around 2% of variants 
identified in an individual will be novel  [73].  In addition to public databases, novelty can be 
assessed by filtering the variant against those found in a set of unaffected controls.  This last is 
of particular relevance because most publically-available data was European in origin at the 
start, and might therefore not be so applicable to non-European or isolated populations. 
This filtering step rests on the assumption that the control populations contain no alleles from 
individuals with the phenotype in question.  However it is likely that reference databases, such 
as dbSNP, contain a small, but appreciable, number of pathogenic mutations [73].  This is due 
in part to incomplete phenotyping of the individuals whose variants are deposited in dbSNP, 
and in part to the second problem of allelic frequency in the population under study.  As more 
variation data becomes publically available it is increasingly likely that pathogenic mutations 
that are present in the general population will be included, in direct proportion to the minor 
allelic frequency.  This is especially relevant for recessive disorders, in which the carrier 
phenotype would not exclude an individual from a control population, but is equally true for 
dominant disorders with incomplete penetrance or advanced age of onset.  With this caveat in 
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mind, it is better to filter out alleles above a MAF threshold of 0.1-1%, in conjunction with a 
larger sample size or in conjunction with pedigree-based approaches [73]. 
The second filtering process is the strategy by which the variants of a single individual can be 
cross-referenced with others to determine potentially pathological ones.  The first successful 
use of next generation sequencing to identify a new Mendelian disorder in 2009 used 
comparison across four unrelated individuals with the same dramatic phenotype [74].  The 
number of individuals required is determined by what is known about the mode of inheritance 
and the possibility of genetic heterogeneity.  Filtering is more efficient for recessive disorders 
because the genome of any one individual has around 50-fold fewer genes with two, rather 
than one, novel protein-altering alleles per gene [73].   
Where possible, the use of pedigree information can significantly reduce the number of 
possible shared variants.  The probability of identity by descent given identity by state is high 
for very rare alleles, even among distantly related individuals.  It is therefore best to compare 
the most distantly related affected individuals within a pedigree, because each additional 
meiosis should on average reduce the shared genomic space by 50%.  Where mapping data is 
available, this process can be refined to utilise those individuals whose shared haplotype is the 
smallest.  Similarly, in recessive disorders arising in consanguineous pedigrees, the individual 
with least homozygosity should be targeted.  An elaboration of this strategy is to look at 
parent-child trios for the presence of de-novo mutations.  This approach is particularly 
applicable for disorders in which most cases are sporadic, and which are suspected to be 
dominantly inherited or in which substantial locus heterogeneity is expected. 
Another challenge for next generation sequencing will be to identify rare variants that underlie 
complex traits.  In the absence of pedigree data there have been two main approaches.  The 
first has been to target those regions that have been identified by association studies.  Based 
on the assumption that rare variants which influence a trait are in linkage disequilibrium with 
common variants that influence risk, this allows capture nearly all of the rare and very rare 
(MAF < 0.1%) alleles that are present in a sample that may be responsible for the association 
(Figure 1.4).  The second approach is the extreme phenotype study design, in which individuals 
at either end of a phenotype distribution are selected for sequencing [75].  It is probable that it 
will eventually become standard to sequence all individuals in a disease cohort, however it 
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remains a major challenge that even with very large sample sizes the power to detect an 
association with a single rare variant is low (see discussion on GWAS). 
The third filtering step is the stratification of candidates on the basis of their predicted impact 
or deleteriousness.  For example, greater weight can be given to frame shifts, stop codons, and 
disruptions of canonical splice sites than to missense variants.  Candidates can be stratified by 
existing biological or functional information about a gene, such as its role in a biological 
pathway or interactions with genes known to cause a similar phenotype.  Where this 
information is not yet known, bioinformatics algorithms can be used to predict pathogenicity 
based on the observation that regions of genes and genomes in which mutations are 
deleterious tend to show high sequence conversion as a result of purifying selection [76].  It is 
possible to model conservation at both nucleotide and amino acid level, resulting in 
enrichment of variants which are likely to have a phenotypic impact. 
Despite the increasingly sophisticated pipeline for the identification of causal variants using 
next generation sequencing, this approach can fail.  Failures are usually either technical or 
analytical [73].  Technical failures arise because of problems with sequence coverage, base 
calling, or sequence alignment.  Technical failures are likely to diminish rapidly over the coming 
years, and for now one strategy to minimise their impact is to utilise a control set of genomes 
that have been generated using the same sequencing technology.  The use of targeted capture 
to generate exome data can be an additional source of error, given the need to define the 
target set for initial enrichment.  Analytical failure can arise from any of the filtering steps 
discussed above.  The major limitation here is genetic heterogeneity in which the same 
phenotype is produced by a number of different alleles.  From an analytic perspective false 
negatives, in which the causative alleles are present in the control data set or exhibit reduced 
penetrance, result in a reduced signal-to-noise ratio that is indistinguishable from genetic 
heterogeneity. 
In conclusion, next generation sequencing technology offers the opportunity to replace both 
linkage analysis and association studies in the near future.  So far there has been most 
progress using exomic data to uncover the molecular basis of Mendelian conditions.  The field 
will probably gradually move to whole genome sequencing as the cost of sequencing continues 
to fall and as our ability to make sense of non-coding variation develops [2, 73].  There remain 
significant technical, statistical and bioinformatic obstacles to the widespread use of this 
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technology in clinical diagnostics.  However, even as these technical hurdles are being 
removed, it becomes even more critical to characterise accurately the phenotypes that are the 
raw material for this analysis.  Lastly, it should be mentioned that the use of next generation 
sequencing for disease gene discovery involves a number of ethical issues, in particular the 
issue of consenting for sequencing research and the return of information, including incidental 
findings, to individuals and the wider scientific community. 
 
1.6  Mechanisms of genetic kidney disease 
It is clear therefore that a significant proportion of chronic kidney disease is due to genetic 
factors.  Single gene disorders account for nearly 15% of individuals with ESRD in national 
registries [14, 15, 77], and have provided remarkable insights into the molecular pathology of 
renal pathophysiology.  Genome-wide association studies have transformed our understanding 
of the genetic architecture of complex disease, but have singularly failed to explain its 
heritability by means of the common variant model [1, 47].  This is a direct result of the 
evolution of the human genome.  The most likely explanation is that complex disease is caused 
by many rare alleles, operating below the threshold for a population wide effect. 
The oldest human alleles originated in Africa, in parallel with the evolution of our species.  
These ancient polymorphisms are shared by all populations and account for approximately 
90% of human variation [78].  Most of these variants have no functional significance and 
persist by chance alone in the absence of selection pressure.  However, new mutations 
continually arise at a rate of approximately 175 per diploid human genome per generation 
[79].  The exponential growth of the human population has therefore resulted in a vast 
number of new alleles, which have generated an immense degree of genetic variation.  These 
new alleles are rare because of their recent origin, and may be confined to just one person or 
family.  Moreover they may not yet have been removed from the population by natural 
selection. 
With such allelic diversity it is perhaps not surprising that genetic factors exhibit a remarkable 
degree of molecular heterogeneity.  Each gene can harbour many hundreds or even thousands 
of rare, pathogenic variants in unrelated affected individuals.  Moreover, the same mutation 
causing loss of function at a particular genetic locus, may lead to different phenotypes in 
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different individuals.  Conversely, mutations in different genes in the same or related pathways 
may result in the same phenotype.  These mechanisms are best illustrated by discussion of two 
illustrative cases; firstly autosomal dominant polycystic kidney disease and secondly von 
Hippel-Lindau disease. 
 
1.6.01 Autosomal dominant polycystic kidney disease 
Autosomal dominant polycystic kidney disease (ADPKD; Mendelian inheritance in man (MIM) 
173900, 263200) is one of the most common of all monogenetic disorders, with an incidence 
of 1 in 400 to 1 in 1000 [27].  ADPKD is the single most common genetic cause of ESRD in the 
adult population, accounting for 6.5% of incident cases of ESRD in the UK.  ADPKD occurs 
worldwide with similar incidence in different populations.  It is a genetically heterogeneous 
condition with two genes (PKD1 and PKD2) identified by positional cloning in 1994 and 1996 
[80, 81].   
Polycystin-1 (PKD1) is localised to the short arm of chromosome 16 immediately tail to tail 
with the tuberous sclerosis gene, TSC2 [82].  This part of chromosome 16 exhibits complex 
duplication, and it was subsequently found to contain six non-coding homologues to PKD1 
(pseudo-genes, PKD1 P1 through P6).  These pseudo-genes share 97.7% identity with exons 1-
33 of PKD1, and have made the process of molecular diagnostics considerably more difficult.  
PKD2 was identified by homology between the predicted PKD1 and PKD2 proteins, highlighting 
it from others in the candidate region [81]. 
Mutations in PKD1 account for ~85% of cases in clinically identified populations, and result in a 
more severe clinical phenotype.  The average age of onset of ESRD is 20 years younger in 
patients with PKD1 mutations compared to those with polycystin-2 (PKD2) mutations, however 
there is a large overlap and it is not possible clinically to differentiate between the two genes.  
ADPKD exhibits a high level of allelic heterogeneity, with a total of 619 pathogenic PKD1 and 
129 pathogenic PKD2 mutations reported to date (ADPKD database [PKDB], 
http://pkdb.mayo.edu).  These mutations are spread across the entire sequence of these 
genes, and the majority are private to a single pedigree.  The majority of mutations are 
truncations, with an additional 25% missense mutations.  The type of mutation does not seem 
to be strongly associated with the phenotype [83, 84]. 
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The PKD1 protein is a large (4303 amino acid) integral membrane protein with 11 
transmembrane domains and an extracellular region consisting of a variety of domains, which 
may be important for protein-protein interaction.  The PKD2 protein is smaller and functions as 
a non-selective cation channel that transports calcium.  Polycystin-1 and -2 interact to form a 
complex, whose major role is to regulate levels of intracellular calcium, located at the primary 
cilium [27]. Primary cilia are membrane-enclosed hair-like organelles that occur on the apical 
surface of renal tubular cells and on cells in many other organs.  The primary cilium appears 
critical for the development of ADPKD as there are now over 50 genes that have been 
associated with ciliary disease and a cystic or dysplastic kidney phenotype [28].   
Renal ciliopathies, including ADPKD, are often accompanied by abnormalities in other organs 
[28].  This is not surprising given that primary cilia occur almost ubiquitously throughout the 
human body.  The pleiotropic phenotypes in these syndromic disorders can be linked to 
defects in ciliary function and provide an insight into the signalling pathways that require 
functional cilia to operate [27].  Many of these genes give rise to distinct, if overlapping, clinical 
characteristics, which is supported by the discovery of discrete protein sub-complexes within 
the cilium.  However individuals from the same family can exhibit widely divergent clinical 
phenotypes, showing that the nature of the individual mutation is less important than other 
genetic and environmental factors. 
The renal ciliopathies provide a good example of the concept of ‘mutational load’, showing 
how monogenetic disease may be influenced by other genes in the same pathway.  Oligogenic 
inheritance, involving mutations in multiple genes, has been reported for most ciliopathies, 
after the first description in Bardet-Biedl syndrome [85, 86].  Emerging data suggest that 
ciliopathy-associated genes have the capacity to contribute pathogenic alleles to multiple 
ciliopathies, and there is evidence to suggest that the final phenotype is an overall measure of 
the disturbance of ciliary function[87].  In support of this, it has recently been shown that two 
hypomorphic PKD1 or PKD2 alleles may result in a more severe phenotype like autosomal 
recessive polycystic kidney disease in utero [88-90].  Moreover, the combination of PKD1 
mutations with other genes, such as TSC2 and HNF1β, also results in a more severe 
manifestation [91]. 
The exact mechanism by which mutations in PKD1 and PKD2 cause ADPKD remains unknown.  
The greater severity of PKD1 appears to be due to the development of more cysts at an early 
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age, not to faster growth [27].  Studies of conditional knockouts in mice indicate a 
developmental switch around postnatal day 13, after which time inactivation of Pkd1 results in 
a much milder disease [92, 93].  In humans, the cells lining cysts show loss of heterozygosity in 
PKD1 and PKD2, indicating a somatic second hit [94, 95].  Loss of polycystin-mediated calcium 
signalling affects a number of intracellular signalling pathways that may contribute to cyst 
proliferation.  The number and developmental timing of second hits that accumulate in an 
individual may thus play an important role in the variable severity in pedigrees.  Moreover, it is 
intriguing that this unrestricted proliferation is not associated with tumourigenisis, as will be 
seen with the case of VHL disease. 
From a diagnostic perspective, ADPKD remains challenging, and molecular testing for ADPKD is 
not recommended in patients in whom a firm positive or negative diagnosis can be made by 
imaging alone [96].  Even after testing, 9% of individuals exhibit no mutation in either PKD1 or 
PKD2.  These patients tend to have milder disease and a negative family history, suggesting 
that they may have more subtle mutations, such as deep intronic changes that are missed by 
the exon-based screening approach [97].  Mosaicism has been described in two ADPKD 
families, and may be more prevalent in de novo cases.  Some PKD1 alleles may show 
incomplete penetrance [98], and there are several ADPKD families that are apparently not 
linked to PKD1 or PKD2.  Given these limitations, it is to be hoped that the application of next 
generation sequencing to molecular diagnostics through the combination of targeted re-
sequencing and whole genome sequencing may finally resolve these issues [99]. 
In conclusion, ADPKD is associated with a low level of genetic heterogeneity, with two genes 
showing a high degree of penetrance and accounting for the vast majority of cases.  However, 
PKD1 especially exhibits extreme allelic heterogeneity, with many hundreds of mutations 
distributed across a large and highly repetitive gene.  At a population level these equate to 
many rare variants conferring a high risk of ESRD.  Investigation of the overlap with other 
ciliopathies has revolutionised our understanding of that structure, and suggested possible 
therapies.  These ciliopathies also provide a clear example of how variants affecting multiple 
genes within a related pathway can combine to modify the overall phenotype. 
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1.6.02 Von Hippel Lindau disease 
The most common cause of inherited renal cancer is von Hippel–Lindau (VHL) disease (MIM 
193300), a dominantly inherited familial cancer syndrome caused by mutations in the VHL 
tumour suppressor gene.  It was named after Eugene von Hippel, who described angiomas in 
the eye in 1904, and Arvid Lindau, who described angiomas of the cerebellum and spine in 
1927.  The incidence of VHL disease is approximately 1 per 36000 live births, with similar 
prevalence in both genders and across all ethnic backgrounds [100, 101].  Most patients with 
VHL disease have a positive family history, but de novo VHL mutations and mosaisicm are not 
uncommon.   
The most frequent manifestations of VHL disease are retinal and central nervous system 
haemangioblastomas, renal cell carcinomas, and phaeochromocytomas.  These are commonly 
multiple and develop at a younger age than similar sporadic tumours in the general 
population.  Patients may develop other tumours, such as endolymphatic sac tumours, and in 
addition to tumours, patients develop multiple cysts of the kidney and other organs including 
the pancreas [101-107].   
Diagnosis of von Hippel-Lindau disease is based on clinical criteria or genetic testing [108, 109]. 
Unlike ADPKD, mutation analysis is recommended to make a definitive diagnosis and has 
become near universal [110].  The VHL gene has 3 short exons, and gives rise to a 4.5 kb mRNA 
with a long 3’ untranslated region.  Direct sequencing is the gold standard for detecting small 
germline VHL mutations [111]. “Mutation negative’’ patients should subsequently be screened 
with techniques capable of identifying gene deletions [112].  Mutation screening should also 
be considered in individuals with apparently sporadic cerebral and retinal haemangioblastoma 
because these are rare in the general population [113-117].   
Unlike ADPKD, autosomal dominant VHL disease has a pleiotropic phenotype.  Early reports 
noted that in different pedigrees there were differing patterns of inheritance of 
haemangioblastoma, phaeochromocytoma, and CCRCC.  This observation implied that 
different mutant alleles at the VHL locus were associated with distinct tumour suppressor 
capabilities [118].  There are now more than 350 distinct mutations in the VHL gene that have 
been linked to familial VHL disease [119].  The clinical phenotype is categorised on the basis of 
incidence of haemangioblastoma, CCRCC and phaeochromocytoma, as shown in Table 1.2.  
Striking aspects of the phenotype-genotype relationship are that loss of function alleles carry a 
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low risk of phaeochromocytoma (Type 1 disease), while some specific missense mutations 
predispose to phaeochromocytoma without other manifestations (Type 2C disease). 
Category Risk of 
Phaeochromocytoma 
Risk of 
Haemangioblastoma 
Risk of Renal Cell 
Carcinoma 
1 Low High High 
2A High High Low 
2B High High High 
C Yes No No 
Table 1.2 Classification of VHL families on the basis of tumour risk 
High risk: tumour type observed in over 50% affected individuals. Low risk: tumour type observed in less than 5% 
of affected individuals.  Yes: tumour type observed in all affected individuals. No: tumour type not observed in 
affected individuals. 
All the clinical manifestations of VHL disease involve somatic inactivation of the wild-type VHL 
allele, in accordance with Knudson’s ‘two-hit’ mechanism of tumour suppression [120].  This is 
similar to what is hypothesised to occur in ADPKD, but the resultant proliferative abnormalities 
lead to tumour formation not renal failure.  In the kidney, the earliest, premalignant lesions in 
VHL patients are almost always in the distal renal tubule, suggesting that the tumours arise in 
this part of the nephron [121, 122].  VHL mutations linked to renal cancer (Type 1 and 2B) 
show complete loss of the ability to regulate HIF, consistent with HIF activation being critical in 
tumourigenesis.  Although the mechanism by which HIF activation leads to tumour formation 
is not fully understood, it occurs as a very early genetic event 
There is evidence that mutations in genes besides VHL can give rise to tumours similar to those 
seen in VHL disease [104, 123].  This may be analogous to the many ciliopathy genes than can 
give rise to a cystic renal phenotype [28, 124].  The VHL gene product has multiple roles, but 
the best characterised is the proteolytic degradation of the alpha subunit of the hypoxia 
inducible factor, HIF [125].  Mutations in other genes that affect this pathway, such as HIF2A, 
fumarate hydratase (FH), or succinate dehydrogenase subunit D (SDHD), have been shown to 
cause paraganglionomas [126] as well as other kinds of kidney cancer. 
In addition to the association with VHL disease, the VHL gene has more recently been 
associated with congenital erythrocytosis syndromes.  Interestingly, erythrocytosis is 
associated with C-terminal VHL mutations and it is inherited in an autosomal recessive fashion.  
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Moreover, mutations in HIF2A have also been associated with autosomal dominant familial 
erythrocytosis [127, 128].  These cases provide a clear link between VHL and systems-level 
response to hypoxia, showing that it plays an important role in determining a number of 
physiological characteristics in humans, including red blood cell production, respiratory rate 
and pulmonary vascular tone [129, 130]. 
 
1.7  Other mechanisms for genetic disease 
The question of penetrance is important in any discussion of genetic disease.  Most mutations 
are associated with significant phenotypic variability, both between individuals and between 
families.  This has been shown in highly penetrant conditions, such as ADPKD, as well as in 
recessive conditions such as nephrotic syndrome due to homozygous mutations in 
phospholipase C epsilon 1 (PLCE1) [131].  The nature and influence of most of the modifier loci 
that modulate the clinical phenotypes of Mendelian traits remain unknown [132].  Conversely 
we know that heterozygosity for a Mendelian disorder can act as a risk factor for complex 
disease [133].   
Digenic or oligogenic inheritance has been suggested for ciliopathies, such as Bardet-Biedel 
syndrome, where the clinical phenotype can be related to the overall mutational load [86].  It 
has also been suggested for patients with nephrotic syndrome carrying heterozygous alleles in 
nephrin (NPHS1) and podocin (NPHS2), as well as for these alleles conferring an increased risk 
of proteinuria in the wider population [134, 135].  The modification of a single gene by one or 
more genes is a phenomenon known as epistasis.  This interaction may explain some of the 
missing heritability in association studies, since the effects of interaction are often 
multiplicative, whereas the method for calculating heritability in GWAS is additive [58]. 
In addition to simple nucleotide polymorphisms, larger copy number variants represent a 
significant source of variation within the human genome.  Re-sequencing has shown that 
fragments of DNA are deleted, duplicated, and inverted and that these genetic 
rearrangements may alter the number of copies for a particular gene [136].  We have seen 
how the existence of pseudo-genes is a source of mutations in PKD1 through the process of 
gene conversion.  Copy number variation may also play a role in the development of 
nephronopthisis [136].  More recently, an internal duplication in the complement factor H-
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related 5 (CFHR5) gene was found to cause complement-mediated glomerulonephritis in the 
Greek Cypriot population [137].  Lastly, it has been shown that structural rearrangements of 
the genome increase the risk of developing complex diseases [138-140].  These structural 
alterations may or may not be tagged by SNPs in linkage disequilibrium, and can be hard to 
detect by next generation sequencing with short read lengths [59]. 
Alternatively, there is the possibility that some of the missing heritability unexplained by 
GWAS studies can be explained by mechanisms other than Mendelian chromosomal 
inheritance.  For example, some traits can be inherited through the maternal line due to 
sequence changes within the mitochondrial genome; so-called extra nuclear inheritance.  
Mitochondrial mutations have been implicated in a range of complex diseases, including 
diabetes, neurocognitive disorders and even aging [141].  A number of complex mitochondrial 
disorders, including Leigh, MELAS and Kearns-Sayres syndromes, incorporate a renal 
phenotype [142].  Increased prevalence of SNPS and deletions, as well as a reduction in 
mitochondrial DNA copy number has been reported in patients with ESRD compared to 
healthy controls [24].  While the mitochondrial genome is small and easily sequenced, the 
issues of variable penetrance, heteroplasmy, nuclear-mitochondrial interaction, and high 
mutation rate of mitochondrial DNA make this area challenging to study [143]. 
According to latest estimates there are barely 20,000 protein-coding genes in the human 
genome, with even fewer disease phenotypes reported (OMIM).  While protein coding 
sequences comprise less than 1.5% of the human DNA, current analysis suggests that 80% of 
the entire human genome is either transcribed, binds to regulatory proteins, or is associated 
with some other biochemical activity [2].  Most gene discovery using next generation 
sequencing has been focused on the exome, and yet the majority of SNPs identified by GWAS 
are intronic.  While it remains technically challenging to demonstrate, it is probable that some 
non-coding variants will have sufficient penetrance to cause Mendelian disease. 
In addition to non-coding variants, there is the possibility that variation in epigenetic 
regulation of gene expression may contribute to heritable renal disease.  Many epigenetic 
studies have focused on male-female differences and in several complex diseases, including 
renal disease, females are relatively protected against disease progression compared to males 
[144].  Epigenetic regulation of X chromosomal genes, such as the angiotensin-converting-
enzyme 2 gene (ACE2) which protects against renal damage, could be hypothesised to 
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influence disease outcome [145].  Similarly, changes in gene specific methylation have been 
reported in renal disease compared to controls [146, 147]. 
Lastly, some portion of heritability will be due to gene-environment interactions.  These are 
almost impossible to study in the outbred human population, especially in the huge 
multinational consortia employed in large GWAS studies.  One approach is to use population 
isolates for their genetic and environmental homogeneity.  Sibling-pair studies can also reduce 
the effect of these factors, and are increasingly attractive as the cost of next generation 
sequencing continues to fall.  Alternatively, inbred rodent strains provide a simplified genetic 
platform from which to study non-Mendelian and environmental inheritance patterns. 
 
1.8  Conclusions 
In conclusion, genetic factors play a significant role in the aetiology of kidney disease.  These 
genetic factors exist on a continuum from rare variants that cause Mendelian disease to 
common variants that confer only small effect size (Figure 1.1).  The major finding from renal 
GWAS studies is that most of the heritability of kidney disease is not accounted for by common 
variants (of any effect size).  Consequently, this heritability must be due to the existence of 
many lower frequency variants.  This thesis sets out to study these rare variants. 
One approach to identifying causative mutations is to study population isolates that are 
enriched for the phenotype in question.  In the third chapter I have studied the Turkish-Cypriot 
population of Northern Cyprus, which has a high incidence of unexplained renal disease.  
Familial renal disease is common in this population, and the clinical presentation of renal 
disease is often different to that seen in Western Europe.  This suggests that novel genetic 
factors or disease pathways may be involved. 
I have studied a number of families where multiple individuals have kidney disease and had 
progressed to ESRD.  Technological advances have greatly simplified the identification of novel 
genetic variants in such cases.  The question therefore becomes one of identifying the 
pathogenic mutation amongst a long list of private variants.  This process may be achieved 
through the use of pedigree information, as well as bioinformatic filtering and an 
understanding of the biological pathways affected, as demonstrated in chapter four. 
Introduction 
Page | 50  
 
In the fifth chapter I have studied a family in which I show that kidney disease is associated 
with a novel mitochondrial variant.  Mitochondrial disease is a source of non-chromosomal 
inheritance, and has recently been implicated in a range of complex diseases.  The regulation 
of the transcription and translation of mitochondrial DNA requires a complex interaction with 
the nuclear genome.  Moreover the mutational load and penetrance often show much greater 
variability than is seen in nuclear encoded genetic disorders. 
Lastly, I have taken a single distinctive phenotype and related it to perturbations in the well-
studied oxygen sensing pathway mediated by VHL and HIF.  VHL mutations exhibit a high 
degree of allelic heterogeneity and there is a strong association between different mutations 
and quite different clinical phenotypes.  This may reflect the ability of VHL to interact with and 
regulate a wide range of biological partners.  It is therefore possible to use distinctive 
phenotypes to uncover novel cellular pathways. 
Throughout this thesis I have used a variety of patient-derived cell lines to study the effect of 
pathogenic variants in vitro.  Beyond the desire to explain missing heritability, these studies 
are the first step toward an improved understanding of biological mechanisms and the 
discovery of novel cellular pathways.  The knowledge gained through human genetic studies 
will have a major impact on medical sciences.   These pathways have the potential to provide 
new therapeutic and preventative strategies for a common and increasingly expensive 
worldwide health problem.  Ultimately, rare variants with high enough penetrance are likely to 
form the basis of personalised genomic medicine in the 21st Century.   
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2.1  Ethical approval 
Collection of samples in Northern Cyprus was approved by the ethics committee of Lefkosa 
Burhan Nalbantoğlu State Hospital.  All participants provided informed consent in writing, in 
accordance with the Declaration of Helsinki (Appendix A).  
Collection of samples in the UK was approved by the ethics committee of the National 
Research Ethics Service (NRES) Committee London – West London.  All participants provided 
informed consent in writing, in accordance with the Declaration of Helsinki (Appendix A).  
Collection of fibroblasts from human volunteers was approved by Newcastle University for the 
MRC Neuromuscular Centre BioBank. 
 
2.2  Recruitment of subjects 
All individuals presenting with end-stage renal disease in Northern Cyprus were invited to take 
part in our study ‘Investigation of familial renal disease in Turkish Cypriot kindreds’ (chapter 3).  
Informed consent was obtained in writing by Dr Deren Oygar or Professor Guy Neild, and blood 
samples collected by those two with the assistance of Meral Yükseliş.  Control DNA from the 
University College London Hospital haemoglobinopathy genetics service was provided by Dr 
Mary Petrou.  21 DNA samples were sent to me from Cyprus along with pedigree information 
for family 1508 (chapter 4).   
Individuals were recruited in the UK in accordance with the approved protocol of the Genetic 
Investigation of Kidney Disease (GIKD) study.  Briefly, those individuals who had already 
volunteered were asked to inform other family members about the study, and to ask them to 
contact our research team if they were interested in taking part.  When these new subjects 
made contact, the study was explained in more detail and a time arranged to meet with them.  
At this subsequent meeting I would then take a full medical history and obtain informed 
consent to take a sample of blood or saliva for genetic analysis.  I would also obtain their 
consent to get any other relevant medical details from their GP or hospital consultant 
(Appendix A). 
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2.3  Demographic comparisons 
2.3.01 Study population 
The study discussed in chapter 3 was conducted at Nicosia State Hospital in Northern Cyprus. 
Nicosia State Hospital is a multi-specialty tertiary care hospital, and provides renal services to 
the whole of Turkish administered Northern Cyprus (TRNC). All citizens of TRNC are entitled to 
free RRT, regardless of ethnicity. All patients with symptomatic chronic kidney disease (CKD) 
from within this population present either through the village practitioners, private hospitals 
or directly to Nicosia State Hospital. Details of every individual admitted with acute or chronic 
renal failure in the last decade were collected with a unique identifier number, thus preventing 
any duplication of records or redundancy of referrals. ESRD was defined as chronic renal 
disease with an eGFR of <10 ml/min/1.73 m2; but patients with diabetic nephropathy often 
started RRT with eGFR<15 ml/min/1.73 m2. 
 The most recent census of the TRNC population in 2006 showed that of 178,031 de jure 
citizens, 120,007 were born to parents who were both themselves born in Cyprus, providing an 
effective measure of the size of the ethnic Turkish-Cypriot population that has been applied 
throughout chapter 3 [148]. 
2.3.02 Variables 
 Basic demographic data (age at ESRD, sex, ethnic group, and probable diagnosis) were 
recorded for all patients receiving RRT at day 1, and again after 90 days on the renal 
replacement programme. Diabetic nephropathy was defined as ESRD in the presence of 
diabetes without evidence of an alternative diagnosis. Family history of ESRD was defined as a 
first or second degree relative with ESRD. 
2.3.03 Data Sources for International Comparisons 
 European data was taken from the European Renal Association – European Dialysis and 
Transplant Association (ERA-EDTA) Registry report for 2008 [15]. Additional data for Greece, 
Turkey, and England were taken from the Hellenic Renal Registry (Dr GA Ioannidis personal 
communication), the National Haemodialysis, Transplantation and Nephrology Registry report 
of Turkey 2008 [149], and the 2008 Renal Registry Report [77]. The denominator population 
for international comparisons was calculated from the relevant national statistics [150, 151].  
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2.4  DNA Procedures 
2.4.01 DNA extraction 
DNA was extracted from peripheral blood, using the QIAamp DNA Blood Mini and Midi Kits 
(Qiagen) spin protocol, and from saliva, using the Oragene saliva kit (DNA Genotek, Ottawa, 
Canada).  DNA was extracted from cultured cells using the QIAamp DNA Blood Mini Kit 
(Qiagen) spin protocol. 
DNA was extracted from fresh urine after the urine was collected into 50 ml falcon tubes and 
centrifuged at 3000 g for 10 minutes at 4°C.  The cell pellet was washed x1 in phosphate 
buffered saline, centrifuged again, and then re-suspended in 425 ul DNA extraction buffer 
(145.5 ml ddH2O, 1.5 ml Tris pH 8.0, 3 ml 1M NaCl, 1 g SDS) to which 10 ul proteinase K (10 
mg/ml), 10 ul DTT (1M), and 1 ul RNAse A (25 mg/ml) had been added.  Digestion was 
performed at 55°C for 3 hours with regular agitation.   
Phenol-chloroform extraction was then performed on the digested cell pellet by the addition 
of an equal volume of phenol/chloroform/isoamyl alchohol (35:24:1 pH 8.0, Sigma), mixing for 
5 minutes, followed by centrifugation at 130,000 rpm.  After 3 such extractions, the aqueous 
phase was again removed and the DNA precipitated by addition of 1/10th volume of 3M 
sodium acetate pH 5.2 (Fisher chemicals), 1 ul glycogen (20 ug/ul, Invitrogen), and 2 volumes 
of 100% ethanol.  The DNA was left to precipitate at -20°C overnight, then pelleted by 
centrifugation at 130,000 rpm for 15 minutes at 4°C, followed by washing in 70% ethanol.  
After drying in air for 10 minutes, the DNA pellet was re-suspended in 100 ul Tris-EDTA buffer 
(Sigma). 
2.4.02 Whole genome sequencing 
DNA was extracted from peripheral blood, using the QIAamp DNA Blood Midi Kit (Qiagen) spin 
protocol.  A total of 5 ug was adjusted to 75 ng/ul and integrity confirmed by running on a 
0.8% agarose gel (Sigma).  Samples were loaded on to a custom 96-well plate and shipped on 
dry ice to Complete Genomics (Complete Genomics Inc., CA).  Sequence information was 
returned to us in the form of BAM files on a 2 terabyte hard drive. 
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2.4.03 Amplification Refractory Mutation System (ARMS) PCR 
Gene Direction Temp Sequence 
COL4A3 G871C Inner forward 68-58 CAGGTCATCAAGGTGAAATGGGACCACCGT 
 Inner reverse TCCCGGATTTCCTGGATATCCTCTTTGGCC 
 Outer forward TCGCCCCACTGCAATCCAGCCTAGAAGA 
 Outer reverse CCTGCACCATGGCCCCTGGTTTCTTACA 
COL4A3 G1334E Inner forward 68-58 GATTTCTAGGATCCATTGGACCTCCCGA 
 Inner reverse AGGTGGTCCTTTTGGCCCAATTGTTC 
 Outer forward CCCAGTGACATGCCAAAACCTATGTGAA 
 Outer reverse CCTGGGCTTCCTGGAAGGGAGATAATCT 
COL4A4 3854delG Inner forward 68-58 GCTAAAAGGGGAGAGAGGAGACCCTGTGA 
 Inner reverse AGGACCTGGAGGAGAGATTCCTGGGCTACA 
 Outer forward ATCACCACTGCAACCAGTTGTTGGTGTC 
 Outer reverse GGACCAGGTGGTCCTGAACTCCCTAAGA 
GRK5 Inner forward 68-58 CTCTGCGGCTTAGAAGACCTCCAACA 
 Inner reverse TCCACTCACCGGTAGACGGTGTTCTAAC 
 Outer forward GATCCTGAGGAGGGAAGTGGAAGTGAGT 
 Outer reverse GCTTCCTGGAGTGGAAAGTCTGTCTGAC 
DMBT1 Inner forward 72-63 CTGGCTCACCCACAACTGTGGCCATCAC 
 Inner reverse CACCTGAGCAGATGACACCAGCGTCTTCACT 
 Outer forward ACTTGGGTGGAGTAGGACATCACTGCTTCT 
 Outer reverse TCCTAAGTGACCACAGGAACACTAGGCAGT 
INPP5F Inner forward 65-54 AGGCTAGTCAGGAAAGAAATCAAATCAC 
 Inner reverse GATTGGGTTTCATTTGAAACTTGATAGC 
 Outer forward ATAGTAGCGTTCATGCTCCTTCAGAGAT 
 Outer reverse CTCTGAAGGAGAAGGAGTTACATGAAGC 
METTL10 Inner forward 68-58 ATGAGCTCGGGCGCTGACGTCG 
 Inner reverse GCCACCGCAGCGCCACCTCT 
 Outer forward GCTCTGCCTGTGCCCCGTCTCTATGG 
 Outer reverse CCTGCCCAGCGTCACACTCACTGCT 
DHX32 Inner forward 68-58 GTTGACACAGGGGATAGGTGATCAAC 
 Inner reverse TGAAAGTAAGGACATTCTACAGCAAGGAA 
 Outer forward GTCATGTATCTCCCATATCCAGCAGTTC 
 Outer reverse ACATAATGTTTGGTGTCTCTCACCACCT 
PCDH15 Inner forward 65-54 ATGCCTGCCGAGAAAATTAAGTCGTC 
 Inner reverse ACACTGTCGTTGTTGATAGCTGTGTCAAAC 
 Outer forward CTCCTCCCTCTCCTCCTTCTATCCCTCT 
 Outer reverse CCCTTGTTTTGTTCAGATGTGATTTCCA 
Table 2.1 Primers used for tetra-primer ARMS PCR 
Primers for tetra-primer ARMS were generated using the genomic DNA sequence available 
(GRch37) from Ensemble (http://www.ensembl.org/Homo_sapiens/Info/Index) and the 
software available from the University of Southampton 
(http://primer1.soton.ac.uk/primer1.html) [152].  PCR analysis was performed using a G-Storm 
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PCR machine (Gene Technologies Ltd., UK), with a touchdown program over the temperature 
range and the primers indicated in Table 2.1.  Products were run out on a 3% agarose gel and 
imaged using a bench-top UV transilluminator (UVP Ltd., UK). 
2.4.04 Sanger Sequencing 
The genotype of all cell cultures and specified individuals was confirmed by Sanger sequencing, 
following PCR amplification using the primers indicated in Table 2.2.  PCR products were 
sequenced at the UCL Woolfson Institute for Biomedical Research using their Applied 
Biosystems kit, following standard manufacturer’s protocols.  Sequence traces were viewed on 
Geospiza’s FinchTV and manually compared to the publically available sequence on Ensembl. 
Gene Direction Sequence 
COL4A3 exon 32 Forward GTTAGTAGGGGAAAGCATTTGTGG 
 Reverse CTATGTACAGTTGACAGAGCCACCT 
Mitochondrial D4 Forward GCCACAGCACTTAAACACATC 
 Reverse TGCTGCGTGCTTGATGCTTG 
VHL exon 2 Forward TCCACCATGGTAGCAGAAAGGGCA 
 Reverse AGCCCAAAGTGCTTTTGAGACACC 
VHL exon 3 Forward CCTTGTACTGAGACCCTAG 
 Reverse GCTGAGATGAAACAGTGTA 
Table 2.2 Primers used for Sanger sequencing 
2.4.05 HSP1 sequencing 
DNA samples were a kind gift of Professor Neil Sheerin.  Amplification of the mitochondrial D4 
region (including the HSP1 sequence) was performed using primers indicated in Table 2.2.  The 
PCR reaction (25 μl) was set up as follows: 0.65 μl of each primer pair (20 μmol/l), 3 μl DNA 
(200 ng/μl), 2.5 μl 10× PCR buffer, 2.5 μl DNTPs, 2.0 μl MgCl2, and 0.2 μl IMMOLASE
TM DNA 
Polymerase (5 units/μl; Bioline, UK). The reaction conditions were one cycle at 94°C for 10 min, 
followed by 30 cycles at 95°C for 45 sec, 60°C for 45 sec, and 72°C for 1 min, and finally 72°C 
for 10 min. The amplified fragments were purified using ExoSAP-IT (Affymetrix, CA) and then 
sequenced using a Big Dye Terminator cycle sequencing kit on an ABI Prism 377 DNA 
sequencer (Appied Biosystems). The sequence data were analyzed using the software 
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packages Factura and Sequence Navigator (Applied Biosystems), and were compared with the 
Cambridge sequence and MITOMAP (MITOMAP 1999). 
2.4.06 Quantification of mitochondrial DNA 
Relative mitochondrial DNA content was measured by expression of mitochondrial ND1 
normalised to nuclear B2M levels.  Real-time RT–PCR analysis was performed with SYBR green 
(ABgene, UK) using an Opticon2 Real-time PCR machine (MJ Research, Waltham, MA) and the 
DNA-specific primers indicated in Table 2.3.  
Gene Direction Sequence 
B2M (genomic) Forward GAATGAGCGCCCGGTGTCCC 
 Reverse TCCAAGCCAGCGACGCAGTG 
ND1 Forward GCCCCAACGTTGTAGGCCCC 
 Reverse AGCTAAGGTCGGGGCGGTGA 
Table 2.3 Primers used for the calculation of mitochondrial DNA copy number 
 
 
2.5  Informatic analysis  
2.5.01 SNP Genotyping 
1 ug of genomic DNA at 75ng/ul was used for SNP genotyping.  Individuals were genotyped 
using 300,000 single nucleotide polymorphism (SNP) markers with an average separation of 
6.1 kb on the Illumina CytoSNP 12 chip (Illumina, CA, USA).  Genotyping was performed at the 
automated, high-throughput system available at UCL Genomics. 
2.5.02 Linkage analysis  
Linkage analysis was performed on pedigrees using the easyLINKAGE Plus v5.05 graphical user 
interface for two-/multi-point linkage analysis [153], with analysis by GeneHunter [154] and 
SimWalk [155].  Pedigrees were confirmed using HaploPainter V.1.043 [156] and PedCheck 
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[157].  For calculation of parametric LOD scores a ‘rare dominant’ model was utilised, with 
disease allele frequency set to 10-4 and disease penetrance vector set to 1.0. 
2.5.03 Calculation of the minimal shared haplotype 
The minimal haplotype shared by 4 discrete pedigrees with the G871C mutation was 
determined using SNP genotype data.  Conflicting homozygosity was assessed in this genotype 
data, using a program written by Dr Daniel Gale and Dr Adam Levine at UCL.  I then 
determined the relative position of the boundary SNPs in centimorgans. 
2.5.04 SNP variant filtering 
The Complete Genomics data was filtered using CGAtools, annotated and filtered again using 
Excel.  Variations in the ‘All variations’ from the reference human genome at the linked loci 
was extracted from the master variants file using CGAtools (http://cgatools.sourceforge.net/). 
These variants were then annotated using Annovar 
(http://www.openbioinformatics.org/annovar/) and filtered to exclude variants that were 
intergenic; intronic (but not including splice site); synonymous or common (>0.5% allele 
frequency in 1000 genomes database). The remaining shared variants that are predicted to 
change amino acid sequences were considered candidate mutations. 
2.5.05 Analysis of pathogenicity 
Variants identified by whole genome sequencing (WGS) were analysed for pathogenicity using 
PyloP, Mutation taster, SIFT, and PolyPhen2.   Evolutionary conservation was assessed using 
the UCSC table browser tool to generate PhyloP scores across 46 vertebrate species 
(http://genome.ucsc.edu/cgi-bin/hgGateway).  The predicted effect of an amino-acid exchange 
was assessed using MutationTaster (http://www.mutationtaster.org/) [158], SIFT 
(http://sift.bii.a-star.edu.sg/) [159], and PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) 
[160]. 
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2.6  Tissue Culture procedures 
2.6.01 Creation of primary cell lines 
2.6.01.01 Dermal fibroblasts 
All fibroblast lines were created at the Rayne Institute at UCL.  4mm skin punch biopsies were 
performed under local anaesthesia using aseptic technique in the patient’s own home.  Skin 
wounds were secured with steri-strips and dressed.  The biopsy tissue was stored in complete 
DMEM supplemented with penicillin/streptomycin at room temperature.  Biopsies were 
collected from affected patients and normal controls on the same day and processed in 
parallel.  
Skin biopsies were divided into two equal portions.  One portion was digested with 2 ml pre-
warmed 2.5% (10x) Trypsin (Sigma) for 15 minutes at 37°C with occasional agitation in a 15 ml 
Falcon tube.  This sample was then centrifuged at 400 g for 5 minutes at room temperature, 
and the supernatant removed.  The tissue was further digested with 2 ml pre-warmed 
collagenase at 1 mg/ml (Sigma, C1889) at 37°C with occasional agitation.  After 90 minutes the 
collagenase was neutralised with 10 ml warmed complete Ham’s F10 media, and the samples 
centrifuged.  The samples were washed once with 10 ml complete media, before being plated 
out in T25 flasks in 5 ml Ham’s F10 media (Sigma), supplemented with 10% foetal bovine 
serum (FBS), 5mM of L-glutamine (Gibco), penicillin/streptomycin antibiotics (Gibco), 1 mM 
pyruvate (Gibco), 50 ug/ml uridine (Sigma), 2.5 ug/ml amphotericin B (Sigma), and 50 ug/ml 
gentamicin (Sigma) (Complete media).  The other portion was cut into small pieces with a 
scalpel and fixed to a T25 flask by air drying for 15-30 minutes.  4 ml complete Ham’s F10 
media was then added to the flask, taking care not to re-suspend the pieces of tissue. 
Following satisfactory growth, cells were maintained in DMEM cell culture medium 
(Invitrogen), supplemented with 10% foetal bovine serum (FBS), 5mM of L-glutamine (Gibco), 
penicillin/streptomycin antibiotics (Gibco), 1 mM pyruvate (Gibco), and 50 ug/ml uridine 
(Sigma).  Fibroblasts were cultured in standard culture flasks (Nunc) at sub confluent density, 
split 1:3 – 1:5 twice a week, and kept in a humidified incubator at 37°C gassed with ambient air 
plus 5% CO2.  All lines were confirmed free of mycoplasma infection. 
Cells were treated with ethidium bromide (Sigma-Aldrich, St Louis, MO) at 50 ng/ml for a 
minimum of 1 week to produce ‘rho zero’ control cells. 
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2.6.01.02 Urothelial cells 
Urothelial cell lines were cultured according to established protocols [161].  Briefly, urine 
samples were collected in sterile 500 ml glass bottles in the patient’s own homes and 
transferred to the laboratory at room temperature.  They were then divided into 50 ml 
aliquots inside a tissue culture hood and centrifuged at 400 g for 10 minutes at room 
temperature.  The supernatant was discarded and the cell pellets pooled and washed in 37°C 
phosphate buffered saline (Gibco) containing 2.5 ug/ml amphotericin B (Sigma), 50 ug/ml 
gentamicin (Sigma) and penicillin/streptomycin.  This was centrifuged at 400 g for 10 minutes 
at room temperature, and washed a second time, if the pellet was especially large.  The 
supernatant was again discarded, and the remaining 0.2 ml of sample was re-suspended in 
primary medium. 
Urothelial cell primary medium contained a 1:1 mix DMEM (Gibco) and Ham´s F12 (Sigma), 
with 10 % fetal bovine serum, REGM™ SingleQuots™ Kit (Lonza), 2.5 ug/ml amphotericin B 
(Sigma), 50 ug/ml gentamicin (Sigma), and penicillin/streptomycin.  The cell suspension was 
divided between the wells of a 12-well plate that had been coated with L-gelatine (Gibco).  
Over the next few days a few add hundred μl of primary medium was added to each well.  
Subsequently the primary medium was changed to Renal Epithelial Basal Medium (REBM™, 
Lonza, Cologne) to which SingleQuots™ supplements and growth factors (hydrocortisone, 
hEGF, FBS, epinephrine, insulin, triiodothyronine, transferrin and gentamicin/amphotericin-B; 
Lonza, Cologne) had been added as per the manufacturer’s instructions.   
Visible colonies appeared routinely after 3-6 days.  After visual inspection to confirm epithelial 
morphology, cells were mobilised when confluent with 0.25% trypsin containing 1 mM EDTA.  
Urothelial cells were cultured in standard culture 6-well plates (Nunc) coated with L-gelatine 
(Gibco) and harvested after 1 or 2 passages. 
2.6.01.03 Lymphoblastoid cells 
The first lymphoblastoid cell lines (LCL) were created at the Institute of Child Health at UCL by 
Dr Jasper de Boer.  Blood was collected from the index patient (Mt1) and normal controls.  
Control lymphocytes from four healthy donors were pooled to give four control lines (C1, C2, 
C5, C6) thus containing the genetic information from 12 individuals.  The second LCL lines were 
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created at the Rayne Institute at UCL by me, using blood collected from the index patient 
(Mt2) and two further normal controls (C3, and C4). 
Mononuclear cells were isolated from peripheral blood by Ficoll gradient centrifugation and 
re-suspended in RPMI-1640 culture medium with 20% fetal calf serum (FCS), 2mM L-Glutamine 
and 1% Penicillin-Streptomycin.  Epstein Barr virus (EBV) supernatant was added, followed 24 
hours later by cyclosporine A (10µg/ ml), with acyclovir (100µM) administered 14 days later.  
Following satisfactory growth, cells were maintained in RPMI 1640 cell culture medium 
(Invitrogen), supplemented with 10% fetal bovine serum (FBS), 5mM of L-glutamine (Gibco), 
and penicillin/streptomycin antibiotics (Gibco).  Lymphocytes were cultured in standard 
culture flasks (Nunc) at a density of 1x106/ml, and kept in a humidified incubator at 37°C 
gassed with ambient air plus 5% CO2.   
2.6.02 Cell culture techniques 
2.6.02.01 Seahorse analysis 
Cells were plated at in the proprietary XF24 cell culture micro-plates 24 hours before analysis 
(Seahorse bioscience, MA).  After counting, the cells were left to attach in 100 ul medium for 5 
hours, before this volume was made up to 250 ul. Analysis plates were calibrated with 1 ml XF 
calibrant fluid at 37°C in a CO2-free incubator for a minimum of 4 hours prior to use.  
Immediately prior to analysis, the culture media was aspirated, the cells were washed with 1 
ml seahorse assay media (Bicarbonate-free DMEM, Sigma, made up as for standard culture 
with antibiotics, glutamine, pyruvate and uridine), and the wash was replaced with 600 ul 
seahorse assay media.  
The measurement of mitochondrial function was performed with the standard mix-wait-
measure cycle of 3 minutes-2 minutes-3 minutes.  4 untreated baseline cycles were followed 
by injection of oligomycin, 3 cycles then injection of FCCP, 3 cycles then injection of 
actinomycin, then a final 3 cycles.  Compounds were added at the concentrations indicated 
below. 
Materials and Methods 
Page | 62  
 
2.6.02.02 Creation of RCC-10 cell lines containing VHL mutant constructs 
The VHL mutant constructs were created by Dr Daniel Gale at UCL.  Point mutants were 
generated in wild-type VHL cDNA in the pCMVR vector using Quikchange (Stratagene).  Each 
mutant was confirmed by sequencing.   
VHL-null RCC-10 cells [162] cells were transfected by Dr Daniel Gale with 2µg of plasmid DNA 
using Lipofectamine 2000 (Invitrogen). Stably transfected cell pools were obtained by geneticin 
(G418, Invitrogen) selection.   
2.6.02.03 Experimental reagents 
Hypoxic experiments were performed using a humidified hypoxic workstation (InVivo2 1000, 
Ruskinn technology, Cardiff, UK) with 1% ambient 02 and 5% CO2 for 16 hours.  Cells were 
treated with the reagents listed below for 16 hours to stabilise HIF-1a Table 2.4.   Cells were 
treated with proteasomal and protease inhibitors listed below for 3 hours. 
Reagent Company Working concentration 
Oligomycin Sigma-Aldrich 5 ug/ml 
FCCP Sigma-Aldrich 7.5 ug/ml 
Antimycin A Sigma-Aldrich 4 ug/ml 
Cycloheximide Sigma-Aldrich 50 ug/ml 
Desferrioxamine (DFO) Sigma-Aldrich 25 uM for 16 hours 
Dimethyloxalylglycine (DMOG) Frontier Scientific, Logan, UT 1 mM for 16 hours 
MG-132 Merck Chemicals Ltd, UK 10 uM for 3 hours 
ALLN Roche Molecular 
Biochemicals 
50 uM for 3 hours 
MG-115 Calbiochem, UK 30 uM for 3 hours 
PD150606 Calbiochem, UK 20 uM for 3 hours 
Caspase 3 Inhibitor II Calbiochem, UK 50 uM for 3 hours 
Cathepsin Inhibitor I Calbiochem, UK 50 uM for 3 hours 
Table 2.4 Compounds used in cell culture experiments 
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2.6.02.04 Lentiviral-mediated knockdown 
Lentiviral transduction particles were obtained from the MISSION shRNA Library (Sigma 
Aldrich).  These particles are produced from a library of sequence-verified lentiviral plasmid 
shRNA cloned into the pLKO.1-puro vector, and express shRNA on the U6 viral promoter.  LCL 
cells were infected at an MOI of 1 in the presence of polybrene (hexadimethrine bromide) at 6 
ug/ml (Sigma-Aldrich, St Louis, MO), and then spun at 1800 RPM for 45 minutes at 25 degrees 
immediately following addition of virus.  Infected cell pools were selected for puromycin 
resistance (Sigma-Aldrich), and expanded over 3-4 weeks until suitable numbers were 
obtained.   
Lentiviral particles derived from five VHL-specific shRNA were assessed by RT-PCR and western 
blot and the one with greatest knockdown was selected.  This shRNA targeted the end of VHL 
exon 2, and contained the sequence: 
5’-CCGGTATCACACTGCCAGTGTATACCTCGAGGTATACACTGGCAGTGTGATATTTT TG-3’. 
The control lentiviral particles were derived from the same pLKO.1-puro vector and contained 
an shRNA sequence targeting Luciferase, Photinus pyralis (GenBank Accession No. M15077). 
The Luciferase shRNA Control Particles are useful as a positive knockdown control in 
experiments using cell lines expressing firefly luciferase but were used in this case as a 
nonsense control since LCL cells do not contain this enzyme. 
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2.7  Western Blotting  
Cellular extracts were harvested using 8M urea buffer with 1/100th volume PMSF (Fluka) [125]. 
Protein levels were quantified using BCA Protein Assay (Pierce) measuring absorbance at 
560nm on a Tecan GENios fluorescence reader.  Equal amounts of protein were mixed with 
1/8th volume loading buffer (12.5 ml 0.5M Tris pH 6.8 (Sigma), 10 ml glycerol (Sigma), 2 g 
sodium dodecyl sulphate (Sigma), 1.55 g dithiothreitol (Fluka), 0.25 mg bromophenol blue 
(Sigma), with deionised H20 to 50 ml).  Proteins were resolved on a polyacrylamide gel and 
transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore).  
Molecular weight standards (BioRad) were used to calibrate the molecular weights of proteins.  
After transferring, the membrane was incubated for one hour with 5% skimmed milk in Tris-
buffered saline containing 1% Tween 20 (Sigma) (TBS-T).  The membrane was then incubated 
with the primary antibody of interest, indicated in Table 2.5.  Then it was washed three times 
in TBS-T and incubated with the horseradish peroxidase (HRP) conjugated secondary antibody 
for 1 hour at room temperature.  After a further 3 washes in TBS-T, immunoreactivity was 
detected by chemiluminescence (ECL, GE Healthcare). Films were developed with a Photon 
SRX-101a film processor (Konica-Minolta). 
Antibody Origin Company Concentration 
VHL Ig32 Mouse BD Pharmigen 1:1000 
HIF-1a Mouse BD Pharmigen 1:1000 
HIF-2a Rabbit Abcam 1:1000 
Tubulin Mouse Sigma 1:5000 
ß-actin Mouse Abcam 1:10,000 
GLUT-1 Rabbit Alpha Diagnostics 1:1000 
MT-CO1 Mouse Abcam 1:1000 
VDAC1 Mouse Abcam 1:1000 
Cytochrome C Mouse BD Biosciences 1:1000 
Anti-mouse HRP Sheep GE Healthcare 1:5000 
Anti-rabbit HRP Goat Santa Cruz 1:5000 
Table 2.5 Antibodies used in western blotting 
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2.8  Real-time RT-PCR 
Total RNA was extracted from cells using RNABee (Biogenesis).  For the analysis of 
mitochondrial transcripts, RNA was then subjected to DNase digestion (Qiagen), followed by 
RNA cleanup using the RNeasy spin column (Qiagen). 0.5 - 1 ug of total RNA was retro-
transcribed using a first strand cDNA synthesis kit (Quanta Biosciences) according to the 
manufacturer’s instructions.   
Real-time PCR analysis was performed using SYBR green (ABgene, UK), using an Opticon2 Real-
time PCR machine (MJ Research, Waltham, MA) and the primers indicated in Table 2.6.  The 
PCR reactions were performed with the following cycling parameters: 95°C for 5 minutes; 40 
cycles of 94°C for 20 seconds, 60°C for 25 seconds, 72°C for 50 seconds; followed by melting 
curve analysis 65°C - 94°C.  All real-time PCR analysis results presented were normalised to 
levels of housekeeping gene expression.  
Gene Direction Sequence 
β-Actin Forward CCCAGAGCAAGAGAGG 
 Reverse GTCCAGACGCAGGATG 
E-cadherin Forward GACAACAAGCCCGAATT 
 Reverse GGAAACTCTCTCGGTCCA 
KRT7 Forward CTGCCACGCCCACTTCCCAG 
 Reverse CAGGCGCGGCTTCCTGTCAA 
L1CAM Forward AGTTGGAGGCCGCCATTGCC 
 Reverse CCAGGGCCAGCTTCACGCTC 
INPP5F Forward TCAGAGTGCACCCTCATTGATGC 
 Reverse AGGCCACGTAGTAGGCAGAGTT 
DHX32 Forward ACCCCTTTGATGGATTGCCA 
 Reverse TGAGGAACCTGAGCGCTCTTAC 
PCDH15 Forward AACCGCAAATCAGCTTTGAGTGAAC 
 Reverse ACTGGCCCAAGCAGATTTCAAAGA 
B2M (RNA) Forward GTGCTCGCGCTACTCTCTCT 
 Reverse TCAATGTCGGATGGATGAAA 
MT-CO1 Forward ACGTTGTAGCCCACTTCCAC 
 Reverse CATCGGGGTAGTCCGAGTAA 
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RNR1 Forward CTAGCCACACCCCCACGGGA 
 Reverse CGCGGTGGCTGGCACGAAAT 
ND6 Forward AGGTAGGATTGGTGCTGTGG 
 Reverse CCAATAGGATCCTCCCGAAT 
VEGF Forward TGCCAAGTGGTCCCAG 
 Reverse GTGAGGTTTGATCCGC 
P4HA1 Forward GCGACTGGGGGCTGAAGAGC 
 Reverse GCCTGGATGAGCCAAAGACTGGG 
PFKFB4 Forward CCAGGACTGTCCCCTCGGGG 
 Reverse CACACCCAGTGCCTCAGCCG 
VHL Forward TGCCATCTCTCAATGTTGA 
 Reverse CTCCGGACAACCTGGA 
Table 2.6 Primers used for gene expression analysis 
In the absence of previously published sequences, primers were designed using the nucleotide 
sequence (http://www.ncbi.nlm.nih.gov/nuccore) and the NCBI programme Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  They were designed to span an exon-exon 
junction to confer additional specificity where possible.  Primers were subsequently validated 
on sequential dilutions of template cDNA in order to determine efficiency of amplification, 
melt curve analysis, and assessment of PCR product by agarose gel electrophoresis. 
  
Materials and Methods 
Page | 67  
 
2.9  Analyses of data 
2.9.01 Population statistics 
The incidence of RRT in the Turkish-Cypriot population was averaged over eight consecutive 
calendar years (2004–2011). Age-standardised incidence rates were calculated using the 
Eurostat EU27 population figures [163]. All comparisons with other populations were made 
using data for chronic RRT; that is those still on RRT at 90 days. The emphasis of this report is 
on age-specific comparisons as these are not affected by age-referral biases. 95% confidence 
intervals were calculated, assuming a Poisson distribution for incidence rates. Statistical 
analysis was carried out using Stata version 11. 
2.9.02 Calculation of target mRNA transcript expression 
Target gene expression was calculated following the determination of the Ct values for each 
experimental sample.  A relative method of quantification was used as described by Pfaffl 
[164], with actin as the internal reference gene by equation 1: 
Equation 1: relative target gene expression = ΔCt target/ΔCt reference 
 In this equation, ΔCt target represents the difference in Ct values of the target gene between 
the calibrator sample and the experimental sample.  Similarly, ΔCt reference represents the 
difference in Ct values of the reference gene between the calibrator sample and the 
experimental sample. 
2.9.03 Analysis of data 
Once relative expression had been determined in all of the experimental samples, the results 
were formatted into the statistical software package GraphPad Prism version 4 (San Diego, 
CA).  Data were analysed using repeated measures ANOVA. 
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3.1  Introduction 
3.1.01 The genetics of island populations 
Renal disease is more common in certain racial and ethnic groups, which reflects a complex 
interaction of socioeconomic, environmental, and genetic factors [14, 15, 77, 165, 166]. These 
genetic factors are determined by differences in allelic frequencies between population 
groups.  Allelic frequencies are stable in large, isolated populations, where mating is random.  
Genetic equilibrium is maintained only in the absence of any appreciable rate of mutation, the 
absence of selection against any particular genotype, and no migration.  Factors that disturb 
these assumptions will result in changes to allelic frequency, and this is particularly seen in 
island populations. 
Island populations can be small, and therefore susceptible to the process of genetic drift.  
Genetic drift describes the change in frequency of a genetic variant due to chance events.  
Such chance events affect the reproductive fitness of carriers of a mutation independently of 
the effect of the given mutation.  When there are few copies of an allele, the effect of genetic 
drift is larger.  Moreover, populations derived from a small number of individuals as a 
consequence of some type of bottleneck will show reduced allelic diversity.  This is important 
because in large populations, high allelic diversity may significantly reduce the contribution of 
risk alleles. 
Reduced allelic diversity may also arise from non-random mating.  In human populations, non-
random mating may occur for a number of reasons: stratification, assortative mating, and 
consanguinity.  Stratification describes a population in which there are a number of subgroups 
that have remained genetically separate during modern times.  Assortative mating is often 
positive, and describes the choice of a mate because that individual possesses some particular 
trait, such as native language or skin colour.  Consanguinity also acts to increase the frequency 
of autosomal recessive disease 
Migration can change the allele frequency by the process of gene flow, defined as the slow 
diffusion of genes across a reproductive barrier.  In contrast to the reasons given for non-
random mating, gene flow usually involves a large population and a gradual change in gene 
frequencies.  In human populations, the barrier may be racial, ethnic, or cultural and not 
necessarily geographical requiring physical movement from one region to another. 
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3.1.02 Genetic disease on the island of Cyprus 
The island population of Cyprus is an interesting example for the renal geneticist.  Cyprus is an 
island country in the eastern Mediterranean that has been occupied by a series of historical 
powers, resulting in waves of successive migration.  The island was first settled in the 10th 
millennium BC by people from the Levant, and has experienced long periods of Greek rule 
from the 2nd millennium BC, and more recently Turkish rule following the Ottoman invasion of 
the island in 1571.  Genetic analysis of the Cypriot population suggests that, despite close 
historical ties, it is different to that of either Greece or Turkey [167, 168].  The distribution of 
thalassaemia alleles within the island also suggests that despite four centuries of cultural 
separation, the Greek and Turkish Cypriot communities show significant gene flow [169, 170].   
Turkish Cypriots form a distinct ethno-linguistic community centered on Turkish administered 
Northern Cyprus (TRNC).  The most recent census of this population in 2006 showed that 
120,007 de jure citizens were born to parents who were both themselves born in Cyprus, 
providing an effective measure of the size of the ethnic Turkish-Cypriot population [148].  
Recently, a number of inherited renal diseases have been described in the Greek Cypriot 
population [137, 171].  Given the evidence for significant gene flow between communities, it is 
probable that these conditions also exist in the Turkish-Cypriot population. 
Several mutations have shown significant geographical clustering in the Greek population of 
Cyprus, affecting medullary cystic kidney disease 1 (MCKD1), frataxin (FXN), pyrin (MEFV), and 
polycystin 2 (PKD2) [81, 172-174].  This may be due to the widespread practice of marrying 
within one’s close local geographical area, which is reflected in the well-known old village 
Cypriot saying:  
Παπούτσιν που του τόπου σου τζιας ευ κομμαδκιασμέυου. 
‘you had better obtain shoes from your own place, even though they may be full of holes’ 
[173]. 
This form of non-random mating is distinct from the consanguineous intermarriage seen in 
some cultures, but has a similar, although lesser, effect on perpetuating recessive and 
dominant mutations. 
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Complement factor H-related 5 (CFHR5) nephropathy, which affects between 1 in 1000 and 1 
in 8000 Greek-Cypriots, is caused by an internal duplication in the CFHR5 gene [137].  It is 
characterised by microscopic haematuria, renal failure, and C3 glomerulonephritis.  The extent 
of the shared haplotype in affected individuals suggests that the mutation arose in a common 
ancestor about 16 generations ago.  It is highly penetrant, and may be a significant cause of 
renal disease affecting inhabitants of the island and their descendants worldwide. 
Three specific mutations in collagen, type-IV, alpha-3 (COL4A43) and collagen, type-IV, alpha-4 
(COL4A4) show a similar founder effect in the Greek-Cypriot population [171].  These 
mutations were identified in 13 pedigrees that co-segregated microscopic haematuria, mild 
proteinuria, and variable degrees of renal impairment.  Renal biopsy gave a dual diagnosis of 
thin basement membrane nephropathy (TBMN) and focal segmental glomerulosclerosis 
(FSGS).  Whilst TBMN is often considered a benign condition, these mutations are associated 
with a significant risk of progression to end-stage renal disease.  Thus 19.6% of heterozygotes 
showed progression to ESRD over three decades of follow-up, and that proportion was 
increased to 46% in those aged over 51 years [171]. 
Given the selective pressure operating against pathogenic variants, single gene disorders are 
usually of recent evolutionary origin [78].  The population arising after a genetic bottleneck will 
exhibit reduced genetic diversity, due to the presence of a small number of founders.  In 
isolated populations, it is probable that all individuals carrying a given mutation will share a 
common founder.  It is possible to look at the ancestral haplotype with genetic markers to 
determine whether the variant was indeed shared by a common ancestor, and thereby to 
determine the age of the mutation. 
Single gene disorders are usually rare in the general population, and therefore unlikely to be a 
significant contributor to the prevalence of renal disease.  However, isolated populations that 
exhibit assortative mating may show increased frequency genetic disorders.  Such populations 
show increased frequencies of homozygosity, and consequently of recessive disease, as seen in 
the Finnish population and Old Order Amish and Hutterite communities [175].  The effect of 
selection pressure to remove these deleterious alleles may also be reduced if the disorder is 
manifest after childbearing age. 
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3.1.03 Renal disease in Cyprus 
Clinical observation suggested that the Turkish Cypriot population of Northern Cyprus 
exhibited a high incidence of renal disease.  We therefore designed a study to quantify the 
incidence and prevalence of renal disease, as measured by those on renal replacement therapy 
(RRT), in this ethnically-defined population disease [176].  The collection of accurate 
epidemiological data is of great importance for healthcare policy planning [14, 15, 77] and this 
is especially true for places where the infrastructure delivering RRT is improving, such as the 
island of Cyprus.  To put these data into context I examined comparable incidence data from 
Greece, Turkey, and the white population of England.  
The incidence of RRT is a complex end-point.  Renal disease has a wide range of aetiologies, 
and survival to ESRD and the provision of RRT is influence by a wide range of factors [9, 177].  
There are considerable differences in the incidence and prevalence of RRT within Europe.  
Registry data demonstrate a North-South gradient, with higher incidence of RRT and lower 
mortality around the Mediterranean [15, 178].  Importantly, data from the Eastern 
Mediterranean is more difficult to obtain, and information on primary renal disease is less 
robust [179].  In order to understand the aetiology of ESRD and chronic kidney disease, which 
affects many more people, it is important to determine the primary renal diagnosis [179].  
ESRD attributed to type 2 diabetes and hypertension continues to rise throughout the world, 
and this is increasingly true for countries such as Cyprus [15, 180-182]. 
An important, and probably unique, aspect of this study is that every single patient on RRT 
provided a DNA sample for research.  Because the Greek and Turkish communities share many 
genetic characteristics [169, 170], I initially undertook genetic testing for two conditions that 
have been identified in Greek Cypriots, CFHR5 nephropathy and thin basement membrane 
nephropathy due to the three mutations in COL4A3 and COL4A4 outlined above [137, 171].  
The aim of this analysis was to evaluate the contribution of these conditions to RRT incidence.  
The discovery of these conditions within the Turkish Cypriot population would further support 
the existence of gene flow between these populations and it would enable more accurate 
determination of the age of these mutations. 
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3.2  Results 
A total of 225 Turkish-Cypriot patients were maintained on renal replacement therapy beyond 
90 days during the study period (01/01/04 – 31/12/11).  More males than females started RRT 
(139 vs 86), but the age distribution was similar between the sexes (Table 3.1).    The average 
crude and age-standardised incidence rates at day 1 for this period were 311.4 and 456.9 per 
million population, respectively.  The Turkish-Cypriot case mix at 90 days included 36.0% with 
ESRD due to diabetic nephropathy, 29.8% with unknown diagnosis, and 3.6% with polycystic 
kidney disease (Table 3.2).   
 
Characteristic Category 
Turkish-Cypriot Turkish minority 
Number Percent Number Percent 
Gender 
Male 139 61.7% 43 64.2% 
Female 86 38.3% 24 35.8% 
Median age of 
adult population at 
ESRD in years 
(lower and upper 
quartile) 
Male 
63  
(54,69) 
 
51 
(39,61) 
 
Female 
64  
(52,74) 
 
58 
(49,66) 
 
Modality of RRT at 
presentation 
Haemodialysis 205 91.1% 60 89.5% 
Peritoneal dialysis 10 4.4% 5 7.5% 
Renal transplant 8 3.5% 0 0% 
Unknown 0 0% 2 3.0% 
Co-morbidities 
Diabetes 93 41.3% 22 32.8% 
Hypertension 145 64.4% 39 58.2% 
Family History 41 18.2% 5 7.5% 
Table 3.1 Baseline characteristics of the incident Turkish-Cypriot renal replacement therapy (RRT) population at 
90 days 
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National registry data shows that Turkey, Greece, and Tunisia have an age-adjusted incidence 
rate at day 90 of 349.1, 159.5, and 238.7 pmp respectively [15].  In comparison the crude and 
age-adjusted incidence rates of chronic RRT for Turkish-Cypriots were 234.4 and 315.0 per 
million population, respectively.  Figure 3.1 shows that the incidence of RRT in each age group 
in Turkish-Cypriots is comparable to that seen in Turkey.  Despite the small number of cases, 
the incidence of RRT in the 45-64 age group in Turkish-Cypriots (412.0 pmp) is significantly 
higher than that seen in the white population of England (123.2 pmp).   
 
Diagnosis 
Turkish-
Cypriots 
Greece Turkey England whites 
pmp % pmp % pmp % pmp % 
Diabetes 84.4 36.0% 53.5 30.3% 61.6 29.9% 24.5 19.5% 
Glomerulonephritis 29.2* 12.4%* 14.8 8.4% 16.4 7.9% 13.5 10.7% 
Hypertension 1.0 0.4% 19.1 10.8% 53.4 25.9% 6.8 5.4% 
Renal Vascular 
Disease 
12.5 5.3% 3.0 1.7% 2.8 1.3% 7.8 6.2% 
Data not available 0.0 0.0% 0.0 0.0% 3.1 1.5% 9.8 7.8% 
Other identified 
Category 
12.5 5.3% 15.7 8.9% 21.0 10.2% 18.2 14.5% 
Pyelonephritis 16.7 7.1% 9.9 5.6% 7.6 3.7% 9.7 7.7% 
Polycystic Kidney 8.3 3.6% 6.7 3.8% 7.8 3.8% 10.1 8.0% 
Uncertain aetiology 69.8 29.8% 53.9 30.5% 32.5 15.7% 25.5 20.3% 
Total incidence at 
day 91 
234.4 100.0% 176.7 100.0% 206.2 100.0% 125.9 100.0% 
*Includes presumed glomerulonephritis not biopsy proven. 
Table 3.2 Provisional renal diagnosis in the Turkish-Cypriot renal replacement therapy (RRT) population 
Incidence at 90 days, expressed as incidence per million population and percentage, in comparison with 2008 
registry data for Greece, Turkey, and the UK. 
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There is a high rate of RRT for ESRD attributed to diabetic nephropathy in all eastern 
Mediterranean countries (84.4 pmp in Turkish-Cypriots, 53.5 pmp in Greece, and 61.6 pmp in 
Turkey) (Table 3.2).  The code ‘uncertain aetiology’ is more common in the Turkish-Cypriot 
registry (69.8 pmp) than in other populations.  However there were also lower levels of 
hypertensive nephropathy in Turkish-Cypriots than in Greece or Turkey (1.0 pmp vs 19.1 pmp 
and 53.4 pmp respectively).  The incidence of polycystic kidney disease was broadly similar 
across all registries (range 6.7 - 10.1 pmp). 
 
 
Figure 3.1 Incidence of renal replacement therapy (RRT) at 90 days by age and gender 
Incidence of RRT at 90 days in Turkish Cypriots compared with 2008 registry data for Greece, Turkey, and English 
whites in males (A), and females (B). Error bars indicate 95% confidence intervals. 
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The incidence of RRT in the minority Turkish population of Northern Cyprus is broadly in line 
with the rate seen in Turkish-Cypriots (Table 3.1).  An additional 67 Turkish patients were 
maintained on renal replacement therapy beyond 90 days during the study period, giving an 
overall incidence of 211.3 pmp in the de jure population of Northern Cyprus.  However data on 
this population is less accurate due to significant migration to and from the mainland of Turkey 
[148]. 
Figure 3.2 shows the percentage of the incident population with a family history of ESRD by 
age and patient group.  18.2% of the incident population had a first or second degree relative 
with ESRD; this rose to 37% in those with ESRD due to uncertain aetiology.  Interestingly, if we 
consider all those with a broadly glomerular or tubular phenotype, then the proportion with a 
family history becomes 62.5%. 
 
 
Figure 3.2 Family history of ESRD in different patient groups  
Family history is especially common in those with unknown diagnosis, and those presenting with a glomerular or 
tubular phenotype [179]. 
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DNA was collected from the entire Turkish Cypriot population on RRT.  Because the Greek and 
Turkish communities share many genetic characteristics [169, 170], we initially undertook 
genetic testing for two conditions that have been identified in Greek Cypriots, CFHR5 
nephropathy and thin basement membrane nephropathy [137, 171].  Table 3.3 shows the 
results of tetra primer PCR in the Turkish Cypriot population with ESRD and a control Turkish 
Cypriot population.  Three individuals demonstrated the G871C mutation in COL4A3 previously 
reported in Greek-Cypriot pedigrees [171].  I did not detect any of the previously cited 
mutations in COL4A4 or the CFHR5 duplication in the ESRD population [137, 171].   
 
 ESRD Control 
Mutation Cases MAF Cases MAF 
COL4A3 (G871C) 3 0.013 0 0.000 
COL4A3 (G1334E) 0 0.000 0 0.000 
COL4A4 (3854delG) 0 0.000 0 0.000 
CFHR5 duplication 0 0.000 0 0.000 
Table 3.3 PCR analysis of mutations in COL4A3, COL4A4, and CFHR5 in the Turkish-Cypriot population 
A total of 225 Turkish-Cypriot patients with ESRD and 76 control patients (from the University College London 
Hospitals haemoglobinopathy genetics service) were genotyped using tetra-primer ARMS PCR.  3individuals were 
found to carry the G871C mutation in COL4A3, giving a minor allele frequency (MAF) of 0.013. 
 
I also examined a number of Cypriot families based in London that showed evidence of 
inherited renal disease.  One family, 1509, consisted of two sisters who were currently on 
dialysis with diagnoses of diabetic nephropathy and analgaesic nephropathy (Figure 3.3A).  
One son (442) was noted to have haematuria and proteinuria whilst he was being worked up 
as a possible live donor for his mother.  Subsequent renal biopsy showed TBMN on biopsy, as 
shown in Figure 3.3B.  His cousin (401), living in Australia, also had haematuria and proteinuria.  
Tetra primer PCR and Sanger sequencing confirmed the presence of the G871C mutation in all 
those clinically affected with renal disease (Figure 3.3C and D).   
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Figure 3.3 Family 1509 
(A) Pedigree of family 1509 showing carriers of the G871C mutation in COL4A3. (B) Representative EM image 
from an affected family member showing thinning of the GBM (arrowed).  (C) Tetra primer PCR showing 
amplification of mutant (Mt) and wild-type (WT) allele in individual 342 (Test) compared to one of the original 
Greek Cypriots with this mutation (+ve) or control DNA (-ve).  (D) Sequence trace demonstrating heterozygous 
c.2512G>T (p.Gly871Cys) in COL4A3 in individual 342. 
 
Two individuals who carried the G871C mutation in the Turkish-Cypriot ESRD population were 
noted to come from a large pedigree that we had recruited at the same time as collecting 
samples from the ESRD population.  This family, termed 1505 is shown in Figure 3.4.  Family 
1505 co-segregated microscopic haematuria, mild proteinuria, and renal impairment, however 
initial linkage analysis failed to show association with a single genetic locus.  Subsequent 
testing for the G871C mutation in this family revealed 15 heterozygote carriers, and the 
presence of four phenocopies that had confounded the linkage analysis.  
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Figure 3.4 Pedigree of family 1505  
The family includes 15 carriers of the G871C mutation in COL4A3 and 4 mutation negative phenocopies with 
evidence of renal disease. 
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In addition to the two individuals from family 1505, I also identified one other individual in the 
Turkish-Cypriot ESRD population who carried the G871C mutation in COL4A3.  In order to 
determine the minimal shared haplotype for all these families with the G871C mutation I 
genotyped one individual from each of the distinct pedigrees that we had access to.  These 
individuals included the 300K SNP data from family 1505, one subject from family 1509 (342), 
the Greek-Cypriot sample sent by Professor Deltas from one of the original three pedigrees 
published [173], and this additional individual from the Turkish-Cypriot ESRD population.  
These samples gave a minimal shared haplotype of 6.05 cM, which corresponds to an 
estimated MRCA 17 generations ago (95% CI 5-61) (Figure 3.5). 
 
 
Figure 3.5 Most recent common ancestor (MRCA) estimation for the G871C mutation in COL4A3  
The MRCA for this mutation is 17 generations using the minimal haplotype shared by individuals from 4 pedigrees 
not previously known to be related. 
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Given that all the individuals carrying the G871C mutation identified thus far shared a common 
haplotype, it is probable that their geographical location within Cyprus would give an idea 
where the mutation originated (Figure 3.6). I have highlighted those families carrying the 
G871C mutation in COL4A3 identified by my research.  There is significant geographical 
clustering of many of these mutations suggesting common founders, notwithstanding 
migration to the island’s capital, Nicosia. 
 
 
Figure 3.6 Map of Cyprus showing geographical clustering of mutations in COL4A3, COL4A4, and CFHR5 
Each oval indicates a distinct family carrying the indicated mutation (adapted from [173]).  I have highlighted the 
three pedigrees carrying the G871C mutation identified by this research in red. 
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3.3  Interpretation 
3.3.01 High incidence rate of renal replacement therapy in Turkish Cypriots 
This study presents the first population-based RRT incidence figure from Cyprus, and reveals a 
higher incidence of RRT than other countries reporting to the ERA-EDTA, with the exception of 
Turkey [15].  Diabetes is a major cause of ESRD overall and specifically in those under 65 years 
of age, with rates comparable to those seen in whites in the USA [14].  We found that the high 
incidence of RRT in Turkish-Cypriots is not due to the specific mutations in COL4A3, COL4A4, 
and CFHR5 assessed in this study [137, 171].  Finally, a third of Turkish-Cypriot patients start 
RRT with unknown primary diagnosis.  This highlights both the need for earlier detection of 
these cases and the possibility that there may be other conditions causing ESRD in this 
population.   
3.3.02 Diabetic nephropathy 
The Turkish-Cypriot case-mix, with a high incidence of RRT for ESRD due to diabetic 
nephropathy, is similar to that seen in Turkey and Greece (Table 3.2).  Diabetes is also a 
common cause of ESRD in developing countries around the Eastern Mediterranean, such as 
Egypt, Kuwait, Lebanon and Saudi Arabia [182].  The incidence of RRT seen in Turkish-Cypriots 
less than 65 years old is striking (Figure 3.1), and there is evidence that a significant portion of 
this is attributed to diabetic nephropathy [176].  Currently data concerning the incidence of 
diabetes in Turkish-Cypriots is lacking.  Diabetes is common in Greek-Cypriots and mainland 
Turkish patients [183-185], but not to the extent seen in some other populations with high 
levels of diabetic nephropathy, such as the Pima Indians of Arizona [165, 186].  Moreover, 
childhood levels of obesity in Cyprus are much closer to those seen in other European 
countries than in the US [187, 188].  It is therefore possible that, in common with other 
registries, some of these cases reflect a co-occurrence of Type 2 diabetes with ESRD due to an 
alternative aetiology [189]. 
3.3.03 Coding ‘Uncertain aetiology’ 
There is a significant group in the Turkish-Cypriot RRT population with unknown diagnosis 
(69.8 pmp).  This group partly reflects late presentation and limited diagnostic investigations.  
Comparative that data from the Eastern Mediterranean is less robust [179, 189], but there is 
evidence for a reciprocal relationship with coding for hypertension in many registries [179, 
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189, 190].  The incidence of hypertensive nephropathy is conspicuously lower in Turkish-
Cypriots than in neighbouring countries.   In the absence of clear diagnostic criteria for 
hypertensive nephropathy, it may be appropriate to combine ‘hypertension’ with ‘uncertain 
aetiology’ in *Includes presumed glomerulonephritis not biopsy proven. 
Table 3.2, which would imply that there is no established primary renal diagnosis in 40% of 
patients on RRT in each of the Mediterranean registries studied. 
The majority of patients with an unknown diagnosis present clinically with minimal proteinuria 
(<1 g protein/day) and asymptomatic disease, consistent with a pathological process primarily 
affecting the renal tubules [179] and similar to the features of medullary cystic kidney disease 
type 1.  A number of families presenting this way in the Greek Cypriot population have shown 
linkage to the region 1q21, but the gene responsible has not yet been  identified [172].  It is 
possible that the medullary cystic phenotype reflects the final common pathway of a number 
of genetic and environmental factors that are common in this population. 
3.3.04 Alternative explanations for the incidence of RRT in Turkish-Cypriots 
Regional variations in RRT incidence may reflect both genetic and environmental factors [9, 
165, 166].  Macroeconomic factors that influence regional variations in RRT incidence include 
per capita gross domestic product (GDP) and health-care expenditure [9].  Northern Cyprus has 
a developing economy, with per-capita GDP that is 76% of that in the Republic of Cyprus, and it 
is dependent on aid from the Turkish government [191].  RRT has only recently become widely 
available in TRNC and there is no long-term provision of private dialysis.  Economic factors also 
influence the management of chronic kidney disease (CKD) and co-morbidities, as well as the 
competing risk of mortality, in the general population [9].  The high incidence of RRT in the 
Turkish-Cypriot population may therefore reflect suboptimal management of diabetes, 
hypertension, and associated complications.  This has significance for healthcare planning on 
the island, and underlines the importance of prospective assessment of kidney function in this 
population.   
3.3.05 Incidence rates in the ethnic Turkish population 
Table 3.2 and Figure 3.1 show that the incidence of RRT in the Turkish-Cypriot population is 
similar to that in neighbouring countries in the eastern Mediterranean.   These populations 
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show both genetic [167], and environmental [15] similarities.  In order to try to differentiate 
between these two factors, I also examined the incidence of ESRD in the ethnic Turkish 
population in Northern Cyprus.  This population is hypothesised to share the same 
environment but have a different genetic make-up. Other useful comparator populations 
would be that of the Greek-Cypriot population in the Republic of Cyprus and the expatriate 
Turkish-Cypriot population in the UK or Australia, however that data was not available. 
The Turkish immigrant population in northern Cyprus comprises 27.5% of the population in 
Northern Cyprus [148].  This population is younger than the Turkish-Cypriot population and 
therefore likely to show a reduced rate of renal disease.    Although the same methods for 
capturing ethnicity and tracking patient data were used as for Turkish Cypriot patients, this 
dataset was noticeably less complete.  Moreover the sample size of the population was very 
small (76 patients over 8 years).   
The incidence of RRT in the Turkish migrant population is not as high as that seen in the 
Turkish-Cypriot population or in the population of mainland Turkey.  The rates are broadly 
comparable, however, and given the caveats discussed, it is not possible to distinguish further 
between genetic and environmental factors using this population. 
3.3.06 Genetic renal disease in the Turkish-Cypriot population 
Congenital factors may also be important in the aetiology of ESRD in this population [192].  
Previous estimates of the prevalence of family history of ESRD amongst incident dialysis 
patients, suggest that 7-15% of Caucasians have a first or second-degree relative with ESRD 
[17, 43].  This proportion is highest in young adults, non-Caucasians, and for those where ESRD 
is caused by diabetes or hypertension [17].  We observed a similar rate of familial ESRD in 
Turkish-Cypriot patients on RRT, which was even higher (37%) in the group with unknown 
diagnosis, suggesting the existence of conditions that are not yet characterised in this 
population.  For comparison, the rate of RRT for ESRD due to polycystic kidney disease was 
similar across all registries.   
In order to assess the contribution of inherited renal disease we collected DNA from the entire 
Turkish-Cypriot population on RRT.  Previous work has demonstrated a number of important 
founder mutations and significant geographic clustering for several monogenetic diseases 
affecting the Greek-Cypriot population of Cyprus, including mutations of COL4A3, COL4A4, 
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PKD2, and MEFV [81, 171, 174].  Although the CFHR5 duplication is common in Greek-Cypriots 
originating from the southern half of the island [193], we did not detect it in our sample of 
prevalent patients.  However, due to the small size of our sample the allelic frequency may still 
lie within that observed for Greek Cypriots [194].  The high incidence of RRT in Turkish-Cypriots 
is likely to be due to environmental factors combined with polygenic contributions from many 
risk alleles. 
3.3.07 Geographical evidence for a founder mutation 
Two major factors which determine the spread of alleles within a population are the origin and 
age of a given variant.  The geographical clustering of families with distinct mutations enables 
us to estimate the likely origin of these mutations.  CFHR5 nephropathy is believed to have 
originated within the Trodos mountains of western Cyprus [137].  Previous work has also 
identified clusters of families with mutations in COL4A3 and COL4A3 [173].  The G1334E 
mutation in COL4A3 appears to cluster around Nicosia and two other villages further east, 
while the 3534delG mutation in COL4A3 has been found only in a village near Larnaka in south-
eastern Cyprus. 
The G871C mutation in COL4A3 was described in three families from villages near Kyrenia in 
northern Cyprus [173].  Although Turkish administered Northern Cyprus (TRNC) extends both 
to Nicosia and Famagusta, the Kyrenia region in northern Cyprus is most completely situated 
within that territory.  This may explain why the G871C mutation was the only mutation 
identified by this study.  This point of origin is further supported by the identification of this 
mutation in a family in the UK that can also trace its ancestry back to the Kyrenia district of 
northern Cyprus. 
3.3.08 Calculation of the age of the G871C mutation 
The existence of a mutation in a population is the result of a number of competing factors.  It 
may exist at steady state levels by recurrent identical mutational events or preserved by 
heterozygote advantage.  Alternatively, it may be on its way to extinction due to negative 
selection, but still detectable due to recent origin or a founder effect.  Allelic age can be 
estimated from the analysis of the decay over time of linkage disequilibrium between the 
mutant allele and one or more adjacent marker loci [195].  Alleles inherited from a common 
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founder will be identical by descent, and will therefore share the same LD between 
polymorphisms. 
Calculation of the age of a mutation using the pattern of linkage disequilibrium at closely 
linked marker loci can be thought of as using a ‘genetic clock’ [196].  This relies on the fact 
that, due to recombination, the extent of LD decays exponentially with generations at a rate 
that is proportional to the recombination fraction (θ).  The true age is the time at which the 
mutation first occurred.  However in many cases, such as with founder effects due to 
immigration, the aim is to determine to time of the most recent common ancestor (MRCA) of 
the mutation bearing chromosomes in a population [197].  MRCA calculation was previously 
performed using micro-satellite markers, however high density SNP arrays can provide a much 
more accurate haplotype measurement. 
We determined the minimal haplotype shared by four discrete pedigrees with the G871C 
mutation by assessing conflicting homozygosity (CH).  CH refers to the situation where 
individuals are homozygous for different (ie. conflicting) alleles at a given locus (Figure 3.7).  
The occurrence of CH means that these individuals cannot be identical by descent (IBD) at that 
locus.  Analysis of CH therefore allows the extent of the shared haplotype to be determined. 
 
 
Figure 3.7 Conflicting homozygosity (CH) analysis 
Each SNP is considered in isolation and CH occurs at SNP 4 in this example.  There is therefore a run of three SNPs 
with no CH, which is consistent with a shared haplotype (identity by descent).  The occurrence of CH, indicates 
that it is not possible for a single haplotype to be shared by all individuals under consideration here. 
Population genetics 
Page | 87  
 
 
Unrelated individuals will have short runs of SNPs that appear to be IBD by chance alone.  The 
expected length of such runs varies as a function of the number of individuals compared and 
the minor allele frequencies of the SNPs in the population from which the subjects are drawn.  
By contrast, a group of individuals that have inherited a region of the genome from a common 
ancestor will have much longer runs without CH.  
This approach is different to that used by Voskarides et al., who used short tandem repeat 
(STR) markers to date the G1334E mutation in COL4A3 [173].  These researchers were not able 
to determine the size of the G871C haplotype using STR markers as they had only three 
families with this mutation.  I was able to determine the shared haplotype using four families 
because of the density of markers used in CH analysis.  Voskarides et al  used 22 STR markers 
over 23 cM to measure a 13.71 cM haplotype, whereas the 300K array used in this 
investigation has a resolution of <0.2 cM (expected runs of 17 SNPS demonstrating no CH, 
given a minor allele frequency of 0.22). 
The advantage of using CH to determine a shared haplotype is that unlike linkage mapping, it 
does not require the exact relationship between pedigrees to be known.  Moreover, it does 
not require the determination of marker frequencies in the general population in order to 
define the boundaries of a shared haplotype.  One disadvantage, however, is that this analysis 
will tend to overestimate the size of the shared haplotype because the actual recombination 
point is likely to occur before the locus demonstrating CH.   
Once the size of the shared haplotype is known it is first necessary to determine the genetic 
distance between the boundary SNPs and the adjacent informative markers.  The probability 
of no recombination between a marker x that is κ Morgans distant from the mutation in n 
generations is expressed by the following equation: 
T(x) = (1- θ K)
n 
And the likelihood of recombination between x and the adjacent marker x-1 expressed as: 
F(x) = T(x-1) – T(x) 
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Assuming T(x-1) = T(x), where x and x-1 are very close to each other, then the probability of 
recombination between one or both individuals at this point is  F(x)2 + 2T(x)F(x) 
Consequently, the likelihood that the observed haplotype was transmitted from an ancestor n 
generations ago is given by combining the likelihood for the contromeric and telomeric shared 
markers as: 
L(n) = K(xcentromeric) x K(xtelomeric) 
The value of n for which L(n) is maximised is therefore an estimate of the number of 
generations since the MRCA.  This equation can be solved iteratively for each additional 
generation, and the resultant curve plotted (Figure 3.5).  This allowed the estimation of the 
maximal value of L(n) as well as a 95% confidence interval. 
Assuming that one generation equates to 25 years, the estimation of an MRCA 17 generations 
ago means that the G871C mutation originated at least 425 years ago.  It is possible, however 
that the mutation arose earlier, prior to the bifurcation of the different families included in this 
study [197].  This is similar to the date estimated for the G1334E mutation [173], and is 
compatible with the theory that most harmful mutations are of relatively recent evolutionary 
origin [78].  One of the pedigrees used in determining the MRCA for the G871C mutations 
came from a sample provided by Professor Deltas from the original three pedigrees published 
[173].  It is possible that the other two pedigrees might define a smaller shared haplotype, in 
which case the mutation is likely to be older than this calculation. 
3.3.09 Phenocopies 
As shown in Figure 3.4, family 1505 is a large pedigree that co-segregated microscopic 
haematuria and mild proteinuria with renal impairment.  The pattern of inheritance suggested 
an autosomal dominant mode of inheritance, and linkage analysis had been performed using 
SNP genotype data.  However this analysis had failed to demonstrate the co-segregation of 
renal disease with any single genetic locus.  Once two individuals were identified with the 
G871C mutation in COL4A3 it became clear that linkage analysis had failed in this family due to 
the presence of multiple phenocopies. 
A phenocopy is an individual whose phenotype is identical to the one of another individual 
whose phenotype is determined by their genotype.  Genetic linkage depends on the 
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association of particular marker loci with a given trait [48].  Since phenocopies exhibit the 
same trait in association with different loci, erroneous associations will be made in the context 
of familial linkage analysis.  The problem of phenocopies can be only be avoided by increasing 
the sample size by several orders of magnitude [198], as in the case of genome wide 
association studies, or minimised by relying on a highly specific phenotype.  Characterising a 
disease phenotype can be difficult, especially when resources are limited.  As discussed 
previously, renal disease is often assessed with surrogate markers, such as serum creatinine, 
which are influenced by a wide variety of events. 
A further question is why there should be so many individuals with renal disease within this 
family.  Given the high incidence of ESRD in the Turkish Cypriot population, it is possible that 
there are other genetic risk factors for renal disease that segregate independently of the 
COL4A3 mutation in this family.  Applying the same technique of CH analysis to these 
phenocopies did not reveal any regions that were IBD, demonstrating that the same genetic 
factor(s) were not operating in all phenocopies. 
3.3.10 Risk of ESRD with the G871C mutation 
Familial microscopic haematuria has long been considered a benign condition; however the 
first description of these Cypriot mutations in Type IV collagen showed a strong association 
with glomerular scarring and progression to ESRD.  Careful follow-up of a large cohort of 
heterozygous carriers of either autosomal or X-linked mutations in type 4 collagen does 
suggest that there is a 15% long-term risk of developing renal failure [199].  Moreover, the risk 
of ESRD in those with heterozygous mutations in COL4A3 or COL4A4, labelled as autosomal 
dominant Alports, is also around 20%, with an age of onset that is almost always above 40 
years [200-202].  Three out of 15 heterozygote carriers are now on RRT in family 1505, giving a 
risk of ESRD of 20% in this small sample. 
Thin basement membrane nephropathy is prevalent in Cyprus.  One study showed that 5.45% 
of all biopsies processed by electron microscopy showed TBMN [203], and up to 53% if only 
biopsies taken for investigation of isolated glomerular haematuria are considered [26].  An 
important question is therefore why some individuals with TBMN should progress to ESRD.  
There is evidence that the R229Q polymorphism in NPHS2 is associated with proteinuria in 
Greek Cypriots [134].  However this effect was slight, and there is still a debate whether this 
variant does indeed act as a disease modifier.  Irrespective of whether there are other modifier 
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genes in the Turkish-Cypriot population, it is probable that these variants giving rise to TBMN 
are not as benign as originally thought.  
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3.4  Conclusions and future work 
This study is the first complete collection of DNA from an ethnically defined population with 
ESRD.  Renal disease is common in Turkish-Cypriots, and there is a significant rate of familial 
renal disease.  The high incidence of renal disease in this population is not due to the specific 
mutations in COL4A3, COL4A4, and CFHR5 assessed in this study [137, 171].  The occurrence of 
the G871C mutation in this population is evidence for gene flow between Greek-Cypriot and 
Turkish-Cypriot.  Given the size of the population sampled it is not possible to say that the 
other mutations do not occur in Northern Cyprus. 
One third of Turkish-Cypriot patients start RRT with unknown primary diagnosis.  This 
proportion may be higher if we accept the limitations of the diabetic and hypertensive 
diagnostic categories.  This highlights the need for earlier detection and more detailed 
investigation of renal disease in this population.  It is tempting to speculate that there may be 
other conditions causing ESRD in this population.  Certainly there are both genetic and 
environmental differences between the Turkish-Cypriot population and the better studied 
populations of Western Europe and North America that may give rise to novel renal pathology.   
Diabetes is a major cause of ESRD overall and specifically in those under 65 years old, with 
rates comparable to those seen in whites in the USA.  In the Afro-Caribbean population of the 
southern United States it is notable that the highest rates of familial renal disease are found in 
those with diabetic and hypertensive nephropathy [17], both diagnostic categories that are 
common in the Turkish-Cypriot population.  It is possible that the familial clustering observed 
with these conditions is due to multiple additive risk factors, rather than few variants with 
large effect size.  It is also likely that environmental factors are important. 
I have shown that the incidence of RRT in the Turkish-Cypriot population of Northern Cyprus is 
amongst the highest in Europe.  It is uncertain what is driving the high incidence of ESRD 
around the eastern Mediterranean. Genetic association studies might help our understanding 
at a population level, particularly if contrasted with populations exhibiting a low incidence of 
renal disease, such as that of Iceland [204].  This population therefore provides an opportunity 
to look for genetic factors associated with an increased risk of ESRD in Cyprus. 
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4.1  Introduction 
Analysis of the Turkish Cypriot population has shown that incidence of ESRD is amongst the 
highest in Europe [176].  Some of this increased incidence may be due to genetic factors, but 
despite close similarities with the Greek Cypriot population, we did not find that this was due 
to four known mutations that are associated with renal disease in that population [137, 171].  
It is therefore likely that other, as yet unidentified, genetic risk factors that operate within the 
Turkish Cypriot population give rise to the high rates of renal disease observed. 
Analysis of the Turkish Cypriot ESRD population showed a high proportion of patients with a 
family history of renal disease.  This was especially true for those with an uncertain aetiology, 
who often present clinically with a minimal proteinuria (<1 g protein/day) and asymptomatic 
disease, consistent with a pathological process primarily affecting the renal tubules.  Given the 
limitations of diagnostic work-up in some countries of the Middle East, Neild et al have 
proposed a revised coding system that essentially divides individuals into the broad categories 
of glomerular or tubular phenotype.  The glomerular phenotype is a clinical history consistent 
with glomerulonephritis, but a renal biopsy may not have been performed [179].  Clinically this 
means a presentation with macroscopic haematuria, nephritic syndrome, fluid retention, 
malignant hypertension, or via routine investigations.  By contrast, the tubular phenotype 
includes patients who reach ESRD with minimal symptoms, minimal proteinuria, no peripheral 
oedema, and without malignant hypertension [179]. 
In order to try to identify additional genetic factors operating in the Cypriot population, I 
studied a large Cypriot family with an inherited form of renal disease.  This family originates 
from the south of the island, and a number of individuals have since emigrated to south 
London.  The clinical phenotype in this family is of proteinuria, microscopic haematuria, and 
renal impairment that appear to be inherited in an autosomal dominant fashion.  Five 
individuals have had a renal biopsy, but there was no common pathological diagnosis.  Four 
individuals have received a renal transplant, one of which has survived for 16 years without 
any evidence of recurrent disease. 
This family came to our attention after the identification of CFHR5 nephropathy [137].  The 
family had heard about CFHR5 nephropathy through the media and wanted to be tested for 
this condition, on account of their extensive family history of renal disease and ethnicity.  DNA 
had been collected in 1994 from some of the family by researchers at the University of Cyprus.  
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This had been used for linkage analysis, employing microsatellite markers, but no clear linkage 
had been identified.  Pedigree information had also been collected from some of the 
individuals living in London by their nephrologist at St Georges’ Hospital; however no analysis 
had been performed on these samples. 
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4.2  Results 
The pedigree of family 1508 is shown in Figure 4.1. The first stage of my analysis in this 
pedigree was to show that none of these individuals carried the duplication in CFHR5 
nephropathy or the mutations in COL4A43 and COL4A4 already described [137, 171] (data not 
shown).  It became apparent that it would be difficult to define a precise phenotype as renal 
disease in many individuals was mild and non-specific.  The condition also shows incomplete 
penetrance as one individual, 1508 202, is an obligate carrier and yet has survived into her 90s, 
with no evidence of renal impairment on laboratory investigation.   
 
Figure 4.1 Pedigree of family 1508 
Affected individuals include all those with evidence of renal impairment.  The individual in blue (1508 202) is an 
obligate carrier with no phenotypic evidence of renal disease.  Unrelated spouses are depicted as unaffected.  
The remaining individuals are phenotypically normal but may go on to develop renal impairment and thus were 
not included in the analysis.   
 
There were just three individuals in the UK with strong evidence of renal disease.  The first of 
these (1508 304) reached ESRD aged 34 and was transplanted.  The second (1508 321) was 
under follow-up in the midlands for stable renal impairment (CKD stage 3).  She was referred in 
2009 with a creatinine of 115 umol/l (eGFR 44 ml/min), intermittent haematuria, and variable 
proteinuria (albumin creatinine ratio (ACR) 42.5 – 184.3), in the context of a new diagnosis of 
type II diabetes, hypertension, and mild obesity.  The third (1508 401) had had a renal biopsy 
aged 16 for microscopic haematuria and proteinuria.  After 18 years of follow up he had 
persistent urinary abnormalities with mildly impaired renal function (creatinine 120 umol/l, 
eGFR 64 ml/min). 
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In order to identify the mutation responsible for the renal disease in this pedigree I collected 
DNA samples from 33 individuals.  I was able to access the renal biopsy reports from four 
individuals; the conclusions from which are summarised in Table 4.1.  DNA samples from 25 
individuals were used to generate 300k SNP genotypes. 
ID Date Age Locn. Findings 
304 1964 17 UK 
5 glomeruli; GBM increased refractility 
Tubules well preserved with no evidence of vascular 
disease or interstitial inflammation 
Non-diagnostic: possibly early membranous 
304 1974 27 UK 
Many glomeruli hyalinised, others segmental sclerosis 
with moderately increased mesangial cellularity 
Severe tubular atrophy and interstitial fibrosis 
Moderate interstitial inflammatory infiltrate 
Advanced nephrosclerosis 
314 1989 37 UK 
‘Alport Syndrome’ - report not available 
No haematuria or hearing loss 
313 1995 46 Cyprus 
Endothelial and mesangial cells normal 
Vacuolated epithelial cells with focal podocyte fusion 
EM: no dense deposits; normal GBM thickness with focal 
thinning and thickening but no splitting 
315 1995 35 Cyprus 
2 glomeruli, no increase in mesangial matrix 
Epithelial cells prominent with many micorvilli 
EM: Lamina densa quite uniform, no dense deposits 
No evidence of Alports 
401 1995 18 UK 
Cortex & medulla; 10 Glomeruli, none sclerosed; 
IF negative, few epithelial foot process effacement 
Minor tubular atrophy and ischemic wrinkling 
EM: no dense deposits or lamina densa 
splitting/duplication 
Non-diagnostic 
Table 4.1 Renal biopsy findings in family 1508 
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Genotypes were analysed using PedCheck, which demonstrated that two of the Cypriot 
samples gave rise to a large number of major Mendelian errors.  Individual 428 and his father 
gave rise to 1316 Mendelian errors, while 321 and her mother gave rise to 666 Mendelian 
errors.  This means that the samples were either from the wrong individuals, or that the 
parentage of the individuals was not as we were led to believe from the pedigree.  Paternal 
discrepancy is common, affecting a mean of 3.7% of the population [205], and may have 
contributed to the failure of the microsatellite linkage analysis performed in Cyprus.  For this 
reason, those individuals were excluded from subsequent linkage analysis. 
Preliminary linkage analysis was performed on this family using a subset of 9600 SNPs in order 
to reduce the analysis time (Figure 4.2).  Genotypes were re-analysed, after the exclusion of 
428 and 321, and 17 Mendelian errors were detected.  These were thought to correspond to 
miscalled SNPs on the chip and were therefore discarded.  The remaining genotypes were 
analysed using GENEHUNTER [154] and SimWalk, using the EasyLINKAGE interface [153].  The 
genotypes were divided into sets of markers (80, 100, or 120) on each chromosome and 
analysis was performed in all individuals in each set, assuming a dominant model of 
inheritance. 
 
Figure 4.2 Linkage analysis of family 1508 
Genome-wide linkage analyses of this pedigree using GENEHUNTER yielded a maximal LOD score of 2.97 in 
association with a region on Chromosome 10 (circled).  Analysis of this peak on chromosome 10 with SimWalk 
gave a maximal LOD score of 4.2. 
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The maximal LOD score using GENEHUNTER to analyse this pedigree was 2.976 in association 
with a region on chromosome 10 (Figure 4.2). Using the maximum probability haplotype 
reconstruction in GENEHUNTER I showed that the haplotype in this region was shared by all 
affected individuals (Figure 4.3), suggesting that individuals had been excluded by the program 
from analysis.  Reanalysis of the linkage peak on chromosome 10 with SimWalk gave a maximal 
LOD score of 4.187.  The region on chromosome 10 extended 15 cM and did not include any 
genes known to cause renal impairment.   
 
 
Figure 4.3 Haplotype reconstruction of the linked interval on chromosome 10   
Eight SNPs are shown indicating that informative meiosis have occurred to limit the shared haplotype, shown in 
red, in individuals 304, 315, 401, and 419. 
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Four individuals in this pedigree had progressed to ESRD (Figure 4.4), all of whom shared the 
linked region on chromosome 10 (Figure 4.3).  The existence of a shared haplotype was also 
confirmed with conflicting homozygosity analysis (Figure 4.5).  CH analysis was used to 
determine which regions of the genome were identical by descent in all combinations of 11 
affected family members that included the four individuals who had proceeded to ESRD.  As 
illustrated in Figure 4.5, the addition of two additional individuals to two first cousins once 
removed significantly reduces the regions that are IBD to just three regions. 
 
 
Figure 4.4 Pedigree of family 1508 showing those individuals who had reached ESRD 
The individuals used for next generation sequencing are indicated by red boxes. 
 
In order to identify the causative variant from within this linked region, two individuals were 
chosen for whole genome sequencing.  I selected two individuals in order to be able to filter 
out variants that were not shared between them, rather than relying solely on the linkage 
data.  Both individuals had ESRD, so that we could be most sure they were not phenocopies.  
Lastly these two individuals had the maximal genetic distance between them, shown in Figure 
4.4.  These individuals were first cousins once removed, and were separated by five meioses.  
Consequently they would share, on average, 3.125% of their genetic sequence.  Table 4.2 
shows the depth and coverage of the sequencing achieved.  We identified ~4 million variants. 
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Figure 4.5 Conflicting homozygosity (CH) analysis in family 1508 
CH analysis of the two individuals used for next generation sequencing (A) and of all four individuals with ESRD 
(B).  Run length above 300 SNPs indicates a significant shared haplotype.  The shared regions circled in B have 
also been circled in in A, and were used to define the shared region that was used to filter out variants shared by 
all four individuals with ESRD in Table 4.3. 
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In order to determine which of the variants identified by WGS was responsible for renal 
disease in this family I employed a number of filtering steps, based on assumptions that 
parallel the reasoning behind the linkage analysis in this family.  First, the sequencing data was 
examined to see whether either individual harboured any single mutation that would have 
been sufficient on its own to cause ESRD.  This was done by searching the data with a list of 
around 50 genes that have well known associations with renal disease, such as collagen, type-
IV, alpha-5 (COL4A5) or NPHS1 [23].  While both individuals were carriers for a number of 
polymorphisms in these genes, none were present in the database as pathogenic.  In essence 
this answers the question of whether either of the two individuals is a phenocopy; that is, 
whether they have ESRD on account of a known genetic cause.   
 
Category Metric 1508 304 1508 419 
Miscellaneous Gender Female Male 
Genome coverage Fully called genome fraction 0.973 0.971 
Exome coverage Fully called exome fraction 0.975 0.977 
Genome coverage Gross mapping yield (Gb) 197.377 197.135 
Genome variations Heterozygous SNP count 2098591 1996406 
Genome variations SNP transitions/transversions ratio 2.133 2.138 
Table 4.2 Sequencing metrics from whole genome sequencing data 
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Subsequent filtering steps were used to further reduce the number of variants identified by 
whole genome sequencing in this study (Table 4.3).  Given that this disease appeared to be an 
autosomal dominant condition, I looked at only heterozygous variants that were shared 
between the two individuals.  I hypothesised that the causative variant would result in a 
change to the amino acid sequence of a protein.  Lastly I assumed that this variant was novel, 
and therefore not present in the databases with a MAF > 0.005.  Four million heterozygous 
SNPs were thereby reduced to six novel variants that were taken forward for further analysis.  
The pathogenicity of these six novel variants was assessed by in silico analysis (Table 4.4).  Four 
complementary programmes were used to investigate whether the variants identified showed 
evolutionary conservation across vertebrate species and whether the predicted amino-acid 
alteration would affect the function of a particular protein domain. 
 
Filtering step Number of variants 
Total heterozygous SNP count in each 
individual 
2098591 and 1996406 
Shared variants 78023 
Coding sequence and splice site 911 
Component: 
Deletion/Insertion/SNP/Substitution 
431 
Impact: All except no change and synonymous 217 
Shared by all four individuals with ESRD 69 
Novel 6 
Table 4.3 Filtering of heterozygous SNPs identified by whole genome sequencing 
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Evaluation of the six variants identified by WGS did not reveal any that were clearly deleterious 
(Table 4.4).  The poor correlation between scores is indicative of the limitations of using these 
tools.  The variant in PCDH15 scored most highly of the six tested with MutationTaster and 
PolyPhen2, suggesting that it was most likely to be pathogenic.  It also scored lowest with SIFT, 
suggesting that it would not be tolerated, although the score was above the threshold of 0.05.  
By contrast the variants in GRK5, DMBT1 and DHX32 all had very low scores suggesting that 
they were benign changes.  Evolutionary conservation was assessed using PhyloP to compare 
conservation among 44 vertebrate species.  The positive PhyloP scores for PCDH15, GRK5, and 
DHX32 show greater conservation at that individual nucleotide than would be predicted by 
chance. 
 
Gene Nucleotide 
substitution 
Amino Acid 
substitution 
Mutation 
taster  
SIFT score PolyPhen2 
score 
PhyloP 
conservation 
PCDH15 G5982C S1862C 3.05 0.11 0.871 1.41583 
GRK5 G1143A R303H 0.79 0.99 0.068 1.28574 
INPP5F  C3140G T991S 1.58 0.25 0.000 0.197701 
DMBT1 CAC3145AGT H1103S 2.43 0.94 0.001 0.193882 
METTL10 C58T G7S 1.53 0.23 0.034 -0.70011 
DHX32 C2630T V713M 0.57 0.93 0.001 1.62439 
Table 4.4 In silico predictions for the six novel variants identified by whole genome sequencing 
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In parallel to the in silico analysis I designed tetra-primer ARMS PCR reactions to genotype the 
Turkish Cypriot ESRD population for the six novel variants generated by the analysis of the 
whole genome sequencing data from this family.  Previous filtering had defined a novel variant 
as having a minor allele frequency of < 0.005 in the dbSNP database.  However, I hypothesised 
that data from relatively few Cypriots had been included in dbSNP and therefore that some of 
these variants might be more common on the island, and therefore not causative.  Three of 
these variants have significant minor allele frequencies, and were therefore not investigated 
further. 
 
Gene 
Turkish Cypriot Greek Cypriot MAF 
Subjects 
tested 
Het Hom 
Subjects 
tested 
Mutation 
positive 
 
PCDH15 270 0 0 146 0 0.000 
GRK5 12 4 0 43 4 0.073 
INPP5F 279 0 0 172 0 0.000 
DMBT1 92 13 0 46 6 0.068 
METTL10 87 17 1   0.094 
DHX32 186 0 0 96 0 0.000 
Table 4.5 Frequency of novel variants in the Turkish-Cypriot population 
 
The same tetra-primer ARMS PCR reactions were used by our colleagues in Nicosia to 
genotype additional Greek-Cypriot patients with renal disease.  This gave us additional 
information on the frequency of these alleles in the Cypriot population, as well as the potential 
to detect additional individuals with the same condition.  No individuals were found to carry 
any of the variants described in PCDH15, INPP5F, or DHX32. 
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In order to investigate the function of the remaining three variants identified by next 
generation sequencing in this family, I obtained a culture of primary urothelial cells from four 
individuals in this family (Figure 4.6).  These patient derived cells were genotyped using tetra-
primer ARMS PCR on cDNA isolated from cultured cells (Figure 4.6).  Analysis of cDNA not only 
confirms the genotype, but it also demonstrates that the variant is expressed as mRNA.  Of 
note, one individual had a functioning renal transplant at the time of urothelial cell collection, 
however all the clones successfully isolated from this individual were derived from the 
transplanted urothelium (patient C3 in Figure 4.6). 
 
 
Figure 4.6 Culture of patient-derived urothelial cells in vitro.   
A. Typical appearance of a type I colony showing the smooth-edged contours and cobblestone-like cell 
morphologies.  B. Genotyping was performed using tetra primer PCR for the T991S variant in INPP5F on cDNA 
extracted from cultured urothelial cells.  Genomic DNA was used as a positive control (+ve) for the presence of 
the mutant PCR product (Mt). 
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Gene expression was analysed in urothelial cells collected from individuals in this family in the 
UK (Figure 4.7).  I analysed three independent colonies from two control patients (C1-2) in the 
family and two individuals affected with renal disease (C3 and M1).  I used real-time PCR to 
examine the expression of a number of genes that have been associated with the urothelial 
lineage in order to confirm the probable origin of these cells.  I then looked at the expression 
of the three candidate genes from the sequencing experiment.  There was no effect of 
genotype on the expression of these genes in this family. 
 
 
Figure 4.7 Gene expression in patient-derived urothelial cells 
Expression of E-cadherin (CDH1), keratin 7 (KRT7), and L1 cell adhesion molecule (L1CAM) was greater in all 
urothelial clones compared to a reference population of primary fibroblasts.  There was no effect of genotype on 
the expression of the genes containing novel variant in this family (INPP5F, DHX32, or PCDH15). 
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4.3  Interpretation 
4.3.01 Linkage analysis 
In order to investigate the genetic basis of renal disease in this family I used linkage analysis to 
determine whether a single genetic region co-segregated with disease.  I generated different 
LOD scores using different analysis programs; however haplotype prediction and CH analysis 
confirmed that a region on chromosome 10 did segregate with renal disease.  The different 
result from the two programs used highlights a number of limitations with traditional linkage 
analysis. 
Linkage is usually reported as a logarithm of the odds (LOD) score.  This score compares the 
likelihood of obtaining the test data if the two loci are indeed linked, to the likelihood of 
observing the same data purely by chance.  At a given linked region, each additional 
recombination (i.e. the addition of another affected first-degree relative to the pedigree) will 
add a maximum of log10 (2) = 0.3 to the LOD score.  Consequently the maximal LOD score 
generated by GENEHUNTER (= 2.97) is below that which would be expected from 14 affected 
individuals (14 x 0.3 = 4.2).  This indicates that either some individuals do not share the disease 
haplotype, or that some individuals have been excluded from analysis for computational 
reasons due to the size of the pedigree.   
GeneHunter uses the Lander-Green algorithm to generate an exact solution to the linkage 
analysis in question [154].  As such it is limited to a pedigree size of around 20 people (the 
pedigree in Figure 4.1 contains 33 individuals).  By contrast SimWalk uses a Markov chain 
Monte Carlo algorithm which allows it to consider the underlying possible inheritance data in 
proportion to their likelihood [155].  This generates an estimate rather than an exact result, 
but it enables the program to process pedigrees that are an order of magnitude larger.  Given 
the higher score seen with SimWalk and the results of CH analysis, it is clear that this low score 
is a limitation with the GENEHUNTER program. 
The significance of the LOD score depends both on the number of individuals included, and 
also on the accuracy of the disease phenotype.  Unfortunately the early stages of chronic 
kidney disease are common and non-specific.  Chronic kidney disease (CKD) may affect up to 
15% of the total population [206, 207], and microscopic haematuria may be found in a similar 
proportion [208, 209].  In the absence of additional markers of syndromic renal disease, it is 
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therefore impossible to say whether the abnormal findings in a given individual are due to an 
early or mild form of the disease in question or due merely coincidence. 
Parametric linkage analysis also assumes that we know the mode of disease inheritance.  The 
family studied here is not in-bred, and the pedigree is consistent with a highly penetrant, 
autosomal dominant condition.  However it is possible that there is more than one gene 
involved, particularly as renal disease is relatively common in this population, as discussed in 
the previous chapter [176].  This might explain why one individual has no phenotypic evidence 
of renal disease, and is therefore an obligate carrier. 
Another limitation with the traditional linkage approach concerns the size of the linked region.  
The 15 cM linked interval contained nearly 170 genes, none of which appeared to be directly 
related to renal pathophysiology.  High density SNP arrays such as that used in this project give 
high resolution of the boundaries of a given linked region.  However, the occurrence of 
homologous recombination in meiosis occurs at a far lower frequency than the information 
that 300,000 markers can provide.  In contrast to the determination of the LOD score, 
determination of the linked region is a stochastic process that depends on the recombination 
frequency at a given locus.  Thus while recruiting additional individuals to the study can give 
additional power to the LOD score, it does not necessarily reduce the size of a linked region.  
Even very large pedigrees may not give a clear association with just a single gene, as seen with 
MCKD1 [210]. 
4.3.02 CH analysis 
As discussed in the previous chapter, a major limitation with linkage analysis is the existence of 
phenocopies.  In family 1505 discussed in the previous chapter, 4 of 19 affected individuals 
were found to be phenocopies.  This rate would reduce the strength of linkage association 
significantly.  I therefore also utilised CH analysis in family 1508 to look for regions that were 
identical by descent (Figure 4.5).   Given the existence of 25% phenocopies in the 1505 
pedigree, we chose to look for shared regions in multiple subsets of the pedigree.   
We arbitrarily selected to investigate all combinations of 11 (out of a possible 14) affected 
individuals that included the four subjects with ESRD.  This approach is equivalent to 
performing parametric linkage analysis on combinations of 11 affected individuals to identify 
all possible linked regions.  However, because CH analysis is so much faster it was possible to 
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perform this sequential analysis in a few minutes, rather than the days it would have taken 
with linkage analysis.     
I assumed in this analysis that none of the individuals with ESRD were phenocopies.  Although 
urinary abnormalities and elevated serum creatinine may be non-specific, ESRD is still a rare 
diagnosis.  Moreover, all of these individuals reached ESRD at a young age, further increasing 
the specificity of this diagnosis.  By fixing on combinations involving the four subjects with 
ESRD this analysis looked to see which individuals shared regions that were IBD with them.  It 
was then possible to evaluate the strength of evidence for renal disease in these individuals.  
The regions that are IBD between these four individuals are shown in Figure 4.5.  I did not 
detect any linked regions in this subset analysis that corresponded to genomic regions 
containing genes that are known to be linked to renal disease. 
4.3.03 Whole Genome Sequencing 
Genotyping technologies have enabled the routine assessment of common variants at up to a 
million sites across the genome in thousands of individuals and have increased our 
understanding of human genetic diversity and its biological and medical impact [211, 212].  
Whole genome sequencing costs have fallen from the >$100 million cost of the first human 
genomes to the point where individual labs have generated genome sequences in a matter of 
months for a material costs of only a few thousand dollars [70, 213, 214].  Sequencing 
technologies use a variety of genomic microarray construction methodologies and sequencing 
chemistries [71]. 
Whilst the cost of the various technologies available is the determining factor for many, it is 
also important to consider the individual methodology.  We utilised human genome 
sequencing using unchained base reads on self-assembling DNA nanoarrays [211].  In common 
with other technologies the first stage of this technology is the construction of a library of 400 
nucleotide genomic DNA fragments.  These fragments are then circularised and a series of 
directional adaptors inserted following recursive cutting with type IIS restriction enzymes.  The 
resulting circles are then amplified to form hundreds of tandem copies in palindrome-
promoted coils, referred to as DNA nanoballs (DNBs). The DNBs are then bound to patterned 
silicon arrays, where they can be read using high accuracy combinatorial probe anchor ligation.  
This generated independent reads up to 10 bases adjacent to each of eight anchor sites, 
resulting in a total of 31- to 35-base mate-paired reads (62-70 bases per DNB). 
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The sequencing data that was returned to us contained information at four levels of analysis.  
First, the vast majority of variants were composed of single nucleotide substitutions, small 
insertions or deletions.  These were defined as variants located within one base of each other, 
with the result that they would affect the same amino acid codon.  The remainder of the 
analysis was directed at other, less frequent, genetic variants, namely: copy number variation, 
chromosomal translocations, and mobile element insertion.  These are harder to detect, as 
they depend on the reliable detection of chromosomal breakpoints, which in turn depends on 
the read depth, and require de novo sequence assembly. 
Quality metrics for the data generated show that our results were in keeping with other 
sequencing technologies.  Over 97% of both genomes and exomes were fully called.  As shown 
in Table 4.2, there were around 2 million of these variants per genome, which is keeping with 
the expected number of this kind of data.  Moreover, the SNP transitions/transversions ratio 
was 2.133 and 2.138, which is again close to the expected ratio of 2 across the whole genome 
and slightly higher in exomic regions. 
4.3.04 Variant filtering 
In order to reduce the number of possible variants I filtered the WGS data in a number of 
ways.  First, I assumed that renal disease is caused by a single variant in a gene, which is 
inherited in an autosomal dominant fashion in this out-bred pedigree.  This variant would 
therefore be heterozygous in both individuals that were sequenced.  Consequently, the first 
filtering step was to search for all those variants which occurred only once in each subject.  The 
number of variants identified at this stage is related to the genetic distance between the two 
individuals we chose to sequence.  Given that they are separated by five meioses they ought to 
share no more than 1/25 = 3.125% of the genome.  We observed that 3.811% of the mean 
2047498 variants were shared, which supports this interpretation. 
The definition of a heterozygous variant is important, as it relates to the quality of the 
sequencing read.  Each variation from the reference genome is scored for quality.  This 
variation score reflects both the depth of read as well as the number of minor allele reads.  
Where the ratio of minor allele to reference reads is in excess of 20/40, this is scored with high 
confidence.  Where the ratio is above 10/20, there is only a 10% chance of the minor allele 
read being correct, and thus the score is low.  Below 10/20 no call is made.  This impacts on 
how we filtered for common heterozygous variants.  The highest confidence can be attached 
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to variants called as 1/0 in each individual; however we chose to include those called as 1/N 
(where 0 is reference, 1 alternative, and N uncalled). 
Next, I elected to concentrate on just those variants which involved the coding sequence and 
splice sites of known proteins.  This significantly reduced the number of variants by a further 
98.832%, which is in broad agreement with the estimate that the total human exome 
comprises 1.5% of the genome [215].  The exome is believed to harbour much of the 
phenotypic variability in an individual, and in contrast to association studies the vast majority 
of genetic variants with a major phenotypic impact have been discovered within protein 
coding regions [216].  The number of variants was then reduced by a further 76% by discarding 
all those which did not change the amino acid sequence of a protein.  This left us with a total 
of 217 single nucleotide polymorphisms, insertions, or deletions shared between two first 
cousins once removed. 
In order to reduce the 217 variants even further, I then used the results of the previous linkage 
analysis.  By looking at just those regions which are IBD in all four individuals with ESRD (Figure 
4.5B), encompassing two regions on chromosome 10 and one on chromosome 1, the number 
of variants of interest was reduced further to 69.  It remains possible that one or more of these 
individuals is a phenocopy; however, I thought this was a necessary assumption to make in 
order to reduce the number of variants to a manageable level. 
With so few variants remaining it became possible to study them in more detail.  In particular 
we wanted to know what proportion of these were novel; the assumption being that if one of 
these variants did cause ESRD it would not be common in the population.  We therefore 
determined the minor allele frequency for each variant by looking at the NCBI and 1000 
genomes databases [217, 218].  A problem with this approach is that these datasets do not 
include any phenotypic information, and so it is possible that variants with reduced or 
incomplete penetrance could be included unknowingly.  Early estimates that ~80% of an 
individual’s nonsynonymous variants are common in the population [215] look to be 
increasingly conservative as more and more sequence data is accumulated, making this 
possibility more likely.  Consequently all variants with MAF > 0.005 were excluded. 
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4.3.05 In silico prediction of pathogenicity 
This left us with a list of six novel variants to take forward to more detailed analysis.  As 
indicated previously, none of the genes in the linked intervals appeared to be directly related 
to renal pathophysiology.  One approach was to use bioinformatic tools to look in silico for the 
consequences of these polymorphisms.  A second approach was to look directly at the 
frequency of these variants in the Cypriot population.  This could tell us both whether the 
variant was common, and also if might be associated with renal disease in another family.  
Lastly we could study any promising candidates in vitro, using both cultured cell lines and 
primary cells derived from patients in this family. 
One of the consequences of the next-generation sequencing technology is the generation of 
vast numbers of genetic variants in an individual, many of which have to be tested for their 
disease-causing potential.  Automated pre-evaluation of sequence variations can help to direct 
the subsequent in-depth analysis to the most promising candidates [158, 219].  The evaluation 
of variants is based on two main factors: the evolutionary conservation of a particular 
sequence across species and the predicted effect of an amino-acid exchange on the function of 
a particular protein domain in a related protein [159].  Evaluation tools are typically trained on 
a dataset consisting of known pathogenic mutations and compared to a dataset of benign 
SNPs [158, 160]. 
4.3.06 Population genotyping 
Most of the genetic variants in any one individual have been previously observed in other 
individuals. However, the proportion of previously discovered SNPs and novel SNPs is changing 
over time as databases are updated. Given the small size of the Cypriot population it is likely 
that there are genetic variants in this population that have not yet been deposited in public 
databases, but which are still common on the island [218]. 
We therefore designed a tetra-primer ARMS PCR reaction to study each of these variants in a 
population that we had access to: the Turkish Cypriot ESRD population (Table 4.5).  However 
this approach does confuse two important issues.  First, by looking at a population with ESRD 
we are potentially selecting for those variants which are associated with renal disease.  
Second, it would have been better to look for these variants in a representative sample of the 
Greek Cypriot population, since that is the population from which the family comes.  As 
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discussed earlier, however, there is evidence of gene flow between the populations.  The 
differences that do exist between the populations make the discovery of these variants if 
anything more significant. 
The result of this experiment shows that three of these variants were associated with 
significant minor allele frequencies.  We were able to interrogate the primary renal diagnosis 
in each of the individuals carrying these variants, and it was apparent from some diagnoses 
that these variants could not be the sole cause for renal failure.  Consequently there were now 
only three variants to consider for function assessment in vitro. 
4.3.07 Candidate gene selection 
In the absence of any clear in silico prediction that one of these three variants was most likely 
to be pathogenic, we had to prioritise the best candidate for functional studies.  This was done 
by performing a thorough literature search on each of these candidates, as well as looking for 
evidence of gene expression in the kidney, and if possible, evidence of a renal phenotype from 
animal knockout studies. 
Protocadherin-15 (PCDH15) has been implicated in the development of cochlear hair cell 
stereocilia.  Mutations in PCDH15 cause Usher syndrome, which is characterised by congenital 
deafness, vestibular dysfunction and retinitis pigmentosa [220]. Deletion in the mouse 
produces the Ames waltzer phenotype, while a rat Pcdh15 knockout also shows severe defects 
in cochlear hair cell stereocilia, collapse of the organ of Corti, and marked reduction of 
ganglion cells.  There is no reported renal phenotype. 
Although PCDH15 lies within the shared haplotype of the four individuals with ESRD, it lies 
outside the linkage peak generated from analysis of the whole family.  Importantly, 1505 401 
who had a renal biopsy in 1996 and continues to have proteinuria, does not carry the variant in 
PCDH15, while his phenotypically normal cousin, 1508 402, does.  If 1508 401 does have the 
same condition as the rest of the family, then this is an informative meiosis, which would 
exclude PCDH15 from the list of candidate genes. 
DEAH (Asp-Glu-Ala-His) box polypeptide 32 (DHX32) is a novel gene with homology to the DHX 
family of RNA helicases. It is expressed in most cell types, and predominantly localised in the 
nucleus and mitochondria. The murine homologue, Dhx32, showed strong expression in the 
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mouse kidney, with significant protein expression in kidney tubules and little expression in the 
glomerulus [221].  The pattern of expression in various tissues was thought to suggest a cell-
type dependent mechanism regulating Dhx32 expression.  There is also evidence to suggest 
that DHX32 expression correlates with human thymocyte maturation [222], and thus may play 
a role in lymphocyte differentiation [223]. 
Inositol polyphosphate 5-phosphatase F (INPP5F), also known as phosphatidylinositide 
phosphatase SAC2, is a 1,132 amino acid protein.  It is ubiquitously expressed, but especially 
abundant in kidney, brain, heart, and skeletal muscle [224].  It exhibits 5-phosphatase activity 
specific for phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-triphosphate.  
However, unlike other 5-phosphatases, such as oculocerebrorenal syndrome of Lowe (OCRL) 
and inositol polyphosphate-5-phosphatase (INPP5E) that have well established associations 
with renal disease [225, 226], INPP5F does not contain the two conserved motifs that are 
essential for 5-phosphatase activity.  The variant we had uncovered was a threonine to serine 
substitution at the C-terminal of the protein, well away from the SAC domain where the 
phosphatase activity is believed to reside. 
Inositol and phosphatidylinositol phosphates are important for numerous cellular processes, 
including neuronal survival and signal transductions from growth factors, neurotransmitters 
and G protein coupled receptors.  INPP5F also modulates the v-akt murine thymoma viral 
oncogene homolog 1 (Akt)/glycogen synthase kinase 3 beta (GSK-3β) pathway by decreasing 
Akt and GSK-3β phosphorylation [227, 228]. It appears to play a role in the developing mouse 
brain, as well as in the response to cardiac hypertrophy.  The mouse with homozygous inpp5f 
knockout was not reported to show a renal phenotype; however the cardiac phenotype under 
study was mild, and required exogenous challenge to manifest itself [227]. 
4.3.08 Urothelial Cell Culture 
As discussed earlier, the clinical phenotype in this family is of progressive renal impairment 
with minimal contribution from proteinuria and microscopic haematuria.  This description 
would fit with a broadly tubular phenotype.  Consequently I sought to look at the expression of 
these candidate genes in renal tissue.  The most direct way of doing this would be to look at 
renal biopsy tissue from this family, however none was available to me, and moreover all the 
biopsies obtained to date had been fixed in formalin.  I therefore sought to look at gene 
expression in cultured renal tubular cells obtained from a number of individuals in this family. 
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As part of normal physiology, approximately 2000 to 7000 cells from the human urinary tract 
detach and are excreted in the urine each day [161].  The majority of these cells come from the 
extensive network of renal tubules, whose total surface area is greater than that of the skin, 
rather than the downstream parts of the urinary tract, including ureters, bladder, and urethra.  
These cells, hereafter termed urothelial cells, are not damaged, but are fully functional and can 
be used for in vitro studies.  
The efficiency with which urothelial cells can be cultured is quite variable, and depends on a 
number of factors, such as urinary pH and retention time, as well as on individual factors such 
as age and medication use [161, 229, 230].  Urothelial cells give rise to two main types of 
morphology, which may correspond to differing renal origins [229].  Urothelial cells also have 
limited lifespan in culture (1-6 passages), which makes it very hard to perform functional 
studies.  
In order to validate this model, I first showed that these cells expressed epithelial markers that 
confirmed that they were indeed of urothelial origin.  A range of urothelial markers have been 
used, mainly for immunohistochemical use or by stem cell biologists.  I designed primers for 
three genes, E-cadherin (CDH1), keratin-7 (KRT7), and L1 cell adhesion molecule (L1CAM), and 
studied expression relative to a control population of primary dermal fibroblasts.  E-cadherin is 
a classical marker of the epithelial lineage, first expressed at the 2-cell stage of embryogenesis.  
KRT7 is a cytoskeletal protein found in simple glandular epithelium, and used as a histological 
marker of epithelial origin in urothelial cancer [229, 231].  L1CAM is a cell adhesion marker 
that is predominantly expressed in the late connecting tubule and collecting duct [232]. 
I cultured urothelial cells from a number of individuals in this pedigree (Figure 4.6).  Of note, 
one individual (1508 304) had a functioning renal transplant at the time of collection, and by 
performing tetra primer PCR I was able to show that three separate urothelial cell colonies 
from this individual were all derived from the transplant donor and not from the individual in 
question, thus confirming the origin of these cells in the upper renal tract.  Analysis of gene 
expression showed that all urothelial cell lines were derived from the renal collecting duct. 
4.3.09 Expression of candidate genes in cultured cells 
Detailed functional analysis has now become the most challenging and time-consuming stage 
of the investigation of novel genetic causes for human disease.  In the absence of characteristic 
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findings on clinical or biopsy examination in this family, we had no a priori reason to choose 
between the three candidate genes identified by next generation sequencing.  I therefore 
designed primers to look at the expression of all three genes in cultured urothelial cells (Figure 
4.7).   
There was no difference in the expression of any candidate genes in urothelial cells from one 
affected patient in this pedigree.  Notably however, both DHX32 and INPP5F are expressed at 
higher levels in urothelial cells than fibroblasts, compared to PCDH15.  This would suggest that 
DHX32 and INPP5F are important in this cell type, and consequently that alterations in function 
might lead to disease. 
There are however a number of problems with this experiment.  First, these cells showed a 
wide variety of gene expression, which may be consistent with the fact that they were a 
primary cell line, and not a homogenous tumour cell line.  Second, although these cells express 
markers consistent with their urothelial origin, I was not able to identify their precise tubular 
origin.  Notwithstanding the role that many other cell types, such a glomerular cells or 
fibroblasts, play within the kidney, it is therefore possible that I was studying the wrong cell 
population.  Third, by sampling adult patients I may have been investigating the wrong 
developmental time point.  Finally, and perhaps most importantly, it is very possible that a 
non-synonymous coding variant may have absolutely no effect on transcript expression.  The 
next stage of analysis would therefore be to look at the effect of these coding variants on 
protein expression and function. 
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4.4  Conclusions and future work 
A number of genes that are critical to kidney function in humans have been discovered in the 
last few years through the investigation of inherited renal disease [23-25].  I have studied a 
large Greek-Cypriot pedigree in order to discover another such gene.  This family contains four 
individuals who developed ESRD at a young age and a large number of individuals with 
evidence of milder renal disease.  Linkage analysis revealed a peak on chromosome 10 that did 
not include any genes known to be associated with renal disease.  Given the size of the linked 
interval, I arranged for whole genome sequencing of two first cousins once removed.  After 
appropriate filtering I was left with six novel heterozygous variants.  Three of these variants 
occurred with significant frequency in the Turkish-Cypriot population and could therefore be 
excluded. 
In order to study the effect of these variants in vitro, I cultured primary cells from individuals in 
this pedigree.  I used urothelial cells derived from the renal collecting duct to look at gene 
expression, but was unable to find any effect. Urothelial cells are easily available; however 
they do not persist for long in primary culture.  Dermal fibroblasts are a much more durable 
source of primary cells and would offer an alternative approach to studying the effect of these 
variants.  Alternatively, urothelial cells could be immortalised, or transformed into induced 
stem cells, allowing long-term culture and the possibility of studying renal development in vitro 
[161]. 
Two candidate variants remain at this stage of the investigation, affecting DHX32 and INPP5F.  
Given the lack of distinctive phenotype in the family it is difficult to know which may be 
responsible.  DHX32 is strongly expressed in renal tubular cells, and may play a role in cell 
differentiation through effects on translational machinery.  INPP5F has been shown to 
modulate the Akt/GSK-3β pathway, which may be more amenable to study in cultured cells.  
However, neither variant is predicted to be especially pathogenic using current bioinformatic 
algorithms.  
The difficulties faced by this study are illustrative of the limitations associated with recent 
advances in next generation sequencing technology.  The main assumptions I have made are 
that the genetic mutation is shared by all four individuals with ESRD in this family, and that it is 
exonic.  I have obtained a large quantity of high quality sequencing data, which has enabled 
me to show that renal disease co-segregates with just two novel variants in this family.  
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However, in the absence of a distinguishing phenotype or candidates with obvious mechanistic 
impact it becomes very difficult to demonstrate how these variants might be responsible for 
renal disease. 
The identification of recessive conditions by next generation sequencing is significantly easier 
than the identification of dominant conditions because the genome of any given individual has 
around 50 times fewer genes with two, rather than one protein altering allele per gene [73].  
Moreover, there remains a significant failure rate in the emerging studies that have used next 
generation sequencing to identify causative mutations in a cohort of patients with a given 
clinical phenotype [23, 233].  The recent identification of mutations in coding variable-number 
tandem repeats causing medullary cystic kidney disease type 1 are indicative of the challenges 
facing mutation discovery using massively parallel sequencing [234].  Consequently, the 
explanation for these failures of exome sequencing may ultimately help with identifying the 
mutation in this family.  Fortunately the sequence data we obtained for this family includes all 
the intronic data that I have excluded from analysis so far.  Furthermore, detailed clinical 
phenotyping of younger members in the family may help to identify candidate genetic 
pathways which we are now able to study in vitro. 
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Chapter 5   Mitochondrial kidney disease 
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5.1  Introduction 
5.1.01 Mitochondrial disease 
Linkage analysis is a robust tool for identifying the genetic basis of familial disease; however it 
assumes the manner of inheritance is understood.  SNP-based linkage studies such as those 
discussed in chapter 4 are well suited to investigation of dominant or recessive autosomal 
conditions.  However parametric linkage analysis requires that the correct mode of inheritance 
is specified, and analysis of sex-linked disease requires a different model.  In addition to 
maternal inheritance due to X-linked disorders, a rare group of maternally inherited conditions 
are due to mutations in mitochondrial DNA (mtDNA). 
Human mtDNA was first sequenced in 1981 [235], and the first pathogenic mutations were 
described within a decade.  The mitochondrial genome is circular double-stranded DNA 
molecule of 16.6 kb, which encodes 13 proteins of the respiratory chain and 24 RNA genes 
[236].  More than 200 molecular defects have subsequently been described in patients with 
mitochondrial diseases [141, 237].  Point mutations can affect the various structural subunits 
of the respiratory chain, or compromise protein synthesis through the RNA genes.  
Alternatively large scale deletions of mtDNA remove one or more essential genes. 
There are three major differences between mtDNA and nuclear genomic DNA.  First, 
mammalian cells contain many copies of mtDNA, ranging from a few hundred to hundreds of 
thousands, depending on the cell type.  Although the amount of mtDNA appears to be 
regulated in a tissue-specific manor, this can change over time through poorly understood 
regulatory mechanisms [238].  Second, pathogenic mutations can affect a variable proportion 
of the many mtDNA molecules, a situation known as heteroplasmy.  The percentage of mutant 
mtDNA can vary between people, between tissues within an individual, and even between 
adjacent cells of the same individual [239].  Cells that contain a high percentage of mutant 
mtDNA express a biochemical defect, and this is often associated with a reduced amount of 
wild-type mtDNA [240].  Tissues and organs that contain many such affected cells may then 
give rise to the clinical features of disease.  Third, mtDNA is exclusively inherited down the 
maternal line [143].  This means that men with mtDNA disease cannot pass on the disorder to 
their offspring.  Women harbouring heteroplasmic mtDNA mutations pass on very different 
levels of mutant mtDNA to their offspring.  This occurs because only a small group of maternal 
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mtDNA molecules are transmitted in oogenesis, resulting in rapid shifts in heteroplasmy levels 
within a generation due to statistical sampling effects [241, 242]. 
Mitochondrial disease typically affects the CNS and muscle tissue; possibly because both are 
post-mitotic and ectoderm derived.  However there is good evidence for renal involvement in 
mitochondrial disease [243].  Thus there is a renal phenotype in some complex mitochondrial 
disorders, including Kearns-Sayre, Pearson, and Leigh syndromes [142]. There is an increased 
prevalence of deletions and SNPs in ESRD, however the extent to which these are contributory 
remains unknown [24].  Typically mitochondrial renal disease is associated with tubular and 
interstitial nephropathy and glomerulosclerosis. 
5.1.02 Transcription of mitochondrial DNA 
Transcription of human mitochondrial DNA is driven by a single subunit RNA polymerase and a 
set of transcription factors [244].  The two strands of mtDNA are differentiated by their 
nucleotide content with the guanine rich strand referred to as the heavy strand, and the 
cytosine rich strand referred to as the light strand [236].  In human cells each strand contains a 
promoter region for transcriptional initiation, the heavy strand promoter (HSP) and light strand 
promoter (LSP) (Figure 5.1) [245].  HSP transcription is initiated from two specific start sites, 
HSP1 and HSP2 [246, 247].  Both heavy strand promoters direct the synthesis of a poly-
cistronic transcript which is subsequently cleaved by excision of the intervening tRNA 
transcripts to generate mature mRNA and rRNA molecules.   
Intracellular levels of mature 12S and 16S rRNAs are in great excess to mRNAs [248].  This is 
now thought to be due to the action of the HSP1 site, which produces a transcript that 
terminates at the 3’ end of the 16S rRNA gene [236].  In vitro measurement of HSP1 activity 
suggests that it is over 100 times stronger than the HSP2, however the HSP2 is responsible for 
the production of a full length heavy strand transcript [249].  Moreover the relative 
insensitivity of the in vitro system means that the exact role of each site in vivo remains 
unclear [244].   
The replication of mtDNA is also carried out by unique enzymatic machinery encoded by the 
nuclear genome.  Transcription from the LSP is not only necessary for gene expression, but it 
also produces the RNA primers required for initiation of mtDNA replication at the origin of H-
strand DNA replication [236].  MtDNA replication occurs continuously throughout the cell cycle 
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[247]; however the switch between genomic length transcription and RNA primer formation 
and subsequent replication is not understood.  
 
 
Figure 5.1 The mitochondrial promoter region 
The mitochondrial D-loop region contains the three promoters that direct transcription of the mitochondrial DNA 
(mtDNA) heavy and light strands (HSP1, HSP2, and LSP), as well as the origin of heavy strand replication (OH).  
Transcription from the HSP1 produces a short transcript encompassing the two ribosomal RNAs (shown in green), 
RNR1 and RNR2, and two tRNA molecules (shown in orange) for phenylalanine and valine (F and V). This 
transcript is terminated by the action of the mitochondrial transcription termination factor (mTERF) which binds 
with high affinity to a site within the leucine tRNA (L).  HSP2-initiated transcription produces the remaining 
mitochondrial mRNAs by processing nearly the full length of the mtDNA, including the genes for NADH-
dehydrogenase subunit 1 (ND1) and  cytochrome B (Cyt b). 
Moreover, the molecular mechanism controlling mtDNA copy number in a given cell remains 
unknown.  There may be an origin of replication for mtDNA maintenance under steady state 
conditions that is distinct from the origin required for recovery after mtDNA depletion and for 
accelerating mtDNA replication in response to physiological demands [250].  Copy number may 
also be influenced by the packaging of multiple mtDNA molecules into nucleoids [236, 251].  
Two mtDNA maintenance proteins, mitochondrial transcription factor A (TFAM) and the 
mitochondrial helicase Twinkle are known to correlate linearly with mtDNA copy number [252, 
253].  Lastly, there is a link between copy number and the energetic requirement of the cell, 
hence the differences in copy number observed between different tissues  [238], and between 
the same cells exhibiting different levels of reactive oxygen species [254].  This last may help 
explain the persistence of DNA within the mitochondria when, according to the widely held 
endosymbiant theory [255], so much of the original proteobacterial genome has been 
transferred to the nuclear genome [236]. 
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5.1.03 Cellular energy production 
The best understood role of mitochondria is the production cellular energy and the regulation 
of cellular metabolism.  Adenosine triphosphate (ATP) is generated through the aerobic 
respiration of pyruvate and reduced nicotinamide adenine dinucleotide phosphate (NADH) by 
over a hundred proteins organised into five respiratory chain complexes on the inner 
mitochondrial membrane.  Each pyruvate molecule produced by glycolysis is actively 
transported into the mitochondrial matrix where it is combined with coenzyme A to form CO2, 
acteyl-CoA and NADH.  The acetyl-CoA is the primary substrate to enter the tricarboxylic acid 
(TCA) cycle.  The TCA cycle oxidizes the acetyl-CoA to carbon dioxide, and, in the process, 
produces reduced cofactors that are a source of electrons for the electron transport chain.  
Reducing equivalents can also be imported from the cytoplasm to feed into the electron 
transport chain.  This establishes a gradient of protons within the inter-membrane space that 
is used to generate ATP. 
In addition to supplying cellular energy, mitochondria are also at the centre of cellular redox-
dependent processes [256].  A small percentage of electrons within the inter-membrane space 
may prematurely reduce oxygen, forming reactive oxygen species (ROS).  Mitochondria both 
generate ROS that drive redox-sensitive events, and respond to ROS-mediated changes in the 
cellular redox state.  Most cellular ROS are partially reduced forms of molecular oxygen that 
result from electron leak during normal respiration in the mitochondrial electron transport 
chain.  There is now a growing appreciation of the role of ROS in modulating cellular processes 
through redox-dependent signalling [256].  The mitochondrion therefore plays a central role in 
modulating metabolic, energetic, and ROS responses to promote growth and survival or cell 
death in response to a wide range of stimuli. 
Efficient mitochondrial function is therefore dependent on the coordinated function of both 
the nuclear and mitochondrial genomes.  The vast majority of respiratory chain components 
are encoded by the nucleus [257].  Moreover all the proteins involved in transcription and 
translation of the mitochondrial genome are also encoded by the nucleus.  Mitochondrial 
disease can therefore be due to mutations of either mtDNA or nuclear DNA. 
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5.2  Results 
I have studied an English pedigree containing 16 individuals with severe renal disease over 
three successive generations (Figure 5.2).  Twelve individuals were recruited in 1996-7 for 
linkage analysis using limited microsatellite markers; however this approach was unable to 
determine a linked interval.  The pedigree at this time included five individuals with ESRD, and 
four further individuals with renal impairment.  One individual (322 412) had died aged 19 with 
a diagnosis of Batten disease, one of the neuronal ceroid lipofuscinoses (NCL).  The clinical 
diagnosis was confirmed with a skin biopsy in 1993 which showed characteristic curvilinear 
fingerprint profiles on EM, and was thought to be unrelated to the renal condition in the rest 
of the family. 
 
Figure 5.2 Pedigree of family 322 
Individuals with evidence of renal impairment (affected individuals, filled shapes).  Other individuals have either 
married in to the family (obligate unaffected, white shapes), or are phenotypically normal but may go on to 
develop renal impairment and thus were not included in the analysis (indeterminate, grey shapes). 
 
In order to identify the mutation responsible for the renal disease in this pedigree I collected 
clinical details and DNA samples from an additional six individuals in this family.  Of these 
individuals, two had reached ESRD and three others had abnormal renal function.  The clinical 
phenotype in this family was notable for a lack of distinctive features.  The newest member to 
reach ESRD had presented, aged 11, with renal impairment, and progressed to ESRD by age 16 
with only mild proteinuria, no haematuria, normal renal tract imaging and autoantibody 
profile.  In particular there was no evidence of renal tubular acidosis.  He had declined a renal 
biopsy, but his mother (322 307) had one in 2010.  Figure 5.3 shows the appearance of renal 
biopsies from two individuals in family 322 and Table 5.1 lists the main findings in all the renal 
biopsies performed on individuals from this family. 
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Figure 5.3 Renal biopsies from family 322 
Light microscopic appearance of the renal biopsy from 322 303 showing an area of focal tubular atrophy that 
stains strongly periodic acid Schiff (PAS) positive (arrowed, A) and a glomerulus with normal appearance by silver 
stain (B).  EM of the renal biopsy from 322 411, showing normal thickness and appearance of the GBM (arrowed, 
C) and normal appearance of tubular mitochondria (D). 
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ID Date Age Location Findings 
303 1987 30 Oxford 
Small and fragmentary with only 3 glomeruli 
No glomerular abnormality, IF not done, no deposition by 
immunoperoxidase but occasional flecks of C3 
Focal tubulo-interstitial damage with tubular atrophy 
Tubular BM strongly PAS positive in atrophic areas 
EM: not performed 
411 1994 22 Oxford 
2/9 glomeruli with global sclerosis 
Immunofluorescence negative 
2 more sclerosed glomeruli on frozen section 
Interstitial chronic inflammation and fibrosis with tubular 
damage 
EM: normal GBM, no immune deposits, normal 
mitochondria 
304 1995 36 Leicester 
2/12 with global sclerosis; otherwise normal appearance 
by light microscopy 
Two small areas of tubular atrophy 
No IF, but immunoperoxidase normal 
EM: single glomerulus with GBM of normal thickness but 
exhibiting odd irregular opacities in place of the lamina 
densa 
301 2010 59 Oxford 
Renal transplant biopsy (23y post-transplant) 
Widespread and focally severe acute tubular necrosis 
Little background chronic damage 
307 2010 43 Leicester 
6/16 glomeruli showing global sclerosis; otherwise normal 
appearance by light microscopy 
Focal tubular atrophy with fibrosis 
No IF, but immunoperoxidase normal 
Congo red stain for amyloid negative 
EM reprocessed from paraffin block but GBM thinned in 
areas (175 to 237 nm) 
Table 5.1 Results of renal biopsies in family 322 
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Seventeen DNA samples were genotyped using the Illumina HumanCytoSNP-12 chip, giving 
nearly 300,000 SNP genotypes per sample.  Preliminary analysis was performed using a subset 
of 9500 SNPs in order to reduce the analysis time.  Genotypes were analysed using PedCheck 
[157], which detected the occurrence of nine Mendelian errors.  These were discarded along 
with 22 genotypes which were thought to be ‘unlikely’ and may correspond to miscalled SNPs 
on the chip.  The remaining genotypes were analysed using GENEHUNTER [154], using the 
EasyLINKAGE interface [153].  The genotypes were divided into sets of markers (80, 100, or 
120) on each chromosome and parametric linkage analysis was performed in all individuals on 
each set, assuming a dominant model of inheritance. 
A number of different definitions of affection status were used, such as only those with ESRD 
or those with CKD in one branch of the family, in case there were phenocopies within the 
pedigree.  Using GENEHUNTER, analysis of the most basic pedigree comprising just those with 
ESRD and obligate carriers gave a LOD score of 2.06.  Analysis of the extended pedigree 
including all those with elevated creatinine produced a LOD score of 2.64.  Importantly, due to 
the size of the pedigree, GENEHUNTER was forced to ignore random individuals from analysis.  
Re-analysis of the linkage peaks on chromosomes 4, 10 and 15 using SimWalk gave a maximal 
LOD score of 1.86.  Haplotype reconstruction demonstrated that no single chromosomal region 
was shared by all individuals with ESRD or with elevated creatinine, as shown in Figure 5.5. 
 
Figure 5.4  Linkage analysis of family 322 
The maximal LOD score using Genehunter was 2.64 in association with a region on chromosome 10.  Haplotype 
analysis revealed that some individuals were discarded by the programme, and repeat analysis using SimWalk 
including all individuals showed that this maximal LOD score was only 1.86. 
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Figure 5.5 Haplotype of family 322 at chromosome 10 linkage peak 
The maximal probability haplotypes generated by SimWalk for the linked region on chromosome 10 were 
visualised using Haplopainter to show the centromeric recombination. 
 
The pedigree shown in Figure 5.2 is also consistent with maternal inheritance, as all affected 
individuals are related in the maternal line, and there is no male to female transmission.  
Parametric analysis assuming an X-linked model of inheritance did not show significant linkage.  
I was also unable to demonstrate a shared haplotype on the X-chromosome using conflicting 
homozygosity analysis.  
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I next proceeded to complete sequencing of the mitochondrial genome.  Fresh urine samples 
were collected from four individuals in this family to obtain DNA for mtDNA sequencing.  
Sequencing was kindly performed by Dr Hudson at Newcastle University.  Table 5.2 shows the 
non-synonymous variants found in all four affected individuals from this pedigree.  The HSP1 
variant was the only one not reported previously.  
 
Variant Location Amino acid MAF 
m.547A>T 
Heavy strand promoter 
1 (HSP1) 
NA Unknown 
m.8508A>G ATP8 Asn>Ser 0.011 
m.8860A>G ATP8 Thr>Ala 0.022 
m.10398A>G ND3 Thr>Ala 0.459 
m.13780A>G ND5 Iso>Val 0.013 
m.14178T>C ND6 Iso>Val 0.020 
m.14766C>T CYTB Thr>Iso 0.256 
m.15326A>G CYTB Thr>Ala 0.008 
Table 5.2 Non-synonymous mitochondrial sequence variants found in family 322 
 
The m.547A>T polymorphism introduces an Mbo1 restriction site into the sequence that can 
then be detected by RFLP analysis, allowing precise quantification of the mutational load using 
labelled primers.  All individuals in the maternal line of this family share the HSP1 
polymorphism at homoplastic levels.  This variant is also amenable to analysis by tetra-primer 
PCR, as shown in Figure 5.6.  In order to determine the sensitivity and specificity of this assay 
for mitochondrial DNA I prepared serial dilutions of patient and control DNA.  The abundance 
of mitochondrial DNA means that this assay could be performed with 1000-fold dilutions of 
DNA, far below the detectable limit of spectrophotometric detection. 
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Tetra-primer PCR was performed on DNA extracted from blood leukocytes, urinary epithelial 
cells and saliva in three individuals with ESRD from family 322.  There was no change in the 
levels of mutant mtDNA in these different tissues.   By comparing DNA collected from 
leukocytes in 1996 and 2011 it was also apparent that there was also no change in the levels of 
mutant mtDNA over time. 
 
Figure 5.6 Tetra-primer PCR analysis of HSP1 polymorphism in family 322 
(A) Occurrence of the m.547A>T polymorphism at homoplastic levels in all individuals descended in the maternal 
line of family 322.  Spouses married in to the family (213, 312, and 327) all show the wild-type PCR product.  (B)  
Sensitivity analysis for the tetra-primer PCR reaction in detecting mitochondrial heteroplasmy.  The mutant 
product is detectable at <5% of starting DNA. 
 
In order to investigate whether the m.547A>T or other HSP1 polymorphisms might be 
associated with renal disease in any other individuals I undertook sequencing of the entire 
HSP1 region in 46 patients with undiagnosed familial renal disease.  Using the D4 primer pair I 
amplified nucleotides 323-752 of the reference sequence, which includes the end of the D-
loop region. Table 5.3 shows the list of variants identified in this region in this cohort. No other 
individuals were found to have the m.547A>T polymorphism described in this family, or any 
other variants in the HSP1 region.  Many other variants were observed, however, including 
those associated with mitochondrial haplogroups such as m.477T>C or m.750A>G 
(http://www.mtdb.igp.uu.se/).    Rare variants were also observed, such as m.368A>G or 
m.523+CA, but the significance of these is not known. 
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Position Region Change Individual MAF Phylotree 
368 LSP A>G 20 0.001 not present 
455 
D-loop 
+T 9, 28 NA 
Present on I1 
(subclade of N) 
462 C>T 18, 42 0.033 J1 
477 T>C 32 0.009 H1 
482 T>C 42 0.007 J1C 
489 T>C 18, 42, 44 0.362 J 
498 delC 39 NA k1c 
513 G>A 8 0.013 homoplastic 
516 C>T 33 0.001 U5b1c2 
523 
TFAM 
+CA 10, 25 NA  
533 A>G 8 0.001 
H10/U5b1f - 
Homoplastic 
573 
D-loop 
+C x7 28 NA 
Common 
tract/repeat 
574 delA 28 0.000  
575 C>T 13 NA H/U - Homoplastic 
709 
RNR1 
G>A 
3, 11, 16, 20, 23, 30, 
35, 36 
0.164 homoplastic 
750 A>G All samples 0.992 All modern humans 
751 A>G 13 NA H2a1e1 
Table 5.3 D-loop variants found in 46 patients with unidentified familial renal disease 
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In order to study the functional significance of this polymorphism, dermal fibroblasts were 
collected from four affected individuals and three of their healthy partners.  Early passage 
fibroblasts were used for all experiments and genotype was confirmed by PCR (Figure 5.7).   
 
 
Figure 5.7 Genotype of primary fibroblasts 
Tetra-primer PCR for the m.547A>T polymorphism shows that DNA extracted from the three control lines (C1-3) 
express the wild-type product (WT) at an equivalent level to DNA extracted from control leukocytes (+ve #1).  The 
four patient-derived lines (M1-4) express the mutant product (MT) at homoplastic levels, equivalent to the 
urinary DNA used in the original sequencing experiment (+ve #2). 
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The function of the m.547A>T polymorphism was assessed in a number of ways, including 
analysis of gene expression and DNA replication.  In order to distinguish between the relative 
importances of mitochondrial transcriptional promoters, I looked at gene expression relative 
to both nuclear and mitochondrial genes (Figure 5.8).  There was a significant reduction in the 
expression of RNR1 (under the control of the HSP1) when expressed relative to MT-CO1 (under 
the control of the HSP2) (Figure 5.8).  This effect was not seen with expression relative to a 
nuclear gene, or with the expression of ND6 (under the control of the LSP) relative to MT-CO1. 
 
 
Figure 5.8 Analysis of gene expression in primary fibroblasts 
Expression of genes under the three mitochondrial transcriptional promoters (HSP1, HSP2, and LSP) was assessed 
by real-time PCR.  There was no effect of genotype on expression of MT-CO1 (A), however the expression of RNR1 
(under control of HSP1) was reduced when expressed relative to MT-CO1 (under control of HSP2, B).  This effect 
was significant when individual cell lines were pooled by genotype (C).  This effect was not seen with ND6 (under 
the control of the LSP, D). 
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I also looked at expression of mitochondrial proteins (Figure 5.9).  There was no effect of the 
HSP1 polymorphism on the expression MT-CO1, when compared the nuclear encoded 
mitochondrial proteins gene, VDAC1 and Cyt C.  It is possible that reduced expression of 
mitochondrially encoded rRNAs would have an effect on the translation of MT-CO1 mRNA.  
However, given that I had previously shown that levels of MT-CO1 mRNA were not affected by 
the HSP1 polymorphism, it is not surprising that there was no effect on protein levels. 
 
Figure 5.9 Analysis of protein expression in primary fibroblasts 
Protein expression of the mitochondrially encoded MT-CO1 was compared to nuclear encoded mitochondrial 
genes, VDAC1 and Cyt C. 
MtDNA copy number appeared increased in patient-derived fibroblasts (Figure 5.10).  This 
difference was significant if control and mutant experimental groups were pooled together 
(Figure 5.10).  However, without knowing the mitochondrial haplogroup of the control 
fibroblasts such comparison may not be valid [258].  
 
Figure 5.10 Analysis of mitochondrial DNA (mtDNA) copy number in primary fibroblasts 
Mitochondrial DNA copy number was assessed in each cell line (A) and pooled (B) by measuring the relative 
expression of ND1 and a single-copy nuclear gene, B2M, using real-time PCR of total cellular DNA [259]. 
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In addition to these measures of transcription and translation, patient-derived fibroblasts were 
used to study mitochondrial function in vitro.  Control cells treated with ethidium bromide to 
deplete their mitochondria were included as a negative control.  Figure 5.11 shows a 
representative trace of the oxygen consumption rate (OCR) measured with the Seahorse 
bioanalyser.  Measurements of oxygen consumption and proton release in patient-derived 
fibroblasts revealed a marked effect of the HSP1 polymorphism (Figure 5.11, Figure 5.12).   
 
Figure 5.11 Oxidative phosphorylation in patient-derived fibroblasts 
Oxygen consumption rate (OCR) was measured every 8 minutes, each data point shows the mean and standard 
error from 3 - 5 replicate wells, normalised for cell number.  Inhibitors of the electron transport chain were added 
at the times indicated, and the measurements used for subsequent analysis are indicated by a yellow star. 
There was a significant reduction in baseline OCR with a compensatory increase in the 
extracellular acidification rate (ECAR) (Figure 5.12).  This was associated in mutant cells with a 
reduction in maximal respiratory rate (after carbonyl cyanide p-[trifluoromethoxy]-phenyl-
hydrazone (FCCP) treatment), respiratory control rate (FCCP – oligomycin), ATP production 
(baseline – oligomycin), spare respiratory capacity (FCCP – baseline), and maximal respiration 
(FCCP – Antimycin A).  However all of these differences disappeared if the results were first 
normalised to basal OCR rates.  The only measure not affected in this way was the proton leak 
(oligomycin – Antimycin A), which was equal under baseline conditions, but significantly 
elevated by normalising to basal OCR (Figure 5.12). 
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Figure 5.12 Analysis of mitochondrial metabolism in patient derived fibroblasts 
Baseline oxygen consumption rate (OCR) measured for all individual cell lines (A) and pooled (B, p < 0.0001).  
Baseline extracellular acidification rate (ECAR) measured for all individual cell lines (A) and pooled (B, p < 0.0005).  
Measurement of proton leak (E), calculated as OCR after treatment with Oligomycin minus OCR after treatment 
with Antimycin (p = NS, but p < 0.05 if corrected for baseline OCR); Ratio of OCR to ECAR (F) showing mutant cells 
have intermediate phenotype (p < 0.005). 
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5.3  Interpretation 
5.3.01 Failure of linkage analysis 
As discussed in chapter 4, the presence of 17 affected individuals in this pedigree would give a 
maximal LOD score of 17 x 0.3 = 5.1.  Consequently, if the kidney disease was due to a single 
genetic variant in this pedigree, linkage analysis should produce a significant LOD score.  That 
this was not observed could be due to one of a number of problems with this type of analysis.  
First, renal disease could be due to the interaction of a number of shared genetic factors 
interacting with a common environment.  However the chance of this occurring in an outbred 
white population is unlikely.  Second, there might be single genetic factor, but the signal from 
linkage analysis be obscured by the presence of phenocopies in the pedigree.  Thirdly, the 
assumption of autosomal dominant inheritance in this family may be erroneous. 
It is difficult to exclude the presence of phenocopies, because the phenotype in this family 
lacks distinguishing features.  As shown in Figure 5.5, if 307 and descendants were all 
phenocopies, this would explain the loss of linkage to this region of chromosome 10.  In 
addition to linkage analysis I also assessed conflicting homozygosity.  Using combinatorial 
analysis I was able to consider different permutations of individuals within the pedigree to see 
whether any groups of individuals shared a haplotype that was IBD.  This analysis did not show 
up any regions that were IBD beyond that expected by chance alone.  Consequently, it is 
unlikely that a small number of phenocopies were obscuring the signal from linkage analysis. 
We therefore concluded that we were incorrect in our assumption of the mode of inheritance.  
The pedigree is also consistent with a maternally inherited disorder, but CH analysis also ruled 
out a shared haplotype on the X chromosome.  MtDNA was not included on the first SNP chips 
used for identifying nuclear disease.  Moreover the high rate of mitochondrial mutation means 
that it is not possible to analyse the mitochondrial genome in terms of linkage disequilibrium.  I 
therefore proceeded to sequence the mitochondrial DNA in this family. 
5.3.02 Mitochondrial sequencing and heteroplasmy 
Due its small size it has been possible to sequence the mitochondrial genome for over 30 years 
[235]. However, the presence of heteroplasmy in most mitochondrial disorders renders the 
sensitivity of this test quite variable.  Levels of a pathogenic mutation can vary both between 
individuals and between tissues [260].  While DNA is commonly obtained from peripheral 
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leukocytes for the assessment of nuclear DNA, it shows high levels of heteroplasmy for 
mtDNA.  Leukocyte DNA may also show progressive loss of mutant mtDNA with time [261, 
262].   
Muscle tissue therefore remains the gold standard for the diagnosis of mitochondrial 
disorders.  However muscle biopsies are invasive and there is evidence that suitable DNA can 
be extracted from other tissues, such as cultured fibroblasts and hair shafts [260, 263].  
Importantly, DNA extracted from urothelial cells shows close correlation with muscle for the 
detection of common pathogenic polymorphisms.  I therefore collected fresh urine samples 
from four affected individuals and one control in this family to obtain DNA for mtDNA 
sequencing. 
Once we had details of the mtDNA sequence I designed a tetra-primer ARMS PCR reaction to 
study the HSP1 polymorphism.  This PCR reaction is dependent on competition between two 
primers with near equal affinity for a DNA polymorphism [152].  With nuclear DNA the reaction 
can give one of three results: heterozygous or homozygous for either allele.  However, given 
the nature of mitochondrial heteroplasmy, allele frequency exists on a continuum from 0-
100%.  The original Sanger sequencing and RFLP analysis that was performed on DNA from this 
family can be used to give an idea of heteroplasmy by looking at the relative intensity of dye 
incorporation, and informed us that this polymorphism was at homoplastic levels. 
I examined the sensitivity of this PCR assay using a range of mixture of wild-type and mutant 
mtDNA.  Figure 5.6 shows that it was sensitive to a 40-fold change in the degree of 
‘heteroplasmy’ for this polymorphism.  It also confirms the observation from Sanger 
sequencing that this polymorphism was at homoplastic levels in this family. 
5.3.03 HSP1 sequencing and mitochondrial polymorphisms 
One important route to determining the pathogenicity of a given polymorphism is to 
determine its prevalence in the general population and in a population with the same 
phenotype.  One of the major issues with the comparison of mitochondrial sequences is the 
high degree of variation within the human population.  There is less publically available data 
on mitochondrial than nuclear sequence variants, however none of the 5680 NCBI sequences 
had the m.547A>T polymorphism and three (including one European) had an m.547A>G 
polymorphism. 
Mitochondrial kidney disease 
Page | 139  
 
In order to investigate whether the m.547A>T polymorphism or any other variants of the HSP1 
region might be associated with renal disease in any other individuals I undertook sequencing 
of the entire HSP1 region in 46 patients with undiagnosed familial renal disease.  These 46 
individuals came from pedigrees that included all modes of inheritance, where known, since 
families with apparently maternal inheritance are so scarce that no single centre is likely to 
have such a collection.  The rationale for sequencing the entire HSP1 region was that if the 
m.547A>T polymorphism did indeed mediate its effect through mtDNA transcription then we 
might have a better chance of picking up other variants affecting promoter binding than just 
looking at a single SNP. 
The mitochondrial haplogroup describes variations from the reference sequence that tend to 
be inherited together.  Other sequence variants reported in this family place it within 
haplotype N, occurring in 1% of the Caucasian population in the UK, and representative of 
early European, Middle Eastern, or Finnish ancestry 
(http://www.mitomap.org/bin/view.pl/MITOMAP/HaplogroupMarkers). 
5.3.04 Fibroblast studies 
Dermal fibroblasts are widely used in studies of human genetic disease.  They are easily 
cultured from a forearm skin biopsy, and are able to survive in culture for a number of 
passages.  Skin biopsies typically contain a mixed population of cells, including keratinocytes 
and micro-vascular endothelial cells; however fibroblasts become the dominant cell type 
within a few passages in routine conditions. 
Adaptation to growth in culture medium is an important limitation with the study of cultured 
fibroblasts.  Fibroblasts become highly glycolytic soon after removal from the body when 
grown in glucose rich medium, such as that used in this study (4.5 g/L) [264].  High glucose 
itself is a mitochondrial stressor [265].  In addition to adaptations to culture media, some 
substrates are critical to the normal growth of cells harbouring certain mitochondrial 
mutations, namely pyruvate and pyrimidines [266, 267]. 
Early studies of osteosarcoma cells that lacked mtDNA showed that they were auxotrophic for 
pyruvate [266].  The leading explanation for this is that excess pyruvate is essential to prevent 
an excessive shift in the ratio of NAD to NADH in the absence of oxidative phosphorylation 
[268].  Cells with mitochondrial mutations are also auxotrophic for pyrimidines, which can be 
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overcome by supplementing cells with uridine [267, 269].  This is due to the coupling of a 
critical enzyme in the pyrimidine biosynthetic pathway, dihydroorotate dehydrogenase, 
located on the inner mitochondrial membrane to the activity of the electron transport chain.  
Consequently all studies were performed in growth medium supplemented with both pyruvate 
and uridine. 
Ethidium bromide is a cationic mutagen capable of intercalating into DNA during replication. 
Because of its positive charge, it concentrates within negatively charged mitochondrial 
matrixes. This allows determination of cell culture concentrations (typically 50 ng/ml) that 
block mtDNA replication without disrupting nuclear DNA replication [266].  Prolonged 
exposure to ethidium bromide causes selective depletion of mtDNA in human fibroblasts [259, 
268].  MtDNA levels can be repopulated if the duration of exposure is short (1-2 weeks), but 
may become irreversible, with attendant loss of expression of respiratory chain enzymes, such 
as Complex IV [266, 267].  I used control fibroblasts treated with ethidium bromide for 1 week 
as a negative control in the experiments in Figure 5.11. 
There are two major limitations with using fibroblasts to study mitochondrial disease.  First, 
they are quite distinct from the tissue which causes the human disease.  Affected members of 
the pedigree under study do not have any skin phenotype that might be associated with 
mitochondrial disease.  Instead this disease appears to be due to pathology of the renal tubule, 
which is derived from epithelial cells of the mesoderm.  Second, fibroblasts continue to divide 
in culture, whereas a number of mitochondrial diseases are only manifest in terminally 
differentiated tissue, such as neurons or myotubes.  These two limitations may help to explain 
the absence of significant findings seen in experiments using primary fibroblasts.  
5.3.05 Mitochondrial gene expression 
Mitochondrial transcription results in the production of a single poly-cistronic transcript that is 
subsequently cleaved to yield individual RNA molecules.  The HSP1 site is significantly more 
active than the HSP2, and results in the synthesis of a transcript encompassing the first four 
RNAs, namely the two ribosomal RNAs, RNR1 and RNR2, and two tRNA molecules (F and V) 
(Figure 5.1).  I therefore examined the expression of transcripts under the control of HSP1 
(RNR1) and HSP2 (MT-CO1) relative to each other, as well as relative to a nuclear 
housekeeping gene (B2M).  It is not possible to assess the level of the tRNAs by real time PCR 
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due to their complex secondary structure.  However given the poly-cistronic transcript, these 
ought to be expressed at a comparable level to RNR1 and RNR2. 
An additional difficulty with the mitochondrial RNA transcript is that it is not possible to design 
RNA specific primers, due to the lack of introns.  In order to overcome this, I included an 
additional DNase digestion step to the RNA isolation protocol.   Mitochondrial mRNAs undergo 
significant post-transcriptional regulation [270].  However, stable polyadenylation of mt-mRNA 
3’-termini is a common feature, and would have been recognised by the oligo (d-T) primers 
included in the retrotranscription kit. 
Given the high abundance of mitochondrial transcripts assessed by PCR, the effect of this 
promoter could be very small.  This may explain why there was no consistent effect of 
genotype on the expression of either RNR1 or other heavy strand transcripts.  The reduction in 
the ratio of RNR1 to MT-CO1 expression is intriguing, however.  Decreased activity at the HSP1 
would be predicted to reduce transcription of the shorter transcript, while leaving full length 
transcription under the control of the HSP2 unaffected.  Whilst this effect was small, and only 
significant when the cell lines were pooled by genotype, it is possible that this may have a 
significant effect in vivo. 
5.3.06 Mitochondrial protein expression 
The vast majority of mitochondrial proteins are encoded by the nucleus.  I therefore looked at 
the expression of both nuclear and mitochondrially encoded proteins.  I studied 
mitochondrially encoded cytochrome c oxidase 1 (MT-CO1) and the nuclear encoded voltage-
dependent anion-selective channel protein 1 (VDAC1) and cytochrome C (CYCS).  MT-CO1 is 
one of three mitochondrially encoded subunits of the complex IV.  VDAC1 forms a channel 
through the mitochondrial outer membrane that allows diffusion of small hydrophilic 
molecules.  There was no effect of the m.547A>T polymorphism on mitochondrial protein 
expression. 
Comparison of mitochondria across different tissues shows significant correlation between 
protein levels and RNA levels [271]. This suggests that, despite the importance of post-
transcriptional regulation, mitochondrial protein mass is controlled largely at the level of 
transcription [272].  Consequently the failure to detect significant changes in protein 
expression is not surprising given the small difference at the mt-mRNA level.  It remains 
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possible that a subtle difference exists that might be shown by serial protein dilution or careful 
quantitation of band intensity. 
5.3.07 Mitochondrial DNA copy number 
The regulation of mitochondrial copy number is poorly understood, despite the importance of 
this process in human physiology and disease [141, 273].  MtDNA replication occurs 
continuously, regardless of growth state, in both proliferating and post-mitotic cells [247].  
Loss of mtDNA in neurones of the substantia nigra has been shown to be a common cause of 
neurodegenerative conditions, and defects of mtDNA maintenance may have a role in the 
mechanism of aging [273].  Of the proteins required for mitochondrial replication, only TFAM 
and Twinkle have been shown to increase copy number in vivo, when expressed at 
physiological levels [252, 253].  Increasing the amount of mtDNA has been suggested as a 
therapeutic approach in diseases with mitochondrial dysfunction. 
There is also a link between mtDNA copy number and oxidative stress that has been observed 
in human cells [274, 275].  Using a murine cybrid model, defective mitochondria were 
associated with increased mitochondrial biogenesis and increased generation of reactive 
oxygen species (ROS) [254].  In this paper the increased mtDNA copy number was abolished by 
treatment with antioxidants such as N-acetyl-L-cysteine (NAC) and Tiron. 
This implies that the increased mtDNA copy number observed in patient-derived fibroblasts is 
compensation for a reduction in some other aspect of mitochondrial function.  As shown 
previously, the net total level of gene and protein expression is unaffected; however the 
expression per copy of mtDNA is reduced.  This might result in an overall change in 
bioenergetics function or free radical production, which would be even greater in a tissue with 
higher mtDNA copy number.  It is not possible to control the copy number using cultured cells, 
however such experiments may be possible in vitro using a recombinant in vitro transcription 
system [244].  An alternative experiment would be use trans-mitochondrial cybrids to control 
for nuclear background. 
5.3.08 Oxygen consumption rate 
In parallel with these measures of transcription and translation, I employed patient-derived 
fibroblasts to study mitochondrial function in vitro using the Seahorse XF bioanalyser [276, 
Mitochondrial kidney disease 
Page | 143  
 
277].  This instrument provides real time measurement of the extracellular flux of both oxygen 
and protons.  Using a probe to create transient ‘microchambers’ about the cells in culture, it 
uses fluorescent sensors to measure oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR).  Up to 20 assay chambers are usable in one assay allowing internal 
replication and direct comparison of multiple cell lines or conditions. 
Fibroblasts from patients with the m.547A>T polymorphism have a significantly reduced 
oxygen consumption rate compared to controls.  OCR was reduced under basal conditions in 
all four patient-derived cell lines, when compared with three control lines that had been 
collected at the same time.  I used oligomycin to inhibit ATP synthase, giving a measure of ATP 
production, FCCP, an un-coupler that enables measurement of maximal respiration, and 
Antimycin, which inhibits complex III, giving a measure of underlying proton leak and non-
mitochondrial respiration.  These measures were all significantly lower in patient-derived cells, 
however this difference was abolished if rates were normalised for baseline OCR. 
Measurement of proton efflux (ECAR) shows that not only are patient cells less oxidative, but 
they are also more glycolytic.  This would enable the cells to maintain the same energy balance 
as control cells, and explains why these cells appeared to behave identically in culture to 
control fibroblasts. 
One limitation of these results is that prolonged growth in culture is associated with a 
progressive decline in respiratory capacity as measured using the Seahorse XF bioanalyser.  
This may represent a switch to glycolysis, as discussed previously, or alternatively it may reflect 
cellular senescence or some other mechanism entirely.  Using a whole cell fluorescent 
measure of ATP, as much as 85-90% of ATP generation in these cells is unaffected by 
treatment with oligomycin (data not shown).  Irrespective of the mechanism, a skin biopsy 
required culture for 3-4 weeks before there were sufficient cells to analyse. 
Although these cells exhibited reduced OCR under standard culture conditions in high glucose 
media, it is hard to explain mechanistically how this has come about.  I utilised specific 
inhibitors for complex III, IV, and V, which did not reveal any differences in in function once 
baseline had been corrected for.  It is also possible to use specific substrates for complex I, II, 
and IV, which should correct loss of function at these earlier stages of the electron transport 
chain [254].  Previous studies of mitochondrial cybrids containing a tandem duplication of the 
HSP region showed no effect on oxidative phosphorylation [278], however it appears that 
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larger deletions including the HSP region show abnormal mitochondrial proliferation and COX 
staining in vivo [279].  It remains unclear, therefore, why this promoter variant has such a 
significant effect on mitochondrial function. 
5.3.09 Genetic factors affecting mitochondrial metabolism 
There are two additional considerations that may be relevant to the differences in oxidative 
metabolism shown by patient fibroblasts.  First, the diagnosis of Battens disease may not be 
entirely unrelated to the disease seen in the rest of the family.  There is evidence of 
mitochondrial involvement in this condition, notably with evidence of morphological and 
functional alterations in both human and animal NCL fibroblast cultures [280, 281].  In the 
English setter model of disease, impaired mitochondrial function was noted in heterozygous 
animals [282].  While I have shown that no single autosomal region can account for renal 
disease in this family, it is possible that a heterozygous NCL mutation might be contributing to 
the mitochondrial phenotype observed in the fibroblasts from the four individuals studied 
here.  Conversely it is possible that the label of Batten disease was in fact a forme fruste of the 
mitochondrial disease evident in the rest of the family. 
Second, there is some work now suggesting that mitochondrial haplogroup can also influence 
oxidative phosphorylation.  Interest in the field was triggered by epidemiological studies 
showing differences in the risk of developing mitochondrial diseases, such as Leber’s 
hereditary optic neuropathy (LHON), in different haplogroups.  Subsequent research was 
conducted in cybrid models, enabling the researcher to reduce the influence of nuclear DNA 
seen in primary cell cultures.  No detectible differences in respiratory function were observed 
when mtDNAs belonging to European haplogroups X, H, T and J were used in a study by Carelli 
et al 2002 [283].  However, more recently haplogroup J cybrids were shown to display lower 
oxygen consumption, mitochondrial inner membrane potential and total ATP levels than 
haplogroup H [258].  Moreover there is good evidence to suggest that variations in mtDNA 
influence the response to various drugs [284].  Given that the haplogroup of this family is rare 
in the UK, it is conceivable that the observed difference in oxidative metabolism is due to 
differences in haplogroup between patients and controls. 
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5.4  Conclusions and future work 
This chapter describes the investigation of another large pedigree with multiple members 
affected by renal disease across three generations.  Linkage analysis was not consistent with 
inheritance of a mutation in nuclear DNA, and the pedigree is consistent with a maternally 
inherited disorder.  Subsequent sequencing of the mitochondrial genome demonstrated a 
novel polymorphism of the HSP region that was thought to be potentially pathogenic. 
I have cultured primary dermal fibroblast derived from individuals in this pedigree with renal 
disease.  Fibroblasts demonstrated two abnormalities; first, an increase in the mtDNA copy 
number, and second, a reduction in oxidative respiration with an associated increase in 
glycolysis.  This occurred in the absence of changes in mitochondrial gene or protein 
expression.  Increased copy number has been suggested to act as a defence mechanism 
against the damage caused by ROS production, which may in turn be a consequence of 
defective mitochondria [254, 275].  There is evidence that increased copy number can be 
maladaptive [273]; however it remains to be determined whether the response seen here is a 
secondary adaptation or part of the primary pathological process. 
In order to pursue this mechanism further, there are three main strategies.  First, we need to 
sequence a large number of similarly affected individuals to see whether this polymorphism 
occurs in any other families with renal disease.  I have already sequenced 46 carefully selected 
individuals; however such a study would ideally consider hundreds of individuals.  The rarity of 
this haplogroup in the UK makes it hard to select an ideal comparator population.  It would 
seem logical to concentrate on the population geographically close to this family, although this 
might just identify other individuals descended from a common founder. 
Second, given the limitations of culture in high glucose medium discussed, it might be 
informative to see how these cells behaved in a medium where glycolysis was inhibited.  One 
possibility here would be to culture the cells in galactose which reduces the amount of ATP 
generated by glycolysis [254, 285].  Third, a significant limitation of these in vitro studies is the 
inability to control for nuclear background.  This could be circumvented by the generation of 
trans-mitochondrial cybrids, which would enable direct comparison of variant and wild-type 
mtDNA sequences.  A further advantage of this experiment is that it is possible to use fresh 
platelets as mitochondrial donors, thereby avoiding the period of time in culture required in 
these fibroblast experiments.   
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6.1  Introduction 
6.1.01 Von Hippel-Lindau disease 
One of the best characterised genetic conditions affecting the kidneys is von Hippel-Lindau 
(VHL) disease. This is a dominantly inherited cancer syndrome (MIM 193300) caused by 
mutations in the VHL tumour suppressor gene.  More recently it has become apparent that 
mutations in this gene are also responsible for cases of congenital polycythaemia (also known 
as familial erythrocytosis-2; MIM 263400), as well as playing a role in pulmonary vascular tone 
[286].  In this chapter, the role of the VHL gene was studied in detail when a young boy 
presented to clinical services with life-threatening pulmonary hypertension and erythrocytosis 
and was found to be a compound heterozygote for two novel VHL mutations [287]. 
VHL is a highly conserved gene that gives rise to a ubiquitously expressed mRNA.  It forms an 
important component of a molecular pathway used by metazoans to sense and respond to 
changes in oxygen [104].  The VHL gene encodes two proteins as a result of alternative start 
codons [288-290] (Figure 6.1).  These two proteins migrate with an apparent molecular weight 
of 24-30 kD and 19 kD and have overlapping biological functions [104].  The VHL protein 
contains two functional sub-domains, termed alpha and beta [291].  The alpha domain 
(residues 155-192) binds to elongin C, and forms part of a multiprotein E3 ubiquitin ligase 
complex [292, 293].  The beta domain (residues 63-154) consists of a largely hydrophobic 
region which acts as a substrate recognition site [291]. 
 
Figure 6.1 Structure of VHL  
The location of the two mutations studied in this chapter (D126N and S183L) are indicated.  The alternative start 
codons are marked by the methionine (Met) residues; the 19 kDa isoform contains amino acids 54-213 of the full-
length protein. 
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One of the best characterised roles of VHL is its ability to regulate the alpha subunit of HIF 
[125].  The HIF pathway has attracted considerable attention in cancer biology because HIF 
acts as a master transcriptional activator of over a hundred genes that generally promote 
adaptation to low oxygen conditions (hypoxia).  HIF is a highly conserved, sequence-specific 
DNA-binding basic helix-loop-helix transcription factor.  The active form is a heterodimeric 
protein composed of a constitutively expressed beta subunit and one of three alpha subunits 
(HIF-1α, HIF-2α, and HIF-3α).  HIF activity is regulated by post-translational modification of the 
alpha subunit, collectively termed HIF-α. 
 
Figure 6.2 Regulation of HIFα by VHL 
A. HIF-α is hydroxylated by the prolyl hydroxylase domain-containing proteins (PHD) at two specific proline 
residues (P402 and P564 in HIF-1α) within the oxygen-dependent degradation (ODD) domain.  This reaction uses 
molecular oxygen as a substrate, and the co-factors iron (Fe) and 2-oxoglutarate (2-OG).  B. The hydroxylated 
form of HIF-α is then recognised by VHL, which acts as an E3 ubiquitin ligase (in complex with elongin B, elongin 
C, and ring box 1 (RBX)) and mediates the ubiquitination of lysines within the ODD domain.  The ubiquitinated 
form of HIF-α is then targeted for degradation within minutes by the 26S proteasome. 
 
The interaction between VHL and HIF-α is critically dependent on the levels of oxygen (Figure 
6.2).  VHL only recognises HIF-a subunits that have been hydroxylated on two specific proline 
residues, at positions 402 and 564 in HIF-1α [294-297].  This hydroxylation reaction requires 
molecular oxygen and 2-oxoglutarate, and is carried out by one of three prolyl hydroxylase 
(PHD) enzymes [298, 299].  Following binding to VHL, HIF-1α is ubiquitinated on three 
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conserved lysines within the oxygen dependent degradation domain [300].  It is then targeted 
for destruction by the 26S proteasome [301]. 
When oxygen levels are low, or when VHL function is compromised, HIFa subunits rapidly 
accumulate and form an active transcriptional complex.  The active transcription factor directly 
activates genes containing hypoxia response elements (HREs), as well as interacting with other 
transcriptional control complexes, and influencing the expression of other transcription factors 
and signalling pathways.  These genes include energy metabolism, angiogenic signalling, 
vasomotor regulation, cell growth and apoptosis. 
VHL also has a large number of HIF-independent functions that may help to explain why loss of 
function is associated both with tumour formation and with erythrocytosis [302].  These 
functions include regulation of apoptosis and transcription [303-305], and association with the 
extra-cellular matrix and microtubule cytoskeleton [306-309]. 
6.1.02 Erythrocytosis and the oxygen-sensing pathway 
Erythrocytes are the vertebrate organism’s principal means of delivering oxygen to the body 
tissues.  Both erythrocyte number and oxygen carrying capacity are able to respond to 
fluctuations in oxygen tension.  Control over erythrocyte number is mediated by the 
glycoprotein hormone erythropoietin (EPO).  EPO levels are determined primarily at the level 
of gene transcription, by HIF binding to an HRE in the EPO promoter [310].  As detailed above, 
HIF levels are determined by the availability of molecular oxygen.  Recently, mutations in VHL, 
PHD2, and HIF2A have been associated with congenital erythrocytosis, providing a clear link 
between the cellular oxygen sensing pathway and systemic responses to hypoxia. 
Erythrocytosis is defined as an absolute increase in the red cell mass.  It can result from defects 
at any stage in the generation of erythrocytes, which can be divided into four broad categories 
(Table 6-1).  The first familial erythrocytosis to be characterised was due to mutations of the 
EPO receptor (MIM 133100).  Mutations in the EPO receptor result in receptor hypersensitivity 
and are associated with subnormal or undetectable levels of EPO [311].  The other three 
recognised forms of familial erythrocytosis (MIM 263400, 609820, 611783) are due to 
mutations in the oxygen sensing pathway, and are associated with elevated or inappropriately 
normal levels of EPO. 
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Aetiology Congenital / Acquired Primary / Secondary 
Defect in erythroid precursors Acquired Primary 
Tissue hypoxia / EPO-secreting tumour Acquired Secondary 
Impaired oxygen delivery by haemoglobin Congenital Secondary 
Defect in oxygen sensing pathway Congenital Secondary 
Table 6-1 Clinical basis of erythrocytosis 
The first erythrocytosis-associated mutation in the oxygen sensing pathway was reported in a 
large cohort of patients from the Chuvash region of the former Soviet Union, in association 
with an autosomal recessive hereditary erythrocytosis syndrome originally described by 
Polyakova in 1974 [312].  This condition was initially thought to be endemic to the Chuvash 
Republic, with a frequency of approximately 1 in 10,000 amongst a population of 1 million.  It 
has subsequently been found in patients from Ischia, North America, Germany, Turkey, and 
Bangladesh [313-316].  The mutation responsible is a 598C>T transition in exon 3 of the VHL 
gene.  This mutation results in an amino acid change of arginine to tryptophan at residue 200 
in the VHL protein (R200W). 
The consequences of the R200W VHL mutation at the cellular level have been studied in 
transformed B lymphocytes derived from patients homozygous for this mutation [317, 318].  
This mutation does not affect the level of VHL protein stability.  However, the mutant protein 
showed decreased affinity for, and reduced ubiquitination of, HIF-1α.  This was associated with 
increased HIF-1α protein under normoxic conditions and comparatively normal levels in 
hypoxia.  Increased HIF-1α protein levels were associated with increased mRNA expression of a 
subset of known HIF target genes, including EPO, vascular endothelial growth factor (VEGF), 
and glucose transporter 1 (GLUT1) [317, 318].  Perrotta et al. reported an increase in normoxic 
levels of VEGF but not EPO mRNA in transformed B lymphocytes carrying the R200W mutation 
[318]. 
Taken together, these findings suggest that the R200W mutation in VHL impairs VHL-mediated 
degradation of the HIF-1α protein under normoxic conditions.  The balance of the HIF 
transcription system is therefore altered, resulting in increased transcription of at least some 
HIF-regulated genes.   Up-regulation of these HIF target genes is therefore hypothesised to 
explain the observed phenotype.   The prevalence and magnitude of altered gene transcription 
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of HIF-regulated genes in different cell types as a result of this mutation have still not been 
clearly established. 
In addition to the R200W mutation, other VHL gene mutations have also been reported to be 
associated with congenital polycythaemia [313, 315, 316].  Such cases are rare, but support 
the idea that altered VHL function is a significant cause of congenital polycythaemia with 
elevated EPO.  These mutations are distinct from those associated with classical VHL disease.  
They lie at the C-terminal end of the protein and are hypothesised to result in a more modest 
loss of function [119].  There is also evidence to suggest these C-terminal mutations exhibit a 
heterozygote phenotype, both with regard to HIF-1α stabilisation [318], and in measurements 
of physiological parameters such as haemoglobin or blood pressure [319-321].  
An important question is why these C-terminal VHL mutations cause erythrocytosis without 
the classical tumour syndrome.  One possibility is that the mutant proteins have insufficient 
effect on HIF-α levels, with initiation of CCRCC and haemangioblastoma requiring a greater 
degree of HIF activation.  Alternatively, these mutations may preserve some specific function 
of VHL other than the ubiquitination of HIF-α.  Note that vertebral haemangiomas have been 
observed in Chuvash erythrocytosis, but it is not known whether they display loss of 
heterozygosity or whether this may be a reflection of the increased levels of VEGF observed in 
these patients [129]. 
In addition to erythrocytosis caused by mutations in VHL, there are now two other types of 
familial erythrocytosis that are caused by mutations in the oxygen-sensing pathway, affecting 
PHD2 and HIF2A.  By contrast with VHL-associated erythrocytosis, these mutations behave in 
an autosomal dominant fashion.  However, they all suggest that erythrocytosis can result from 
abnormal activation of this pathway. 
The first PHD2 mutation to be described in association with erythrocytosis, P317R, impairs 
binding to HIF-α, diminishes the capacity of PHD2 to down-regulate an HRE reporter gene, and 
results in a loss of function against HIF-α [322].  Subsequent mutations have also been shown 
to have substantial effects on the catalytic domain of the protein, whether local missense 
mutations or frame shifts which are N-terminal to it [323-325].  This has two implications: first, 
that erythrocytosis is caused by haploinsufficiency, and second, that PHD2 is the critical PHD 
isoform controlling EPO in humans.  This in turn implies that PHD2 loss of function is sufficient 
to allow HIF to escape PHD2 and PHD3 negative feedback suppression in EPO-producing cells 
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[286].  This notion is supported by a number of mouse knockout models that have 
demonstrated a critical role for PHD2 in the control of red cell mass [326, 327]. 
In contrast to loss of PHD2 function, mutations in HIF2A causing erythrocytosis have been 
shown to cause partial gain of function.  Thus the G537W mutant impairs PHD2-mediated 
hydroxylation and subsequent recognition of the hydroxylated HIF-2α by VHL, resulting in 
normoxic stabilisation of HIF-2α [128].  All mutations in HIF2A described thus far are 
concentrated in a small region located C-terminal to the primary hydroxyl-acceptor proline 
(residue 531) [127, 328].  There is heterogeneity in the functional defects associated with 
HIF2A mutations; whereas many mutations impair interaction with both PHD2 and VHL, the 
M535V mutation only affects interaction with PHD2 [329].  These findings would suggest that 
HIF-2α has a critical role in EPO control in humans, a position that is supported by both loss-of-
function and gain-of-function mouse models [330, 331].  However, HIF-2α may have a role in 
the control of red cell mass beyond the regulation of EPO, as seen by HIF-2α regulation of 
vascular cell adhesion molecule-1 (VCAM-1) in haematopoietic tissue and its role in promoting 
intestinal absorption of iron [286]. 
6.1.03 Pulmonary hypertension and the oxygen sensing pathway 
Much less is known about how mutations in the oxygen sensing pathway are able to cause 
alterations in cardiac and pulmonary responsiveness.  Pulmonary hypertension has been 
observed in association with erythrocytosis-causing mutations of VHL and HIF2A but not PHD2 
[127, 319, 332].  Patients with Chuvash polycythaemia exhibit disordered vascular physiology, 
showing a higher incidence of vertebral haemangiomas, varicose veins, lower blood pressures, 
and elevated serum VEGF concentrations [129].  These patients show an exaggerated 
physiological response to hypoxia, characterised by abnormalities in respiratory and 
pulmonary vascular regulation [333, 334].  This response is similar to that seen in association 
with acclimatisation to the hypoxia of altitude.  Studies of the Chuvash knock-in mouse 
support these findings, with evidence of pulmonary vasoconstriction and enhanced normoxic 
ventilation, similar to that seen in human patients with this mutation [335].  Superimposing 
decreased HIF-2α activity resulted in partial protection against pulmonary vascular 
remodelling, haemorrhage and oedema [335]. 
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6.2  Results 
6.2.01 Clinical Background to the D126N and S183L mutations in VHL 
In 2011, Bond et al. reported a novel compound heterozygous mutations of VHL in a boy 
presenting at two months of age with a severe clinical phenotype [287].  He presented with 
severe pulmonary artery hypertension, and required medical treatment in an intensive care 
unit.  Consistently raised haemoglobin concentrations of over 21 g/dL (normal range 11-16 
g/dl) prompted further investigation.  Serum erythropoietin concentration was grossly 
elevated at 4120 IU/L (normal range 2.5-10), greatly in excess of that expected with chronic 
hypoxia.  Apart from EPO levels, serum levels of HIF target genes, such as VEGF and 
plasminogen activator inhibitor-1 (PAI-1) [319], were not elevated.  Regular venesection was 
commenced and coincided with a steady amelioration of his cardiovascular symptoms and 
pulmonary vascular measurements.  Now nearly eleven years old, his clinical course has far 
exceeded initial prognostic predictions.  
Given the combination of erythrocytosis with elevated EPO levels, and early onset suggesting a 
congenital condition, genes from the oxygen sensing pathway were sequenced.  The patient 
was found to be a compound heterozygote for mutations in exon 2 (376 G>A) and exon 3 (548 
C>T) of the VHL gene, coding for the amino acid changes Asp126Asn (D126N) and Ser183Leu 
(S183L) respectively (Figure 6.1).  Sequencing of DNA obtained from the patient’s parents 
revealed heterozygosity for 376 G>A in the mother and 548 C>T in the father.  
His parents are genetically unrelated and come from distinct ethnic populations (Caucasian 
and North African).  They appear clinically unaffected and have normal haemoglobin 
concentrations.  They have no evidence of pulmonary hypertension or features of VHL disease.  
He has two siblings, neither of whom carries either mutation.   
6.2.02 Expression of VHL mutants in a renal cancer cell line 
In order to study the effect of the D126N and S183L mutations identified in this boy, a VHL-
deficient renal cancer cell line was first used to study the effect of these mutations separately.  
The mutations found in this patient were compared with four controls: the Chuvash 
polycythaemia mutant, R200W, a ß-domain mutant, N78S, which is deficient in HIF-binding, a 
wild-type VHL positive control and an empty vector negative control.  The RCC10 cell line has a 
deletion of nucleotides 474-477 in VHL, resulting in a premature stop codon and no detectable 
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VHL mRNA [162].  These cells therefore allow the reconstitution of wild-type or mutant VHL 
function in the absence of endogenous VHL function.    Figure 6.3 shows that levels of both 
HIF-1α and HIF-2α protein are increased in cells expressing the D126N and S183L VHL mutants 
when grown at ambient oxygen levels. 
 
Figure 6.3 The D126N and S183L VHL mutations result in increased basal levels of HIF-α protein 
RCC10 cells expressing the D126N or S183L mutants show increased levels of HIF-1α and HIF-2α protein compared 
with cells expressing the wild-type protein (VHL).  This is comparable to the R200W mutant and less than the 
N78S mutant that is deficient in HIF binding and the empty vector control (pCMV).  
 
Figure 6.4 The D126N and S183L VHL mutations result in impaired degradation of HIF-1α 
The rate of reduction in HIF-1α protein levels was measured following addition of cycloheximide to inhibit 
protein translation. The half-life of HIF-1α was increased in RCC10 cells expressing the D126N and S183L mutants, 
comparable to the R200W mutant and less than the N78S mutant. 
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In order to show that the increase in HIF-1α observed in Figure 6.3 might be due to reduced 
protein destruction, I studied the degradation of HIF-1α.  Following stabilisation of HIF-1α by 
exposure to 1% O2 for 16 hours, the cells were treated with cycloheximide to inhibit protein 
synthesis and then re-exposed to oxygen.  Figure 6.4 shows that both mutants result in 
reduced HIF-1α degradation compared to wild-type, in a manner analogous to the Chuvash 
mutant.  This could be due to reduced HIF-1α binding, impaired ubiquitin ligase activity, or 
both. 
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6.2.03 Expression of VHL in patient-derived LCL cells 
In an attempt to study the biochemistry of these mutant proteins in patient samples I obtained 
a population of B-cells (LCL cells) that had been immortalised by infection with Epstein-Barr 
virus (EBV) from the patient described above and healthy controls.  This procedure was carried 
out on two separate occasions, using different blood samples, and different donors for the 
control lines.  Exons 2 and 3 of VHL were sequenced in all LCL lines used to confirm their 
genotype (Figure 6.5). 
 
Figure 6.5 VHL sequence in patient-derived LCL cells 
Heterozygosity for the D126N and S183L mutations was confirmed by Sanger sequencing in both mutant LCL 
lines.  Control lines were confirmed to have the wild-type sequence. 
As shown in Figure 6.6, the D126N and S183L mutations did not affect the level of VHL mRNA 
in LCL cells.  However VHL protein expression was reduced in the LCL cells derived from the 
patient (Figure 6.6).  In common with a number of other cell lines, LCL cells predominantly 
express the 19kD isoform of VHL.  Previous studies would suggest that erythrocytosis is caused 
by impaired degradation of HIF-α under conditions of ambient oxygen.  However there was no 
increase in the levels of HIF-1α in normoxia (Figure 6.6).  LCL cells do not express HIF-2α so this 
could not be assessed [336].   
Given the evidence of abnormal HIF-1α degradation in RCC10 cells, I sought to replicate this 
experiment in LCL cells.  Following stabilisation of HIF-1α by exposure to 1% O2 for 16 hours, 
the cells were treated with cycloheximide to inhibit protein synthesis and then re-exposed to 
oxygen.  Figure 6.7 shows that the mutant cells exhibit reduced HIF-1α degradation compared 
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to wild-type.  This suggests that there is impaired degradation of HIF-1a even when both 
mutants are expressed at physiological levels. 
 
Figure 6.6 Expression of VHL in lymphoblastoid cells 
A. expression of VHL mRNA is equivalent in control (C1 and C2) and mutant (Mt1) cell lines.  B.  VHL protein 
expression in lymphoblastoid cells compared to a renal cancer cell line (RCC4) that lacks VHL (-) or with full-length 
VHL reconstituted (+).  Due to post-translational modification a number of species are recognised by the VHL 
antibody; the 19 kDa isoform is the main one in LCL cells.  Despite reduced VHL expression, there is no increase in 
basal levels of HIF-1α. 
 
Figure 6.7 Degradation of HIF-1α in lymphoblastoid cells 
The rate of reduction of HIF-1α protein levels was measured following treatment with cycloheximide to inhibit 
protein translation and exposure to oxygen for the times indicated. 
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6.2.04 Abnormal ubiquitination of HIF-1a in hypoxia  
Both mutant and control LCL cells demonstrated increased levels of HIF-1α in hypoxia, due to 
the decreased availability of oxygen for hydroxylation (Figure 6.8).  Treatment with 
dimethyloxalylglycine (DMOG) or desferrioxamine (DFO) also led to increased levels of HIF-1α.  
DMOG is a 2-oxoglutarate analogue that non-specifically inhibits PHD activity, while DFO is a 
more potent agent that prevents HIF hydroxylation by chelation of the ferrous ion required as 
a co-factor by the PHD enzymes for the hydroxylation reaction.  Treatment with either of these 
agents prevents hydroxylation of HIF-a, thus leading to stabilisation of the protein. 
 
Figure 6.8 Mutant LCL cells show reduced levels of high MW HIF species 
Treatment of LCL cells with desferrioxamine (DFO) blocks prolyl hydroxylation and results in the stabilisation of 
unmodified HIF-1α.  Treatment with hypoxia results in stabilisation of HIF-1α.  Mutant LCL cells show reduced 
levels of high MW species, which may correspond to poly-ubiquitinated HIF-1α. 
 
In addition to a band corresponding to monomeric HIF-1α at around 120kD, all the control 
lines exhibited a number of higher molecular weight species when exposed to 1% oxygen 
(hypoxia), but not when treated with DFO or DMOG (Figure 6.8).  I hypothesised that these 
higher molecular weight species detected may correspond to poly-ubiquitinated HIF-1a 
molecules.  Importantly, these were consistently absent from the mutant cell line (Figure 6.8). 
This suggests that the VHL mutant LCL cells may have defective ubiquitin ligase activity. 
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Figure 6.9 Mutant LCL cells are deficient in HIF-1α ubiquitination 
Accumulation of poly-ubiquitinated HIF-1α is seen in control but not mutant LCL cells (A) and is specific to 
treatment with proteasomal inhibitors (B). 
 
Addition evidence showing that mutant LCL cells are deficient in HIF-1α ubiquitination was 
provided by pharmacological inhibition of proteasomal degradation.  MG132, MG115, and 
ALLN are all peptide aldehyde inhibitors of the proteasome with respectively decreasing 
specificity.  Inhibition of the proteasome leads to accumulation of ubiquitinated HIF-1a in 
control, but not mutant cells (Figure 6.9).  It is important to note that all of these inhibitors 
may have off-target effects against calpains and cathepsins.  To control for this, LCL cells were 
also treated with PD150606, which is a more specific calpain inhibitor, caspase inhibitor II and 
cathepsin inhibitor I, which are more specific to their respective peptidases.  Figure 6.9 shows 
that accumulation of high molecular weight HIF-1α species was only seen in LCL cells treated 
with inhibitors of the proteasome.  This implies that the degradation of HIF-1α in both mutant 
and control LCL cells is proteasome dependent. 
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6.2.05 Expression of endogenous HIF-1a target genes 
Given the evidence for abnormal ubiquitination and impaired degradation of HIF-1α, I 
examined the expression of various HIF target genes in LCL cells (Figure 6.10).  VEGF is a well-
characterised HIF target gene that has been used in previous studies of familial erythrocytosis 
[317, 318].  Prolyl-4 hydroxylase alpha-1 (P4HA1) and 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4 (PFKFB4) are both HIF target genes that show a particularly high level of 
hypoxic induction in LCL cells [130].    
 
Figure 6.10 Expression of HIF target genes is not affected by the D126N and S183L VHL mutations 
The experiment was repeated for independent transformations (A and B) of B-cells from the patient (Mt1 and 
Mt2) and controls (C1-C4). 
Gene expression was assessed at baseline (normoxia) and after induction by overnight culture 
at 1% O2 (hypoxia).  All genes tested showed highly significant induction by hypoxia (p < 
0.0001).  Surprisingly, VEGF showed significantly reduced expression in normoxia (p < 0.005; 
Figure 6.10A), however this difference could not be replicated (Figure 6.10B).  I also examined 
a number of other HIF target genes, including erythropoietin, HIF-2a, PHD3, adrenomedullin, 
aldolase C, with similar results (data not shown). 
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Previous work on the Chuvash polycythaemia mutant in LCL cells had only shown a difference 
in baseline function [317, 318].  These authors did not show any difference in hypoxic 
induction of gene expression  Furthermore, the normal inter-individual differences in HIF 
pathway gene expression are seen to diminish at extreme hypoxia conditions [335].  Given that 
no difference in gene induction was observed at more permissive oxygen levels, it is not 
surprising that there was no difference in hypoxia. 
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6.2.06 VHL knockdown   
In addition to reconstituting individual VHL mutants in a VHL-deficient cell line, I also looked at 
the effect of VHL knockdown in LCL cells.  LCL cells typically grow in suspension and I therefore 
used lentivirus-mediated introduction of a short hairpin RNA (shRNA) targeting VHL.  This 
approach achieved 70-80% knockdown in a pool of LCL cells, as measured by RT-PCR (Figure 
6.11), and a marked reduction in VHL protein levels (Figure 6.11).  These cells showed 
increased levels of HIF-1α in normoxia in both mutant and control lines (Figure 6.12).  
Moreover, they also showed a decrease in the level of higher molecular weight HIF-1α species 
in both control LCL cells. 
 
Figure 6.11 Lentiviral-mediated shRNA infection results in efficient knockdown of VHL mRNA and protein 
VHL expression was analysed in LCL cells treated with VHL shRNA (VHL) and control (luciferase, Luc) by RT-PCR (A) 
or immunoblotting (B). 
 
Figure 6.12 VHL knockdown increases HIF-1α levels in normoxia LCL cells in both normoxia and hypoxia 
VHL knockdown also decreases poly-ubiquitinated HIF-1 α in control cells in hypoxia. 
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6.2.07 Response to proteasomal inhibition following VHL knockdown 
Treatment of control cells with VHL knockdown (Figure 6.13A) shows a remarkable 
recapitulation of the failure to accumulate poly-ubiquitinated HIF-1α seen in mutant cells 
(Figure 6.8).  Treatment of mutant cells with VHL knockdown does not show additional 
reduction of poly-ubiquitinated HIF-1a (Figure 6.13B).  This provides further evidence that the 
higher molecular weight HIF-1α species are related to VHL ubiquitin ligase activity, which is 
reduced in both VHL knockdown and the D126N and S183L mutants. 
 
 
Figure 6.13 VHL knockdown impairs ubiquitination of HIF-1α 
Control (A) or mutant (B) LCL cells were treated with a lentivirus encoding control (Luc) or VHL-specific (VHL) 
shRNA.  Subsequent treatment with MG132 at the concentrations indicated showed that VHL knockdown 
decreases poly-ubiquitinated HIF-1a in control cells in a similar manner to that seen in mutant cells. 
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6.2.08 Expression of endogenous HIF-1α target genes following VHL knockdown 
Given that VHL knockdown was sufficient to increase levels of HIF-1α protein in normoxia, the 
expression of various HIF target genes in LCL cells was then examined (Figure 6.14).  
Surprisingly, while hypoxia resulted in significant induction of HIF target genes, VHL 
knockdown did not increase levels of HIF target genes.  VEGF was the only gene that showed 
any change in expression following VHL knockdown, and this was only apparent in the mutant 
cells.  This might indicate that HIF is only able to activate target genes once VHL activity has 
been reduced below a certain threshold. 
 
 
Figure 6.14 Expression of HIF target genes in control and mutant LCL cells treated with VHL knockdown 
VEGF expression was increased in mutant LCL cells treated with VHL knockdown at baseline and in hypoxia (p < 
0.05), but there was no significant difference in the expression of PFKFB4. 
 
  
Familial erythrocytosis and von Hippel-Lindau disease 
Page | 165  
 
6.3  Interpretation 
6.3.01 Justification for the use of a transformed B lymphocyte model to assess the 
HIF-system 
A number of previous studies of erythrocytosis caused by mutations in the oxygen sensing 
pathway have employed transformed B lymphocytes [130, 317, 318, 322, 333].  Using such 
cells ex-vivo offers the chance to conduct extreme physiological manipulation of the HIF 
pathway in human cells.  Such cells retain the genetic identity of their donor, and thereby 
allow the detailed examination of rare human mutations.  
EBV is the only virus known to immortalise human B lymphocytes.  Only a proportion of the 
circulating B cells are immortalised (~1 in 100), and resting cells are immortalised in preference 
to activated ones [337].  T cells from EBV seropositive individuals suppress B cell 
immortalisation by EBV in culture, hence the need to remove these cells by selection.  EBV-
immortalised B cell lines are initially polyclonal and secrete all major classes of 
immunoglobulin, although after prolonged culture in vitro they become oligoclonal or 
monoclonal [338].  LCL cells can be cultured for 150-200 passages, at which point their 
characteristics change [339].  A minority will senesce, while the majority develop chromosomal 
instability and become immortalised.  Although early passage cells were used in these 
experiments, it is important to note that it takes four weeks to generate sufficient cells to 
conduct experiments, and a further four weeks following lentiviral infection. 
It is clear that the process of immortalisation has significant effects on cellular function, and 
that there are significant differences between the function of independent transformations of 
B cells from the same donor [130].  Alternative strategies have employed non-transformed 
peripheral mononuclear cells (PBMCs), or a number of separate EBV transformations [130].  I 
was able to study two independent transformations of B-cell from this patient, giving largely 
consistent data. 
6.3.02 Reduced expression of VHL 
The D126N and S183L VHL mutations provide an ideal opportunity to dissect the molecular 
pathophysiology of this patient.  The oxygen-sensing pathway is well understood, but this 
patient would be the youngest to present with erythrocytosis and pulmonary hypertension.  
This could imply that these mutations have a more profound effect than those previously 
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studied.  Our collaborators and I therefore looked first at the effect of a introducing the 
individual mutants into a VHL-deficient renal cancer cell line (RCC10). 
The D126N and S183L mutants showed reduced protein stability compared to wild-type 
following cycloheximide treatment [287]. VHL is degraded by the proteasome, and it is known 
that both elongin B and C are required for maximum stabilisation [340].  Thus the S183L 
mutation, which is predicted to lie within the alpha-domain at the surface, could impact on 
binding to other components of the ubiquitin ligase complex.  These data provide evidence 
that both mutations contribute to the patient’s phenotype, but do not differentiate between a 
loss of function and a dominant negative mechanism of action. 
Impairment of VHL function can lead to the sustained rates of high rate of anaerobic-like 
glycolysis even in the presence of oxygen, known as the Warburg effect [341, 342].  This has 
been shown to result from HIF-mediated enhancement of glycolysis and suppression of 
mitochondrial respiration [343].  Our collaborators therefore assessed VHL protein function in 
vitro by measurement of the pH of the media used to culture RCC10 cells carrying the D126N 
and S183L mutants [287].  Both these mutants exhibited an effect on pH that was intermediate 
between wild-type and the N78S mutant [287]. 
I examined whether the Warburg effect was associated with HIF-α stabilisation in these cells. 
Both mutants showed stabilisation of HIF-1α and HIF-2α that was again intermediate between 
wild-type and the N78S mutant and similar to the levels seen with the Chuvash mutation.  In 
order to examine this in more detail I looked at the effect of VHL mutation on HIF-1α stability.  
Previous experiments have shown that the half-life of HIF-1α is just a few minutes, extending 
to over an hour in cells deficient for VHL [125].  Our results confirm that both mutants impair 
HIF-1α degradation, with kinetics comparable to that seen with the R200W mutant. 
Since stably transfected cell pools exhibit a range of expression of the introduced protein I next 
looked at a more physiological model, using patient-derived lymphoblastoid cells.  This allowed 
me to look at cells with a normal level of VHL expression, but meant that I had to look at the 
function of both mutations together.  Although there are now a number of reported mutations 
in VHL associated with erythrocytosis [119], only a minority of these have looked at functional 
studies in lymphoblastoid cells.  I found that these cells showed normal levels of VHL mRNA, 
which is in agreement with studies showing that the Y175C mutant did not affect VHL mRNA 
levels [320].  Importantly, however I saw a marked reduction of VHL protein expression.  This 
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may well be explained by the reduction in VHL protein stability seen in RCC10 cells, but it 
stands in contrast to previous studies [317].   
VHL exists in two isoforms with overlapping function [104].  In order to confirm the specificity 
of the p19 species that we detected most abundantly in LCL cells, we used a lentiviral 
mediated shRNA to knockdown VHL in these cells.  Knockdown of VHL leads to a reduction in 
protein levels comparable to that seen in the mutant LCL cells.  This was associated with an 
increase in HIF-1α stabilisation in normoxia in both control and mutant LCL cells, a finding that 
has been reproduced in other cell lines [344].  This shows that these mutants cause a loss of 
function, rather than acting in a dominant negative manner. 
6.3.03 Functional effects 
Given the impaired Warburg effect seen in RCC-10 cells [287], and the reduced levels of VHL 
expression in LCL cells (Figure 6.6), I expected that the LCL cells would show evidence of 
activation of the oxygen sensing pathway.   HIF-1a is a highly labile protein, and consequently 
small differences in protein levels may be affected by experimental technique.  I therefore 
looked for more robust evidence of HIF activation, manifest as increased expression of HIF 
target genes.   
Despite the wide variety of genes that are modified by HIF levels, previous studies of 
erythrocytosis have concentrated on a few well-established HIF-target genes, such as VEGF or 
EPO.  Given the importance of cell type in determining the abundance of gene expression, a 
more robust approach is to examine those genes which show the greatest hypoxic response 
specifically in B cells or their EBV-transformed derivatives.  VEGF, P4HA1, and PFKFB4 have all 
been shown to have significant up-regulation in response to hypoxia in LCL cells, and have 
been used before to identify inter-individual differences in HIF pathway biology [130].  Analysis 
of expression in normoxia provides the most sensitive test for alterations in function, since 
inter-individual differences are diminished in hypoxia [333].  It is also important for semi-
quantitative RT PCR to ensure that the reference gene transcript is not affected by hypoxia.  
It remains intriguing to consider how activation of different HIF pathways might play a 
particular role in the pathophysiology of these patients.  Clearly, the activity of HIF on the EPO 
promoter must be of major relevance in the generation of erythrocytosis.  That does not 
explain the findings of increased pulmonary responsiveness to hypoxia, or the tendency to 
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venous thromboses seen in Chuvash patients.  I did not see a difference in levels of EPO 
expression in the mutant cells, in keeping with our findings with the other genes.  This may be 
due to low levels of HIF-2A and EPO expression seen in lymphoblastoid cells [336], however it 
stands in contrast to the strikingly high levels of EPO seen in the patient himself [287].  It 
therefore highlights the importance of tissue-specific EPO expression. 
Previous studies have had variable success showing up-regulation of HIF-target genes, with 
some studies showing significant normoxic induction in all genes tested and others unable to 
do so [322].  As mentioned previously, there are problems with using EBV-transformed B 
lymphocytes, particularly the unquantifiable effects of transformation and prolonged culture.  
However this system is relatively easy to perform, with minimal inconvenience to the patient 
and control donors.  An additional caveat is that the existence of increased levels of HIF-1α 
protein does not necessarily mean that it will be transcriptionally active. 
Contrary to expectations, the gene expression data suggest that these mutations in VHL affect 
neither HIF-target gene expression at baseline, not its induction by hypoxia.  These results 
show a high degree of internal consistency, and have sufficient power to support the null 
hypothesis that there is no significant difference between this case and controls. 
6.3.04 HIF regulation 
The central question remains, therefore, why we do not see stabilisation of HIF-1α in patient-
derived LCL cells, given that expression of VHL p19 is reduced in these cells and HIF-1a does 
appear to be stabilised in  RCC-10 cells transfected with the individual mutants?  The pattern 
of ubiquitination seen in mutant LCL cells appears to be abnormal, suggesting that VHL’s E3 
ligase activity is in some way compromised.  One possibility is that in these LCL cells there is 
another mechanism at work regulating HIF-1α levels.  However, HIF-1α was stabilised by 
inhibition of the PHD enzymes by DFO and by the use of proteasomal inhibitors, implying that 
this alternative mechanism requires both prolyl hydroxylation and a functional proteasome. 
Previous studies have shown stabilisation of HIF-1α in patient–derived LCL cells [317, 333], 
although not all studies of hereditary erythrocytosis have been able to use LCL cells to show 
activation of the oxygen sensing pathway [322].  This case presented with a much more severe 
clinical phenotype than has been observed in other cases of hereditary erythrocytosis.  
Patients with Chuvash polycythaemia do exhibit a reduced life expectancy, but live well into 
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their 4th decade [319].  Moreover, the small number of patients studied so far with mutations 
in PHD2 or HIF2A have also presented in adulthood [127, 322, 328].  We might therefore 
expect that the D126N and S183L mutants might produce greater activation of the oxygen 
sensing pathway. 
I was also unable to show activation of HIF-2α.  HIF-2α is not highly expressed in peripheral 
blood mononuclear cells or LCL cells [336].  Given the evidence outlined in the introduction to 
this chapter that HIF-2α has a critical role in EPO control in humans, this is a significant 
limitation in the usefulness of LCL cells for the study of hereditary erythrocytosis. 
The ubiquitin-proteasome system is the major cytosolic proteolytic system in eukaryotes; the 
specificity of the system is determined by the numerous E3 ligases that mediate substrate 
recognition [345].  Polyubiquitin chains linked through lysine 48 are the principal signal for 
targeting substrates to the 26S proteasome.  Longer ubiquitin chains seem to associate more 
tightly with the proteasome, but the minimal signal for efficient proteasomal targeting is a 
tetra-ubiquitin [346].  However, protein modification by ubiquitin is involved in the regulation 
of numerous cellular functions besides protein stability.  Ubiquitin is a highly versatile 
molecular signal because of its ability to modify substrate proteins in its monomeric form or to 
be conjugated to preceding ubiquitin moieties in a variety of orientations to form many types 
of ubiquitin chain [347].  Following binding to VHL, HIF-1α is ubiquitinated on three conserved 
lysines within the oxygen dependent degradation domain [300].  It is then targeted for 
destruction by the 26S proteasome [301].  Very little is known about the type and length of 
ubiquitination that is required for this process.  Moreover it is not known whether HIF-α 
ubiquitination can be associated with any function other than degradation. 
These results show that the pattern of ubiquitination of HIF-1α in the mutant LCL cells is 
abnormal.  They suggest that mutant cells are unable to form long-chain poly-ubiquitinated 
molecules due to an impairment of VHL’s ubiquitin ligase activity.  This deficit is not associated 
with stabilisation of HIF-1α in normoxia, however, or with up regulation of HIF target genes. 
There exist a number of possibilities why HIF-1α is not stabilised in these cells.  First, there is 
the technical issue of using just two transformations of LCL cells from this patient.  An 
important positive control would be LCL cells carrying the Chuvash mutation, or indeed other 
mutations associated with hereditary erythrocytosis.  It would also be interesting to study 
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heterozygous cells derived from the patient’s parents, however if each mutation results in a 
mild loss of function, the remaining normal allele may entirely compensate for such deficiency. 
Second, there may be a threshold effect, since HIF degradation is an extremely rapid process 
[125].  The length of ubiquitin chain may not affect proteasomal degradation significantly 
enough to result in functional consequences in vitro.  In patients with classical VHL disease 
somatic inactivation of the remaining wild-type allele results in constitutive HIF activation.  By 
contrast, erythrocytosis is hypothesised to arise from mild activation of the HIF pathway in 
every cell.  Lentiviral knockdown of VHL resulted in normoxic stabilisation of HIF in LCL cells, 
with reduction of the polyubiquitinated HIF-1α species in control cells seen in hypoxia or 
following proteasomal inhibition.  Moreover, despite these effects, knockdown of VHL did not 
lead to changes in HIF target gene expression.  This implies that the D126N and S183L 
mutations may simply result in a loss of function below the threshold for detection. 
An alternative possibility is that these results expose a novel mechanism of HIF-1α regulation.  
Although VHL results in rapid degradation of HIF-1α in normoxia, there is evidence of HIF-1α 
turnover in VHL -/- cells treated with hypoxia and DFO [348], in cells transfected with HIF-1α 
that has had both hydroxyl-acceptor prolines [349] or all three ubiquitin-acceptor lysines 
mutated [300], and in cells with an inactive E1 enzyme [348].  The receptor of activated 
protein kinase C 1 (RACK1) has been shown to compete with HSP90 for HIF-1α binding, and 
results in VHL and oxygen-independent proteasomal degradation [350].  Activation of p53 by 
DNA damage leads to p53 E3 ubiquitin protein ligase homolog (MDM2)-mediated HIF 
ubiquitination and destruction by the proteasome [351].   
A number of proteins show degradation through both ubiquitin-dependent and ubiquitin-
independent pathways, including p53 and p21 [352].  There is evidence of ubiquitin-
independent HIF-1α degradation in VHL -/- cells with an inactive E1 enzyme [348].    COMMD1 
(copper metabolism (Murr1) domain containing 1) has been shown to complex with HIF-1α 
and HSP70 (heat shock 70kDa protein), resulting in ubiquitin-independent degradation by the 
20S proteasome [353].    By analogy with MDM2 it is possible that VHL may promote direct 
binding to the proteasome, and that this may require different regions than those required for 
ubiquitin ligase activity [354].  Certainly, direct association of other SCF complexes with the 
proteasome has been observed [345], and there is some work to suggest that HIF-1α is able to 
bind directly to the PSMA7 subunit of the 20S proteasome [355].  Intriguingly, this is the same 
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subunit that has been shown to interact with a number of other cellular and viral proteins, 
including p21 [356] and EBNA3 [357]. 
Finally, it may be that another function of VHL entirely is responsible for the phenotype 
observed in this patient.  The type 2C VHL mutations that are associated with 
phaeochromocytoma are normal with respect to HIF regulation [358], and may instead cause 
disease through effects on JunB [359] or fibronectin [308].  Despite the clear relationship 
between HIF and EPO, it is less obvious how abnormal VHL function contributes to pulmonary 
hypertension.  Whilst lymphoblastoid cells offer a highly convenient model system with which 
to study the effects of these mutations, it is possible that another cell type, such as dermal 
fibroblasts or even induced pluripotent stem cells derived from patient urothelial cells, could 
provide more information. 
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6.4  Conclusions and future work 
In conclusion, I have characterised the effect of two novel VHL mutations on the oxygen 
sensing pathway.   These mutations result in reduced VHL protein stability and impair HIF-1α 
degradation in both RCC-10 cells and patient-derived lymphoblastoid cells.  In particular, these 
mutations result in profoundly abnormal ubiquitination of the HIF-1α protein, a phenotype 
which can be recapitulated by lentiviral mediated knockdown of VHL in lymphoblastoid cells.  
However, despite this abnormal ubiquitination, HIF-1α is not stabilised in normoxia and there 
is no evidence of activation of HIF-target genes.  This may represent the activity of a novel, 
VHL-independent, HIF regulatory pathway.   
There are two main routes to take this work forward.  First, new technologies, such as zinc-
finger nucleases or Transcription Activator-Like Effector Nucleases (TALENs), offer the 
potential to produce a complete VHL knockout in lymphoblastoid cells.  This would allow us to 
determine whether VHL ubiquitin ligase activity exhibited a threshold effect.  It would also 
enable the re-expression of individual mutants in these cells.  A second goal would be to 
generate a mouse model of VHL depletion in the B cell lineage.  There is evidence for the 
importance of VHL function in T cells, and it would be intriguing to see if B cells did indeed 
harbour a novel HIF regulatory pathway. 
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7.1  Thesis summary 
This thesis describes four renal disorders that are caused by the inheritance of a genetic 
variant.  These disorders have arisen in different populations and are caused by diverse 
biochemical mechanisms.  In each case, renal disease is due to a rare mutation that may be 
unique to that family.  Many of these rare mutations originate in a single founder and are 
dispersed by his descendants in the population.  The population frequency of the mutation is 
therefore related to the age of the mutation [197].  Successful linkage analysis requires that a 
mutation be highly penetrant, in order that the phenotype and thus affection status, can be 
determined accurately [48].  This helps to understand the mechanistic basis of these 
conditions, since highly penetrant disease is likely to be caused by a significant disturbance of 
the relevant biochemical pathway. 
In chapter 3 I have studied the occurrence of renal disease in the Turkish-Cypriot population of 
Northern Cyprus.  This small population has a high incidence of renal disease, much of which is 
undiagnosed and may be familial in origin.  Recent reports have shown evidence of significant 
geographical clustering for a number of monogenetic conditions in Greek-Cypriots, which is 
consistent with a degree of population stratification.  Given the genetic similarities between 
Greek- and Turkish-Cypriot populations on the island, I hypothesised that we would find 
evidence of the same renal conditions in the Turkish-Cypriot ESRD population that are found in 
the Greek-Cypriot population.   
I identified three individuals with the G871C mutation in COL4A3, but no cases of CFHR5 
nephropathy, the G1334E mutation in COL4A4, or the 3854delG mutation in COL4A4.  Two 
individuals with the G871C mutation were part of a large pedigree with renal impairment and 
microscopic haematuria, but the third was not known to be related.  I then used conflicting 
homozygosity analysis to demonstrate a minimal haplotype that was shared between four 
Cypriot families with this mutation, thus dating this mutation to 17 generations ago.  This is in 
agreement with evolutionary theory which argues that pathogenic variants with large effect 
size are of recent origin. 
In chapter 4 I sought to identify a novel genetic cause of renal disease a large Greek-Cypriot 
kindred.  This family had a very high incidence of renal disease, consistent with autosomal 
dominant inheritance, but with a variable clinical phenotype on renal biopsy.  I used linkage 
analysis to identify a 15 cM region on chromosome 10, with a maximal LOD score of 4.187, 
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that contained no genes currently associated with renal disease.  Next generation sequencing 
was performed in two first cousins from this pedigree, which identified six novel, non-
synonymous coding variants within this region.  Although these variants were described as 
novel by database comparison, I found that three of them occurred with significant frequency 
in our reference population of Turkish-Cypriots with and without renal disease.   
I assessed the expression of three variants identified by next generation sequencing in primary 
cells derived from individuals in this pedigree.  I studied renal tubular urothelial cells.  These 
cells are easy to obtain, enable non-invasive study of renal tissue, and have the potential to 
generate induced pluripotent stem cells.  This chapter demonstrates the use of discrete 
filtering steps to identify private variants in this family that may be responsible for renal 
disease.  The next step is to show by what mechanism one of these variants is responsible for 
renal disease. 
In chapter 5 I studied another large pedigree with adult-onset renal failure and a variable 
clinical phenotype on renal biopsy.  In this instance, linkage analysis was unable to 
demonstrate co-segregation of a single genomic region with renal disease.  This could have 
been due to polygenic inheritance, the presence of phenocopies within the pedigree, or an 
alternative mode of inheritance.  Sequencing of the mitochondrial genome in this family 
demonstrated the presence of a novel polymorphism in the HSP1 region at homoplastic levels. 
Subsequent examination of mitochondrial function in primary fibroblasts demonstrated a 
significant reduction in baseline oxidative respiration with a compensatory increase in 
glycolysis.  Mitochondrial disease is a source of non-chromosomal inheritance, and has 
recently been implicated in a range of complex diseases, including renal disease.  As such, 
mitochondrial disorders may be an important source of the ‘missing heritability’ that renal 
GWAS have failed to identify. 
Lastly, in chapter 6 I have taken a distinctive phenotype in a single individual and related it to 
perturbations in the well-studied oxygen sensing pathway mediated by VHL and HIF.  This 
phenotype was so distinctive that it was possible to use candidate gene sequencing to identify 
the causative variant [287].  However, VHL mutations exhibit a high degree of allelic 
heterogeneity which may reflect the ability of VHL to interact with and regulate a wide range 
of biological partners.  Recent studies suggest that erythrocytosis associated with VHL 
mutations is due to the combination of two hypomorphic alleles, resulting in partial activation 
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of HIF [286].  However the variants that I studied in patient-derived B-cell lines showed 
abnormal degradation of HIF without activation of HIF target genes.  It is therefore possible 
that these cells are able to employ some kind of VHL-independent HIF regulatory mechanism. 
All these studies demonstrate, in differing ways, the challenges of linking phenotype to 
genotype.  It is difficult to study renal pathology directly, and so we are forced to use a series 
of surrogate markers with variable relevance to the underlying physiology.  Where the 
phenotype is not distinctive, this increases the experimental ‘noise’, and reduces the strength 
of genetic association or linkage.  Alternatively, the lack of association can indicate the 
contribution of multiple genes, or the existence of non-chromosomal inheritance.  The hope, 
of course, is that new genetic discoveries will uncover novel genetic, physiological, and 
therapeutic pathways.  The incredible power of next generation sequencing technologies now 
makes it possible to determine all the possible causative variants within a few weeks.  
However, identification of the underlying biochemical mechanisms is likely to remain a 
considerable challenge for the future. 
 
7.2  The GIKD study 
Many of the DNA samples studied in this thesis were collected as part of the genetic 
investigation of kidney disease (GIKD) study (UKCRN Portfolio ID: 3946).  This study was set up 
in 2007 in order to identify the genetic and molecular basis of inherited kidney disease.  The 
inclusion criteria were simply the presence of renal disease that appeared to be transmitted 
genetically, but for which there was no established genetic diagnosis.  A secondary objective 
was the creation of a bank of DNA and blood samples to allow future investigations into these 
or related diseases. 
In its first inception the GIKD study was designed to recruit large pedigrees that could be 
solved by linkage analysis.  An important part of the recruitment process was the identification 
of affected relatives who might not be known to the renal team at the recruiting centre.  This 
process was facilitated by the recommendation in 2008 from the national institute of clinical 
excellence (NICE; Clinical guidelines, CG73) that testing for CKD should be offered to all those 
with a family history of stage 5 CKD.  The expectation was that with adequately sized pedigrees 
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it would be possible to use SNP linkage studies to identify a region of the genome in which to 
look for a causative mutation. 
The identification of CFHR5 nephropathy was the first success for the GIKD study [137].  The 
findings of Gale et al. illustrate a number of issues that have been important to the studies in 
this thesis.  Most importantly, CFHR5 nephropathy exhibits a highly unusual renal phenotype, 
manifest as deposition of complement C3 without detectable immunoglobulin on renal biopsy.  
This made the existence of phenocopies highly unlikely, and therefore it was possible to 
combine two pedigrees together with reasonable confidence.  Further confidence to combine 
pedigrees came from the close geographical origin of these two pedigrees, suggesting that a 
single mutation had arisen in a common ancestor.  By combining pedigrees it was possible to 
generate a significant LOD score and exclude a large portion of the genome from further 
analysis. 
Prior to the widespread use of next generation sequencing, the identification of a linked 
interval left a large number of genes to be sequenced manually on a candidate by candidate 
basis.  However, the renal phenotype in CFHR5 nephropathy strongly suggested that the 
underlying abnormality was a gene directly involved in complement regulation.  Consequently 
the best candidate genes for further study were associated with the regulator of complement 
activation gene cluster on chromosome 1.  Finally, this disorder arose from an internal 
duplication, rather than a point mutation, and as such exhibited a normal Sanger sequencing 
sequence. 
To date, the GIKD study has recruited samples from 145 pedigrees across four hospital sites in 
England.  Dr Gale and I have performed SNP genotyping on 15 of the largest pedigrees, 
including the three discussed in this thesis.  A significant limitation of the study has been the 
question of how to define the renal phenotype.  Renal biopsy provides the best phenotypic 
marker in the absence of extra-renal signs, but may not have been performed even in those 
with ESRD, and may not include all diagnostic techniques, such as electron microscopy.  In the 
absence of a clear renal phenotype linkage analysis can easily be confounded by phenocopies, 
as discussed in chapter 3.  Finally, even with significant LOD scores, there remains the question 
of candidate gene sequencing, which can be expensive, time consuming, and may even miss 
the causative variant. 
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Fortunately, next generation sequencing has now become a standard technique for this kind of 
analysis.   We have had over 40 exomes sequenced, with discovery of the likely pathogenic 
mutation in 14. Although the identification of novel pathogenic mutations requires exome data 
from more than one individual per pedigree (in the absence of other informative data), it is 
possible to uncover known causative mutations with the sequence data from just one 
individual.  In this way it is possible to screen pedigrees with a limited renal phenotype for 
mutations in genes associated with, for example, microscopic haematuria or focal segmental 
glomerulosclerosis.  Given the expense of commercial sequencing for individual genes (£670 
each for COL4A3 and COL4A4), it makes economic sense to pursue next generation sequencing 
in such cases (£800 per exome).  Moreover, once the index case has been sequenced it is then 
possible to decide whether it is appropriate to sequence additional individuals. 
With such a tsumami of information [360], the question turns to the more difficult one of 
proving that a given variant is pathogenic.  There have been a few ethical amendments to the 
GIKD study protocol that may assist with this.  First, the need to screen relatives was 
addressed early on, with the design of a template that could be sent out to relatives for them 
to take to their local GP.  Second, it is important to confirm that all affected individuals in a 
pedigree carry the same variant.  Occasionally this can only be ascertained by means of 
examining archived histological tissue, or even by testing stored DNA samples (for example if 
that individual was on the transplant register) after the individual had died.  Finally, it becomes 
increasingly important to study the effect of variants in vitro.  Dermal fibroblasts are 
commonly used for this purpose, as discussed in chapter 5, but it is preferable to look at the 
function of renal cells.  Urothelial cell culture is a step in this direction (chapter 4), and the 
ability to transform these cells into pluripotent stem cells offers even greater promise [161]. 
 
7.3  Personalised genomic medicine 
The studies illustrated in this thesis provide an example of the direction that personalised 
genomic medicine is moving in.  Within a decade, the scientific community has moved from 
the collaborative effort and cost that resulted in the first complete human genomic sequence 
to the generation of equivalent volumes of data by one lab within weeks for just a few 
hundred dollars [70].  Given the importance of the information thus generated it is inevitable 
that this process will move into the clinical sphere, as suggested by Sir John Bell’s recent report 
Discussion 
Page | 179  
 
to the Human Genomics Strategy Group [361].  The question, then, is how can this information 
best be used and what ethical issues need to be addressed for the optimal use of this data. 
Gene discovery is the starting point both for understanding the genetic mechanisms 
underlying diseases and for providing clues to therapeutic approaches.  In the short term, the 
ability to classify diseases into sub-phenotypes from genetic information may result in 
improved treatment and an expanded use of pharmacogenomics.  This is especially true for 
cancer, where combinations of drugs could be used to target the abnormal molecular 
pathways seen within each tumour.  Drug treatments might be anticipated to show larger 
treatment effects where treatment is matched to the underlying genetic cause.  Thus the 
ability to stratify individuals according to genotype has the potential to make clinical trials 
more cost-effective and time-efficient by enrolling a much smaller number of patients [59].  
Even now, the ability to differentiate between genetic and non-genetic causes of the nephrotic 
syndrome in children has the possibility to influence treatment options. 
In the longer term, the discovery of further genetic risk factors for kidney disease will facilitate 
the discovery of new drug targets through the understanding of novel molecular pathways.  
The use of selective inhibition of VEGF and other angiogenic growth factors in VHL-driven 
kidney cancer is exactly the kind of rational drug discovery that is possible with a detailed 
understanding of the genetic defect in a given renal disease [19].  The major uncertainty here 
is the extent to which rare and unique mutations mediate their effects through common 
genetic pathways that are amenable to drug development.  To put this in context, the US Food 
and Drug Administration define orphan diseases as those occurring in less than 200,000 cases 
in the United States, and have adopted this definition because it is roughly the cut-off point for 
willingness by pharmaceutical companies to work on treatments for a disease [362].  
Significant changes will be required to the partnership between academia and industry in this 
regard to consider targeted drug developments for very rare diseases [362]. 
Another long-term consequence of personalised genomic medicine is the ability to predict 
disease susceptibility.  There are two areas in which this may come about.  First, there is the 
question of finding the genetic modifiers that influence a person’s risk of disease [57].  
Oligogenic inheritance has been demonstrated in vitro for the ciliopathies [87], and work is on-
going to uncover factors that influence the risk of disease over and above the simple additive 
model looked at by GWAS studies.  Second, as our understanding of genetic disease grows it 
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will become increasingly possible to study a healthy person’s genome for evidence of rare 
mutations that confer a significant risk disease.  Given that we each contain around 175 de 
novo mutations [78], it is likely that this kind of predictive information is relevant to us all. 
However, the ability to generate and share large amounts of individual-specific information by 
next-generation sequencing generates new manifestations of perennial ethical issues such as 
consent, feedback, protection of privacy and the governance of research [363-365].  Two areas 
of research ethics are especially pertinent to the current discussion: the limitations of the 
current consent process and the management of individual research results. 
Whilst informed consent has been a guiding principle of medical investigation since the mid-
20th century, genomics research moves away from this principle in several respects [71].  First, 
DNA provides information not just on an individual, but also on their relatives and ethnic group 
in a format that is easily accessible across international borders.  Second, the quantity of 
information available from DNA is such that even with personal identifiers removed it may be 
possible to identify the original donor.  Third, DNA is often archived in online repositories, such 
as mutation and variation databases.  These are increasingly important for the wider scientific 
community; however the complexity of genomics research along with the difficulty of 
providing precise specifications for the future use of data raise questions as to whether 
consent can be truly ‘informed’. 
At an individual level, an important ethical issue is the question of reporting findings back to 
the participant [71].  Most study participants are motivated by trying to discover what is 
responsible for the disease in their family, whether they themselves are affected or not.  
However the question arises how to manage findings that are incidental.  There appears to be 
some agreement that, where there is a serious treatable condition, researchers have a moral 
obligation to feed this information back to research participants [366].  However, where 
findings are of a less serious nature, are untreatable or of uncertain significance, the potential 
benefits for participants of being informed need to be balanced against the participant’s right 
not to know. 
Final issues for personalised genomic medicine are the questions of cost and of data storage.  
The cost of genome sequencing has fallen by several orders of magnitude over the last decade.  
It has now reached the point where it will soon undercut the current cost of NHS accredited 
genetic testing.  If whole genome sequencing is to replace current genetic testing, not only will 
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staff need the technical and ethical training to ensure proper conduct and competence to 
practice, but clinical staff will need substantial bioinformatics support.  Whilst the cost of data 
storage has also fallen dramatically, there remain issues of how to back the data up and how 
to ensure that it is accessible for analysis and collaboration while safeguarding aspects of 
patient privacy.  Automated data management and storage provides the most efficient use of 
resources, but has additional implications for data security and confidentiality.  Given the 
density of information storage on the DNA molecule, this may even form the most durable and 
cost-effective long-term information store [367] . 
 
7.4  Future directions 
Current sequencing technologies have revolutionised the field of medical genetics.  It is 
increasingly affordable to generate volumes of data that are many orders of magnitude greater 
and less expensive than they were just a decade ago.  Whilst technical advances have 
revolutionised the process of sequence acquisition, there remain several areas where focused 
efforts are likely to advance the field substantially [73]. 
The first is the more accurate description of phenotypes, particularly in the context of 
Mendelian disorders.  As has been discussed repeatedly in this thesis, the definition of 
accurate phenotypes is of central importance in all kinds of genetic analysis.  There are 
hundreds, perhaps thousands of poorly defined familial phenotypes that are rare or unique, 
especially in high risk or non-European populations [73].  The discovery of the underlying 
genes would be greatly facilitated by the detailed clinical investigation of such cases.  
Moreover, collaborative storage of such descriptive information in international repositories 
would facilitate the delineation of new Mendelian disorders and allow samples from similar 
phenotypes to be combined. 
For non-Mendelian conditions, the challenge is to define phenotypes that would be amenable 
to study.  Examples of suitable renal phenotypes include acute kidney injury or transplant 
rejection [47].  A refinement of this technique is the search for genetic modifiers, such as those 
that influence the speed of progression of chronic kidney disease.  These might be studied in 
the context of a defined genetic background, such as ADPKD or mutations in COL4A3/A4. 
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Another issue is the need for improved technical, statistical and bioinformatic methods for 
data analysis.  Technical issues related to current next generation sequencing protocols include 
the methods for reducing false-positive and false-negative variant calls, calling indels, 
prioritising candidate causal variants, and predicting and annotating the potential functional 
impact for disease gene discovery or molecular diagnostics [73].  Statistical issues include the 
need for models of non-additive genetic effects, including gene-gene and gene-environmental 
interaction.  Such technical issues may pose a hurdle for clinical laboratory accreditation [71].  
That said however, next generation sequencing is likely to be introduced into the clinical 
setting before these challenges are fully resolved owing in part to their ability to facilitate 
diagnosis and inform therapy [360, 368, 369]. 
It is now a realistic goal to identify a candidate gene for every recessive disorder using as few 
as one affected individual per disorder [73].  Solving all dominant disorders will be more 
difficult, requiring technical and analytic improvements that should take place over the next 
few years.  This will require the coordination and cooperation of the human genetics 
community and funding agencies.  However, efforts are already underway at multiple centres 
throughout the world to establish the collaborative framework and physical infrastructure 
required.  Even after the genetic basis of all Mendelian disorders has been identified [73], work 
will still be required to understand disease mechanisms better and develop improved 
therapeutics.  Given the rate of de novo mutations, however, the diagnostic challenge may 
never entirely fade away. 
Human genetic disorders therefore provide us with an extraordinarily large array of natural 
experiments.  Given the population of the planet, it is probable that there exist individuals with 
mutations in the vast majority of coding genes.  Technology now affords us the chance to 
identify markers and even the individual variant that is associated with every phenotype that 
we encounter.  With the techniques of association so well established, research is now 
required to demonstrate how a given variant is sufficient to cause a disease.  This thesis traces 
the path of gene identification from its origins in a human population, and offers a range of 
insights into how causality can be demonstrated.  This step is now the most difficult, and 
therefore has become limiting in the analysis of the genetic basis of kidney disease. 
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Participant Consent Form 
 
Title of project: 
 
 
Genetic Investigation of Kidney Disease 
 
The participant should complete the whole of this sheet him or herself. 
 
(please tick each statement if it applies to you) 
 
I have read the Information Sheet for Patients and 
Healthy Relatives               
 
I have been given the opportunity to ask questions and 
discuss this study          
 
I have received enough information about the study      
 
The study has been explained to me by:   
 
Prof/Dr/Mr/Mrs/Ms_______________________________________ 
 
 
I understand that I am free to withdraw from the study at 
any time, without having to give a reason for withdrawing 
and without affecting my future medical care    
 
I agree to my general practitioner and/or nephrologist being  
informed of my participation in this study 
 
I agree for my genetic material to be extracted, analysed and stored 
for this study 
 
I agree to the use of my archived specimens (eg kidney biopsy tissue)  
for this study, if surplus to clinical requirements 
 
I agree to the creation of stem cells from my urine sample for this study 
 
Please tick this box if you would like to be informed when a result is available 
 
 
 
Signed.................................................................................Date................................. 
 
(NAME IN BLOCK 
CAPITALS).............................................................................................…………….. 
 
 
Investigator’s signature....................................................…Date: .............................. 
 
(NAME IN BLOCK 
CAPITALS)...................................................................................……………………... 
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Protocol version 3.0 for 
Genetic Investigation of Inherited Kidney Disease (GIKD) 
 
1. Recruitment 
a. Patient with strong family history of renal disease identified by 
nephrologist responsible for their care  
b. Inclusion criteria: 
i. Individuals from a family in which two or more individuals are 
affected by a rare kidney disease (eg glomerulonephritis) 
ii. Individuals from a family in which three or more individuals are 
affected by a common kidney disease (eg diabetic 
nephrosclerosis) 
c. Exclusion criteria: 
i. Individuals with an already well−understood genetic renal 
disease (such as typical adult polycystic kidney disease) 
ii. Families where the inheritance is not clearly Mendelian genetic 
(ie a single-gene defect is unlikely) 
iii. Individuals who are unable to give appropriate consent 
d. With patient’s consent, referral made to GIKD research doctor 
nephrologist 
e. Patient invited to attend with affected/non-affected family members 
 
2. Acquisition of samples 
a. With consent, blood sample taken from all family members for DNA 
extraction, analysis and storage 
b. With consent of affected family members, contact made with potentially 
affected family members to arrange clinical screening (by their GP) for 
kidney disease and DNA extraction for analysis/storage 
 
3. Genetic Analysis 
a. If clinical features suggest candidate genes responsible: 
i. Known mutations in these genes excluded by sequencing  
ii. Limited SNP analysis of candidate genes to identify SNPs co-
segregating with condition (and therefore affected gene/region of 
gene) 
iii. Appropriate regions will be sequenced 
b. If no clear candidate genes, or if candidate genes excluded, then a 
genome-wide SNP screen will be done to identify region of genome 
likely to be responsible  
c. This region will be investigated as above 
 
4. Use of archived tissue 
a. We will review biopsy material from affected individuals in the family in 
order to determine an accurate clinical phenotype. 
i. This may include archived tissue from family members who are 
now deceased. 
b. In rare instances we may use historical patient samples that are surplus 
to clinical requirement for the investigation: 
i. With consent, we may use the tissue to look at gene expression 
to refine the results of a genome-wide SNP screen. 
ii. It is possible to get limited genetic information from the archived 
tissue of deceased individuals which can inform the results of a 
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SNP screen and confirm the results of candidate gene 
sequencing. 
 
5. Storage of Samples and Information 
a. Clinical details will be anonymised and stored on a secure computer in 
Professor Maxwell’s laboratory. The key for the anonymised patient 
details will be stored in a locked metal cabinet 
b. DNA will be stored in Professor Maxwell’s laboratory for future 
investigation by us and other researchers in kidney disease 
i. Access to laboratory is swipe-card controlled 
ii. Samples will be labelled with a code 
iii. Key to code will be kept on password-protected computer and in 
a locked metal cabinet 
iv. Researchers will have access to code to identify samples as 
necessary 
 
6. Generation of induced Stem Cells from Urine 
a. With consent, urine samples will be collected from up to 3 individuals 
with kidney disease per family and a corresponding number of healthy 
relatives. 
b. Renal tubular cells will be isolated from these urine samples and 
cultured to produce induced pluripotential stem cells. 
c. The stem cells will be used to generate differentiated cell lineages with 
which to study the effect of the causative mutation in that family. 
d. All cell lines generated by these experiments will be stored in Professor 
Maxwell’s laboratory for the duration of the study. 
e. If any patient decides to withdraw from the study we will discard any 
cells they have contributed along with their DNA. 
 
7. Further Investigation 
a. Once the causative mutation has been identified the molecular effects of 
this will be investigated using cell-free and cell-based techniques, as 
appropriate 
 
8. Dissemination of Results 
a. Anonymised results of each family investigation will be published in 
peer-reviewed journals 
b. All participants will be informed of outcome of investigation and offered a 
further clinic appointment with a clinical geneticist to discuss implications 
of their condition for them and their family 
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CONFIDENTIAL PATIENT INFORMATION SHEET 
 
 
 
Study organiser (Cyprus):  Dr Deren Oygar, Consultant Nephrologist, State 
Hospital, Nicosia. 
Study organiser (London): Professor Guy Neild (Professor of Nephrology) 
 
Investigation of familial renal disease in Turkish Cypriot kindreds. 
 
(To describe the symptoms and find the responsible gene for inherited kidney 
disease in Cyprus) 
 
You are invited to take part in this research study. 
 
Inherited kidney disease is common in Cyprus. We are trying to find the gene 
responsible for these diseases and make detailed investigation of the urine.  
 
From our urine research we hope to find a particular chemical or protein in the urine 
which will allow us to identify affected members of the family long before their 
kidney function starts to deteriorate. Early detection will we hope will lead to new 
ways to treat the disease. 
 
We will take a small blood sample (10 ml); and collect a sample of urine passed at 
the beginning of the day. DNA will be made from the blood and stored until use. 
The urine will be kept frozen. The samples will be taken to the UK for research 
investigations. 
 
If you have any questions about this study at any time, Please contact Dr Deren 
Oygar or Professor Guy Neild, the study organisers. 
 
Please note you do not have to take part in this study if you do not want to. If 
you decide not to take part you may withdraw at any time without having to 
give a reason. Your decision whether to take part will not affect your care and 
management in any way. 
 
All proposals for research using human subjects are reviewed by an ethics 
committee before they can proceed. This proposal was reviewed by the Ethics 
Committee at State Hospital, Nicosia and the Joint UCL/UCLH Committees on the 
Ethics of Human Research. 
 
 
Dr Deren Oygar, MD. 
Professor GH Neild, MD, FRCP, FRCPath. 
Study Organisers 
November 2008 
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CONFIDENTIAL CONSENT FORM FOR PATIENTS 
 
 
 
Investigation of familial renal disease in Turkish Cypriot kindreds. 
 
 
Please read this form and then answer each question as appropriate. 
 
Have you read the information sheet about this study? YES/NO 
 
Have you had an opportunity to ask questions and discuss this study?  YES/NO 
 
Have you received satisfactory answers to all your questions? YES/NO 
 
Have you received enough information about this study? YES/NO 
 
Which doctor have you spoken to about this 
study?…………………………………… 
 
Do you understand that you are free to withdraw from this study  
at any time 
without giving a reason for withdrawing 
without affecting your future medical care YES/NO 
 
Do you agree to take part in this study? YES/NO 
 
I agree to take part in the Study called “To describe the clinical phenotype and 
identify the genotype of familial tubular disease in Turkish Cypriot kindreds” 
 
I agree to provide a blood sample so that my blood sample can be tested for 
genes causing kidney disease. 
 
SIGNED…………………………………………..#       DATE……………………. 
 
NAME (PRINT)…………………………………..# AGE (IF UNDER 18)……….. 
 
*Please delete as appropriate 
#If participant is under 18, form must be signed by a parent/guardian 
 
 
SIGNATURE OF INVESTIGATOR………………………………………………. 
DATE………………………… 
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